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Abstract
Using site-directed mutagenesis and whole-cell patch clamping, this study investigated 
the structure of the GABAa receptor in relation to its function. The baculovirus 
expression system was used to express human ocißi subunits in Sfi cells. The GABAa 
receptor is widely distributed throughout the central nervous system and is the site of 
action for many anaesthetic drugs. The mechanisms that underlie receptor activation by 
GABA and modulation by drugs are not well understood and are, therefore, the focus of 
this study. The role of highly conserved residues in the first and second membrane- 
spanning regions was investigated. Site-directed mutations were made in either the otj 
subunit, the ßi subunit or both to examine possible subunit-specific effects on receptor 
function. Assembly of receptors in the plasma membrane was monitored by 
immunofluoresence using flow cytometry. The binding of radiolabelled muscimol, a high 
affinity GABA analogue, to receptors in permeabilised cells was used to determine 
whether subunits had formed heteromeric receptors. Changes in the characteristics of 
the whole-cell current in response to GABA showed the functional effects of the 
mutations. Possible changes in receptor pharmacology were also investigated. All 
mutations carried out showed subunit specificity in their effects indicating that subunits 
contribute unequally to receptor function. Most mutated receptors showed changes in 
desensitisation that varied depending upon the position of the residue and the 
substitution made. The response to GABA was abolished when a threonine residue at 
the 13' position in M2 was mutated to alanine in the ß subunit. The apparent affinity for 
GABA was decreased when a leucine residue at the 9' position in M2 was mutated to 
either phenylalanine or tyrosine in only the ß subunit. These effects demonstrate the 
importance of the M2 region of the ß subunit in transmitting conformational changes 
involved in GABA-activation. Potentiation by pentobarbital was abolished when the 
T12'Q mutation was in the ß subunit implicating a discrete site in the action of 
pentobarbital. The response to GABA was reduced when tyrosine at position 231 in the 
M l region was mutated to leucine in the a  subunit. This indicates a role for M l in 
GABA-activation that is a subunit specific. The findings in this study demonstrate roles 
for residues in M l and M2 in coupling between agonist binding and channel activation 
and indicate separate mechanisms of action for GABA and the potentiating effect of 
pentobarbital.
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Chapter One
1. Introduction
21.1 GABA Receptors in Neuronal Function
1.1.1 From Crustaceans to Cloning
GABA is the most widely distributed inhibitory neurotransmitter in the vertebrate central 
nervous system (Rabow et al, 1995; MacDonald and Olsen, 1994; Burt and Kamatchi, 
1991; Olsen and Tobin, 1990). Its role as a neurotransmitter was first established in 
1957 in the crayfish stretch receptor by Bazemore et al. In the 1960s it was found to be 
an inhibitory neurotransmitter at the crustacean neuromuscular junction (Takeuchi and 
Takeuchi, 1965). By 1981 GABA had been identified as a neurotransmitter at 
interneuronal synapses in the vertebrate central nervous system (Rabow et al., 1995). 
Since its discovery, GABA has been found to activate three pharmacologically distinct 
types of receptors, GABAa, GABAb and GABAr receptors. GABAa receptors have an 
integral chloride selective ion channel and are specifically antagonised by bicuculline. 
GABAb receptors act indirectly through G proteins to block calcium channels and to 
activate potassium channels (Nicholls et al., 1992). The more recently identified 
GAB Ac receptors (Yeh and Grigorenko, 1995) are similar to GABAa receptors in that 
they have a GABA-gated chloride channel but are insensitive to bicuculline (Cherubini 
and Strata, 1997). GAB Ac receptors are predominantly restricted to the vertebrate 
retina (Bormann and Fiegspan, 1995).
GABA activates GABAa receptors on the postsynaptic membrane that mediate rapid, 
transient, synaptic transmission. This provides a stabilising influence upon the cell­
resting potential and is therefore inhibitory. GABAa receptors are found on virtually 
every neuron in the brain and spinal cord (Johnston, 1996). It is estimated that 
approximately half of all synapses in the central nervous system are GABAergic 
(Seeburg et al., 1990). GABAa receptors are involved in the regulation of anxiety, 
sleep, epileptogenic activity and muscle tension (Mohler, 1997). They are also 
expressed at relatively high levels in peripheral tissues including, the uterus, placenta, 
heart, pancreas, urinary bladder, and pituitary and adrenal glands where their role is not 
well understood (Hedblom and Kirkness, 1997; Garret et al., 1997). Cloning of the 
GABAa receptor a i and ßi subunits from bovine brain in 1987 revealed that it belongs 
to a superfamily of ligand-gated ion channels (Schofield et al., 1987).
31.1.2 The GABA a receptor
The GABAa receptor contains binding sites for many important pharmacological agents 
which modify receptor function (Macdonald and Olsen, 1994; McKerman and Whiting, 
1996; Bradley et al., 1998). Many of these modulatory agents are widely used as 
therapeutic and anaesthetic agents. Some of these are: benzodiazepines, barbiturates, 
steroids, loreclozole, ethanol and general anaesthetics. The clinically important 
benzodiazepine class of compounds have sedative-hypnotic, anxiolytic, muscle relaxant 
and anti-convulsant actions (Darlison and Albrecht, 1995; Sigel and Buhr, 1997). An 
example is diazepam (Valium) which is a widely prescribed anti-anxiety medication. 
Barbiturates are used for anaesthetic, sedative-hypnotic and anti-epileptic medications 
(Bowman and Rand, 1980; DeLorey and Olsen, 1992; Sieghart 1992; Tanelian et al., 
1993; MacDonald and Olsen, 1994). Despite the wide use of some of these drugs for 
many years, little is known about where they bind or how they alter GABAa receptor 
function.
The purpose of this study was to relate the structure of the GABAa receptor to its 
functional properties. Using site-directed mutagenesis, specific changes in receptor 
structure were made by altering the chemical and physical properties of a single residue. 
Human cxißi receptors were expressed in Sf9 cells using the baculovirus expression 
system. Immunofluorescence labelling was used to assess receptor assembly and 
radioligand binding assays were used to detect changes in high affinity agonist binding. 
Patch-clamp studies were used to investigate functional changes in GABA-activation, 
desensitisation and receptor pharmacology. The combination of these techniques 
provides a powerful tool with which to investigate the molecular mechanisms that 
underlie ion channel structure and function.
Four key drugs were used with the patch-clamp technique; pentobarbital, bicuculline, 
picrotoxin and penicillin. They alter receptor function in different ways and are used to 
investigate possible changes in the function of the mutated receptors.
Pentobarbital: Barbiturates were first introduced as anaesthetics around 1900, but it 
wasn't until 1963 that they were shown to potentiate GABA-mediated inhibition in the 
spinal cord by Eccles et al. (for review refer Johnston, 1996). They prolong both 
inhibitory post-synaptic currents and spontaneous inhibitory post-synaptic currents in rat 
hippocampal neurons (Gage and Robertson, 1985; Otis and Mody 1992). It is now well
4established that pentobarbital both potentiates the response to GABA and directly 
activates native GABAa receptors in the absence of GABA (MacDonald and Olsen, 
1994; Akaike et al., 1985; Peters et al., 1988; Robertson 1989; Yakushiji et al., 1989; 
Rho et al., 1996). Both effects are blocked by bicuculline and picrotoxin (Akaike et al., 
1985; Peters et al., 1988; Robertson 1989).
Bicuculline: A defining feature of the GABAa receptor is the specific antagonism
induced by the plant alkaloid bicuculline. It was first identified as a GABA antagonist in 
the mammalian brain in the 1970s (Curtis et al., 1971). Bicuculline is considered a 
classic competitive receptor antagonist. It competes with GABA for binding to the 
GABA binding site, but does not itself activate the channel (Rabow et a l, 1995).
Picrotoxin: The convulsant picrotoxin was initially isolated from Anamirta cocculus, a 
poisonous plant of the moonseed family (Johnston, 1996). The blocking effect of 
picrotoxin on ’membrane currents elicited by GABA was initially demonstrated at the 
inhibitory neuromuscular junction of the crayfish (Takeuchi and Takeuchi, 1969). 
Picrotoxin is generally thought to be a non-competitive inhibitor (Takeuchi and 
Takeuchi, 1969; Akaike et a l, 1985; Yakushiji et al., 1987; Inoue and Akaike, 1988), 
but both competitive and non-competitive inhibitions have been reported (Inoue and 
Akaike, 1988). Picrotoxin is probably more correctly classified as a negative allosteric 
modulator (Johnston, 1996). It consists of two components, picrotoxinin the active 
constituent and picrotin which is less active (Simmonds, 1982; Kerr and Ong, 1992). 
Picrotoxin is not a structural analogue of GABA and exerts its effect via a distinct site 
from GABA.
Penicillin: A depressant effect of penicillin on GABA-induced inhibition in the
mammalian central nervous system was originally demonstrated by Curtis et a l, (1970). 
Penicillin is a convulsant. It is 100-times less potent than bicuculline (Johnston, 1996) 
and acts by an open channel block mechanism (Hochner et al., 1976; Yakushiji et al., 
1987; Twyman et al., 1992).
Ligand binding assays were carried out using the GABAa receptor agonist muscimol. 
Muscimol: Muscimol is a psychomimetic compound that was isolated from the
hallucinogenic mushroom Amanita muscaria (DeLorey and Olsen, 1992). It has a 
strong structural resemblance to GABA (Kerr and Ong, 1992). It is widely used in
5binding studies because it is very selective and is more potent then GABA, binding with 
higher affinity (Andrews and Johnston, 1979).
1.1.3 Ligand-gated ion channel structure
Direct structural information on ligand-gated ion channels comes from electron imaging 
studies by Unwin (1993b, 1995) of the nicotinic acetylcholine receptor from Torpedo ray 
at 9Ä resolution. The images reveal five a-helical structures arranged symmetrically 
around a central pore, surrounded by possible ß-sheet structures that face the lipid 
bilayer. Comparison of receptors imaged in both closed and open states shows that 
agonist binding at an extracellular site may initiate conformational changes which are 
transmitted to structures in the membrane spanning region that enable the channel to 
open.
GABAa receptors share sequence homology with other neurotransmitter-gated ion 
channels that form a family of ligand-gated ion channels including: nicotinic
acetylcholine (nACh), glycine, and 5-hydroxytryptamine (5-HT3) receptors and an 
invertebrate glutamate-gated chloride channel (Karlin and Akabas, 1995; Rabow el a/., 
1995). The nACh and 5-HT3 receptors are selective for cations, whereas glycine 
receptors like GABAa receptors are selective for anions. The general structural features 
of GABAa receptor subunits are shared with other members of the nACh receptor 
superfamily.
1.1.4 Subunit structure
GABAa receptors are thought to be composed of 5 subunits (Figure 1.1). The proposed 
secondary structure for a subunit is shown in Figure 1.2. The hydropathy profile for 
each subunit sequence suggests that there are four hydrophobic regions, predicted to 
constitute transmembrane regions one to four (Ml to M4). The M2 region is highly 
conserved between GABAa receptor subunits (Figure 1.3). A numbering system will be 
used for the M2 region in which 1' is located at the intracellular end and 19’ at the 
extracellular end (Miller, 1989). Each subunit includes a large hydrophilic N-terminus of 
about 200 amino acids located extracellularly (Schofield et a l., 1987; Rabow et al., 
1995). This domain has a cysteine loop located in approximately the same position in all 
subunits. It consists of two disulphide bonded cysteine residues separated by 13 amino 
acids (Amin et al., 1994). Residues in this domain have been implicated in GABA 
binding (Smith and Olsen, 1995). It also contains potential glycosylation sites. All
Figure 1.1 Subunits and membrane-spanning regions in GABAa receptors
GABAa receptors are thought to consist of 5 subunits grouped round a central pore 
(upper diagram). GABA binds to its recognition site on the receptor and activates a 
chloride-selective ion channel. Subunits consist of 4 membrane-spanning regions (Ml- 
M4); M2 is thought line the pore of the channel (lower diagram). EC is extracellular 
and IC is intracellular.
N-terminal
C-terminal
Extracellular
Intracellular
Cytoplasmic Loop
Figure 1.2 Subunit secondary structure
Residues at various positions in Ml and M2 are shown for reference.
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6GABAa receptor subunits have a large intra-cellular loop between M3 and M4 which is 
poorly conserved among subunits. This loop contains many consensus sites for protein 
phosphorylation, that vary in number and position among subunits (Kellenberger et al., 
1992).
1.1.5 Subunit diversity
Various combinations of GABAa subunits can assemble into receptors that differ in their 
functional properties. This provides diversity in receptor function that can be specific to 
certain regions of the brain. The GABAa receptor consists of six distinct subunit classes 
or families of receptors (a, ß, y, 5, s and n) which are markedly homologous in sequence 
but are coded for by different genes (Smith and Olsen, 1995; Sivilotti and Nistri, 1991; 
Sigel and Buhr, 1997). GABAa receptor families have multiple isoforms which to date 
include, oti_6, ßi^, yi^, 5, s and n (Rabow et al., 1995; Sigel and Buhr, 1997). ß4 and y4 
subunits have not been identified in mammals and 'll is predominantly restricted to the 
uterus (Hedblom and Kirkness, 1997). There is about 70 - 80% sequence identity within 
GABAa subunit families, 30 - 40% between families, and 20 - 30% with other members 
of the ion channel superfamily (Unwin, 1993a; MacDonald and Olsen, 1994). pi_2 
subunits are generally classified as GABAc receptors but are sometimes included with 
GABAa subunits because they share 30 - 38% sequence identity (Bormann and 
Fiegenspan, 1995). Subunits assemble in various combinations that are thought to form 
hetero-oligomeric proteins in the cell membrane.
GABAa receptors are assembled from at least 17 different subunits, providing many 
theoretical receptor combinations. It appears however, that particular subunits are 
restricted to specific brain regions and this limits potential receptor assemblies. It is also 
becoming apparent that there are preferred assemblies of particular subunits. 
Heterogeneity in receptor subunit composition is thought to determine physiological and 
pharmacological properties of receptors and to contribute to flexibility in signal 
transduction and drug-induced modulation. This heterogeneity enables a single 
neurotransmitter to have diverse effects upon neuronal function (Seeburg et al., 1990). 
The most abundant subunits in the adult brain are oci, ß2 and y2. These particular 
subunits are the ones most frequently colocalised within individual neurons (Fritschy and 
Mohler, 1995; Persohn et a /.,1992).
7Most GABAa receptors in neurons in the brain contain at least one a  subunit isoform 
along with either, ß2, or ß3 and y2, The different a  subunit isoforms contribute greatly to 
heterogeneity in receptor expression and their varied distributions (Fritschy and Mohler, 
1995). Pharmacological studies show that the particular a  subunit isoform(s) present in 
recombinant aßy receptors is a major determinant of the functional properties of the 
receptor (Ebert et al., 1994; Verdoon 1994; Gingrich et al., 1995). Colocalisation of 
different a  subunit isoforms may indicate the existence of receptors containing several a  
subunit isoforms. GABAa receptors containing two different a  subunit isoforms have 
pharmacological profiles distinct from those containing a single a  subunit isoform, 
allowing for further functional heterogeneity (Fritschy and Mohler, 1995; Ebert et al., 
1994; Verdoon 1994). The functional characteristics of receptors also vary depending 
upon the subunit isoforms of ß and y expressed with the a  subunit (Ducic et al., 1995).
The heterogeneity of some GABAa subunits is further increased by alternate RNA 
splicing. An example is the two forms of the y subunit, y2S and y2L, the latter of which 
contains a phosphorylation site for protein kinase C (Whiting et a l., 1990). The 
expression of a mature form of the e mRNA transcript appears to be regulated by a 
neuronally restricted RNA splicing mechanism (Whiting et a l., 1997). In addition, two 
forms of the human ß2 subunit may arise by differential splicing (McKinley et al., 1995).
1.1.6 Receptor stoichiometry
The subunit composition and stoichiometry of native GABAa receptors is not known. 
GABAa receptors are generally thought to form pentamers based on homology with the 
nicotinic ACh receptor. While there is no direct evidence for this in the GABAa 
receptor, many functional and biochemical studies using a variety of different methods 
support this hypothesis (1m et al., 1995b; Chang et al., 1996; Tretter et al., 1997). 
Several studies in different expression systems agree with a stoichiometry of two a  
subunits, two ß subunits and one y subunit for QL^iyi (Im et al., 1995b), otiß2y2 (Chang 
et al., 1996) and otiß2y receptors (Backus et al., 1993).
The stoichiometry of a ß  receptors is controversial but most studies propose a 
pentameric structure. A functional study by Im et al (1995b) supports a pentameric 
structure for aöß2 receptors consisting of three ae and two ß2 subunits. Results obtained
8in a biochemical study by Tretter et al (1997) indicated that a iß 3 receptors 
predominantly form pentamers, consisting of two a i subunits and three ß3 subunits. 
Reasons for the discrepancy between these two studies are not clear. The otiß3 subunit 
combination forms receptors that respond to GABA in this expression system indicating 
that these subunits are able to assemble into functional receptors (Dominguez-Perrot et 
al., 1996). The differences may be due to the different combinations of subunit isoforms 
used which may have different preferred assemblies. Variation in receptor 
stoichiometries may be another means by which heteromeric receptors provide 
functional diversity in the central nervous system.
Results from a biochemical study by Gorrie et al (1997) favour a tetrameric structure for 
otiß2 receptors consisting of two oti subunits and two ß2 subunits. Tretter et al., (1997) 
noted the presence of significant amounts of dimers, trimers and tetramers in addition to 
the formation of pentamers, which may account for the differences between the studies. 
It appears that in some conditions certain combinations of aß  subunit isoforms may form 
tetramers but that the preferred arrangement is probably pentameric.
7. 7.7 Receptor assembly and trafficking to the plasma membrane 
In order to assemble into functional receptors ion channel subunits must fold and 
oligomerise properly as well as undergo numerous post-translational modifications. 
Some of these include: formation of disulphide bonds, proteolytic cleavage,
glycosylation, trimming of oligosaccharides and phosphorylation. In contrast to the 
assembly of less complex membrane proteins, the assembly of ion channels is slow and 
inefficient. It is thought that folding of ion channel subunits is completed after the 
formation of specific subunit-subunit interactions, to avoid subunit misfolding and rapid 
intracellular degradation (Green and Miller, 1995).
There is evidence that interactions between the N-terminal regions of subunits are 
important for specific subunit associations in the nACh receptor (Verrall and Hall, 
1992). Ligand-gated ion channel subunits contain an N-terminal signal sequence that is 
translocated into the endoplasmic reticulum (ER) where it is proteolytically cleaved. It 
is in the ER that N-terminal residues become glycosylated and membrane proteins fold, 
oligomerise, and assemble into a quaternary complex. They are then transported out of 
the endoplasmic reticulum to the cell surface via the golgi (Green and Miller, 1995).
9Several studies suggest a role for the ß subunit of GABAa receptors in trafficking of 
receptors to specific membranes (Perez-Velaquez et al., 1993; Connolly et a/., 1996; 
Wan et al., 1997). In S fi  cells expressing the cxi subunit, the level present in the plasma 
is reduced by 50%, compared to the level for cells expressing both oti and ßi GABAa 
subunits (Tierney et al., 1996). This suggests that the ßi subunit may normally interact 
with the oti subunit to enable efficient transport of receptors to the plasma membrane.
1.1.8 Glycosylation
A post-translational modification that is required for normal function of some proteins is 
glycosylation. It involves the attachment of sugars or oligosaccharide chains to the 
protein. It can protect against proteolytic degradation, target proteins to intracellular 
compartments or ensure proper insertion and orientation of the protein in the membrane. 
Consensus sites for N-linked glycosylation are located in the N-terminal region of each 
GAJ3Aa subunit. Complex branching glycosylation involves the attachment of an 
oligosaccharide chain to an asparagine residue on the protein, and is limited to 
eukaryotic cells (Rich Rosner, in Thilly, 1986).
Buller et al., (1994) found that removing the two glycosylation sites present in oil 
subunits of a iß 2Y2 receptors did not prevent expression of functional receptors in 
Xenopus oocytes. They showed that both consensus sequences for N-linked 
glycosylation are used, but their function remains unclear.
1.2 GABAa Receptor Function
The model receptor used in this study consists of oti and ßi subunits. The oti subunit is 
expressed in most regions of the brain. In contrast, the ßi subunit is largely confined to 
the hippocampus, but is also expressed in the cerebral cortex and cerebellum, and in 
some cell types in the olfactory bulb (Persohn et a l., 1992; Rabow et a l., 1995). This 
combination provides a simple receptor for a structure function study. It has been 
shown that zinc potently blocks GABA-activated currents in receptors formed by oti and 
ßi subunits coexpressed in HEK 293 cells, but this effect is abolished if the y subunit is 
also present (Draguhn et al., 1990). GABA-activated whole-cell currents in cultured rat 
cerebellar granule cells are blocked by zinc, strongly suggesting that the a ß  subunit 
combination exists without y in native neurons (Kilic et al., 1993).
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Expression of cxi and ßi subunits together produces receptors that respond to GABA in 
a dose-dependent manner and are specifically inhibited by bicuculline and picrotoxin and 
are potentiated by pentobarbital (Schofield et al., 1987; Blair et a l., 1988; Pritchett et 
al., 1988; Malherbe et al., 1990a; Moss et a l., 1991; Porter et al., 1992; Horne et al., 
1993; Birnir et al., 1992, 1995). Receptors composed of only a  and ß subunits do not 
respond to benzodiazepines, as this requires the y2 subunit (Pritchett et a l,  1989; 
Malherbe et al., 1990b; Moss et al., 1991; Horne etal., 1993).
Homomeric receptors composed of either a  or ß subunits expressed separately can form 
in some expression systems but their function is generally limited (Blair et al., 1988; 
Malherbe et al., 1990b; Krishek et al., 1996). Expression of both oci and ßi human 
subunits is required in S fi  cells to produce receptors that respond to GABA and bind 
muscimol (Tierney et al., 1996).
1.3 Molecular Mechanisms of Receptor Function
Ligand binding and channel activation are controlled at a molecular level. Small changes 
in receptor structure can have large effects on the action of agonist and modulation by 
different drugs.
1.3.1 Ligand binding
Agonists: The GABAa receptor contains a recognition site for GABA located in the 
N-terminal extracellular region. A binding pocket for GABA is thought to be located at 
an interface between two subunits, although there is little direct evidence for this (Sigel 
and Buhr, 1997; Smith and Olsen, 1995). GABA binding can be detected with high 
affinity in the nanomolar range, and with low affinity in the micromolar range (Sieghart, 
1992). Micromolar concentrations of GABA are required to produce a chloride current 
in functional receptor studies. Concentrations of neurotransmitter (10 pM to 10 mM) 
can occur in the synaptic cleft that are high enough for binding to the low affinity site 
during normal synaptic transmission (Edgar and Schwartz, 1992). It is now generally 
assumed that GABA exerts its physiological effect by acting at the low affinity binding 
sites and that the high affinity state of the receptor is probably not responsible for the 
chloride current elicited by agonist, but may represent a desensitised form of the GABAa 
receptor (Sieghart, 1992; Edgar and Schwartz, 1992). The functional relevance of the 
high affinity state is not known. It is not clear whether it is a distinct site, separate from
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the low affinity site, or whether it represents an interconvertible conformation (Sigel and 
Buhr, 1997; MacDonald and Olsen, 1994).
It is possible that the very high affinity binding sites detected in many binding studies 
may be due to the low temperature at which these experiments are carried out and may 
not represent a physiological conformational state of the receptor. [?H] muscimol 
binding to rat brain membranes at 0 °C gave two values for the dissociation constant 
(Kd=20 nM and Kd=365 nM) but when the temperature was increased to 22 °C, the high 
affinity component was not seen (Ka=246 nM) (Yang and Olsen, 1987). In 
synaptosomes, low affinity [JH] muscimol binding was detected at 30 °C (Kd=2 pM) 
(Edgar and Schwartz, 1992). The lower binding affinities agree more closely with 
physiological dose-response curves.
A high affinity GABA binding site has been identified on the ß subunit in a [‘'H]muscimol 
binding study of purified GABAa receptors from bovine brain (Casalotti et al., 1986). 
More recently Im et al., (1995b) showed that ocö and ß2 subunit dimers are sufficient to 
bind ßHJmuscimol (Kd=2.5 nM). They do not, however, produce a current in response 
to 20 pM GABA unless coexpressed with either a 6 or y2 subunits, indicating that the 
formation of low affinity sites probably requires the formation of pentameric receptors.
A study by Amin and Weiss, (1993) showed that the apparent affinity for GABA and 
muscimol (but not pentobarbital) is markedly reduced by mutations (Y157F, T160S, 
T202S or Y205F) in the N-terminal region of the ß2 subunit of otiß2y2 receptors. 
Substitution of either asparagine or serine for tyrosine produced a much greater 
reduction in sensitivity to GABA, suggesting that the aromatic ring may be essential for 
GABA activation. Mutation of the corresponding residues in either the a  or y subunit 
did not affect the apparent affinity for GABA or muscimol. These findings are 
consistent with two separate GABA binding domains on the ß subunit which each 
contribute a tyrosine or a threonine essential for activation by GABA.
A phenylalanine residue in the N-terminal region of the oti subunit (position 64) has also 
been implicated in agonist binding (Sigel et al., 1992). In addition, a  homomers can 
respond to GABA but the currents produced are only about 10% of that produced by 
heteromeric aß  receptors (Pritchett et al., 1988). It appears that both subunits are 
probably required for normal GABA binding and receptor activation.
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Pentobarbital: Pentobarbital both potentiates the response to GABA and directly
activates receptors. It shifts the GABA dose response relationship to lower 
concentrations without affecting the maximum current (Akaike et al., 1985; Rho et a/., 
1996). Pentobarbital enhances GABA binding to crude synaptosomal membranes from 
rat brain (Willow and Johnston, 1980). Several studies suggest that pentobarbital may 
facilitate conversion of low-affinity sites to high affinity sites without changing the total 
number of binding sites (Friedman and Redburn, 1990; Yang and Olsen, 1987; Davies et 
a/., 1998). The potentiating effect of pentobarbital has been reported in virtually all 
subunit receptor combinations examined that respond to GABA.
The ability of pentobarbital to directly activate the GABAa receptor occurs through a 
distinct mechanism from GABA (Amin and Weiss, 1993). It appears to depend upon the 
subunits expressed and the expression system used. Pentobarbital activates human otißi 
receptors expressed in mouse fibroblast cells (Horne et al., 1993) and in Xenopus 
oocytes (Sanna et al., 1995) but not in HEK293 cells (Pritchett et al., 1988). 
Homomeric ß receptors are activated by pentobarbital but are largely insensitive to 
GABA (Sanna et al., 1995; Krishek et al., 1996; Cestari et al., 1996).
Bicuculline: Recent evidence from a mutagenesis study by Ueno et al.,( 1997) suggests 
that in addition to its action as a competitive inhibitor, bicuculline may also act as an 
allosteric inhibitor of channel opening. Mutation of Y157S in the ß2 subunit of oc^ Y zl 
receptors (implicated in GABA binding by Amin and Weiss, 1993) resulted in weak 
agonist activity in response to bicuculline. Bicuculline also potentiated the response to 
alphaxalone (an anaesthetic steroid analogue). While it appears that bicuculline and 
GABA probably share some of the same binding determinants, bicuculline also appears 
to be capable of inducing conformational changes in the GAB Aa receptor.
Picrotoxin'. The mechanism of action and location of the picrotoxin binding site are 
controversial (MacDonald and Olsen, 1994). It is thought that picrotoxin acts at the 
level of the chloride channel (Takeuchi and Takeuchi, 1969; Inoue and Akaike, 1988). 
Early evidence for this comes from its ability to reversibly block chloride dependent 
responses to both GABA and ACh in R2 abdominal ganglion cells of Aplysia (Yarowsky 
and Carpenter, 1978). It is not clear whether picrotoxin binds in the channel lumen and 
acts as an open channel blocker by physically occluding ion permeation, or whether it
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inhibits channel function allosterically, or whether it acts by a combination of these 
mechanisms (MacDonald and Olsen, 1994; Xu et al., 1995; Gurley et al., 1995).
Binding experiments have found that unlike bicuculline, picrotoxin does not completely 
inhibit [3H] muscimol binding in rat cerebral cortex membranes, supporting an allosteric 
effect of picrotoxin upon GABA-recognition sites (Supavilai et al., 1982). Picrotoxin 
suppression of GABA-activated currents shows little or no voltage dependence, 
suggesting that it does not act directly within the channel (Yakushiji et al., 1987; 
Newland and Cull-Candy, 1992).
Single channel recordings in rat sympathetic neurons show that picrotoxin reduces the 
probability of GABA channel opening but does not affect burst duration. This is not 
consistent with an open channel block, but may suggest that picrotoxin acts via a 
complex channel block mechanism to stabilise a closed receptor conformation, possibly 
involving allosteric inhibition (Newland and Cull-Candy, 1992). Experiments in 
dissociated rat hippocampal neurons indicate that picrotoxin may act by two separate 
mechanisms, and does not necessarily act as an open channel blocker (Yoon et a/., 1993). 
Picrotoxin use-dependent block is also observed, perhaps indicating that a 
conformational change initiated by GABA binding is required to expose a picrotoxin 
binding site or that the binding site is in the lipid phase. A block is also observed that is 
independent of time and GABA concentration.
Residues in the M2 region have been implicated in the action of picrotoxin. In the 
GABAa receptor in Drosophila, the mutation A2'S in M2 confers resistance to dieldrin 
(a cyclodiene insecticide) (ffrench-Constant et al., 1993). Picrotoxinin and cyclodiene 
insecticides competitively displace each other from the same binding site. 
Electrophysiological studies show that this mutated receptor has reduced sensitivity to 
picrotoxin (Zhang et al., 1994).
Gurley et al., (1995) found that the mutation T6T in p2 subunit M2 region of rat otiß2Y2 
receptors conferred insensitivity to picrotoxin. Use of the substituted cysteine 
accessibility method by Xu et al., (1995) to examine differences in the exposure of 
residues in M2 in the presence and absence of picrotoxin implicated V2' in the oti 
subunit of rat a iß iy2 receptors in the action of picrotoxin. It is not clear whether 
picrotoxin binds in the channel at the level the 2’ residue or whether it binds at a distant 
site and induces conformational changes in the channel region.
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Penicillin: Kinetic analysis of penicillin reduction of single channel GABAa receptor 
currents are consistent with a simple open channel block (Twyman et al, 1992). 
Penicillin decreases the average GABAa receptor current to a greater degree at positive 
potentials, than at negative potentials. The voltage sensitivity of penicillin block 
together with the fact that it is a large molecule (MW=350) suggest that the penicillin 
binding pocket is close to the outer surface of the receptor channel (Twyman et al, 
1992).
1.3.2 Channel-activation and gating
Exactly how conformational changes induced by agonist binding at an extracellular site 
are transmitted to a channel gated located some distance away is not well understood. 
Structural studies by Unwin (1993b, 1995) detected differences between open and 
closed conformations, a-helical structures identified in the membrane-spanning regions 
appear to have a kink in the middle. Unwin infers that this is the M2 region and that a 
highly conserved leucine residue (L9') lies at the level of the kink and that an L9' residue 
from each subunit interacts in a ring formation in the closed conformation to form the 
gate of the channel. The binding of agonist then initiates rotations in the subunits 
relative to one another which are propagated to the membrane-spanning region and 
destabilise the leucine ring. Once rotated, the helices interact with residues around a 
barrel composed of other membrane spanning structures, and a polar face of the helix 
becomes exposed in the channel to allow ion permeation.
Several mutagenesis studies report that when L9' is replaced with smaller polar residues, 
receptors have a high resting conductance (Tierney et al., 1996; Bertrand et a l., 1997; 
Chang and Weiss, 1998) or an increase in the frequency of channel openings in the 
absence of agonist (Labarca et al., 1995; Pan et a l., 1997). These observations are not 
restricted to mutations in this residue alone as spontaneous channel openings in the 
absence of GABA have also been reported in T6'A mutated in GAB Ac receptors 
composed of rat pi subunits (Pan et al., 1997). L9' may occlude the flow of ions in the 
closed channel but does not necessarily form the gate. The findings from several 
mutagenesis studies using nACh receptors suggest the L9’ is involved in gating 
mechanisms but is unlikely to form the gate (Filatov and White 1995; Labarca et a l., 
1995). Cysteine substitution accessibility studies suggest that the gate is at a more 
intracellular location than L9' in GABAa (Xu et a l., 1995) and nACh receptors (Akabas
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et al., 1994). A recent study by Wilson and Karlin (1998) in nACh receptors implicates 
residues at the intracellular end of M2 in the gating mechanism.
There is increasing evidence that residues in several membrane-spanning regions 
influence channel gating properties. It is possible that residues in these neighbouring 
membrane-spanning regions may interact with residues in M2 as the helices rotate. 
Mutation of residues located toward the extracellular end of the M3 region of a.2ßi 
GABAa receptors produces an increase in spontaneous channel openings in the absence 
of agonist (Mihic et al., 1997). Similar results were observed for the glycine receptor. 
An effect of the M3 region upon channel gating has been reported in neuronal nicotinic 
ACh receptors (Campos Caro et al., 1997). Mutations in the M4 region of Torpedo 
californica nACh receptors also alter channel gating (Ortiz-Miranda et a l, 1997). 
Residues in the M2-M3 loop have been implicated in coupling between agonist binding 
and channel activation in neuronal nACh (Campos Caro et al., 1996) and glycine 
receptors (Rajendra et al., 1995; Lynch et al., 1997). These studies show that many 
residues may influence gating, possibly indicating that the gating mechanism is 
structurally more complex than previously thought.
1.3.3 Ion permeation
Ligand-gated receptors in the ACh receptor family have an integral ion channel that 
enables ions to cross the membrane. Ions are predicted to cross the membrane by 
electrodiffusion (Hille, 1992). The idea that channels act as molecular sieves with ionic 
permeability being controlled by molecular size was proposed by Eccles in 1964. This 
was extended in Eisenman’s Theory, that ion-selectivity for channels is based on 
electrostatic interaction between hydrated ions and binding sites in the channel wall 
(Eisenman and Horn, 1983). In the case of anionic channels, anions are transferred from 
water to cationic sites in the channel. The field strength of the binding site and the 
hydration energy of the anion are major determinants of ion permeation (For a review on 
ion permeation see Bormann, 1987). The diffusion path of an ion in a channel can be 
described in terms of energy barriers and wells, whereby ions hop between potential 
energy minima. The hydration shell surrounding an ion creates a barrier to its movement 
into the pore. The ion must therefore shed its surrounding water molecules to move 
through the channel. This is achieved by replacing the water molecules with solvation 
from the wall of the channel (Hille, 1992).
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The mechanism used to transport ions across a pore is generally dependent upon the 
diameter of the pore compared with that of the ion. A minimum pore size of 5.6 Ä is 
predicted for GABAa receptors with at least two binding sites for small anions 
(Bormann, 1987). Residues that are exposed in the channel and are capable of 
interacting with water molecules are potential candidates for providing solvation for ions 
and therefore facilitate ion permeation. Experiments using chimeric nACh receptors 
identified M2 as the most important region for ion conduction (Imoto et al., 1986). 
There is increasing evidence to suggest that residues in the M2 region are exposed in the 
channel in nACh receptors (Revah et al., 1991; Xu and Akabas, 1993, 1996; Akabas et 
al., 1994; Wilson and Karlin, 1998; Pascaul and Karlin, 1998; Zhang and Karlin, 1998).
Xu and Akabas (1993, 1996) used the substituted cysteine accessibility method to 
identify residues in the M2 region of the oti subunit of otißiy2 GABAa receptors that are 
exposed in the pore of the channel. Residues accessible to covalent modification by 
charged, sulfhydryl-specific reagents added extracellularly in the presence and absence of 
GABA included those at the following positions: V2'C, T6'C, T7'C, L9'C, T10C', 
T13'C, I16'C, S17'C, and N20'C.
When this method was applied to the Ml region of nACh receptor, it was found that 
residues located toward the extracellular end of this region are exposed in the channel 
(Akabas and Karlin, 1995; Zhang and Karlin, 1997). This is supported by earlier 
evidence that the M l region can be labelled by photoactivatable [3H] quinacrine azide, a 
channel blocker (DiPaola et al., 1990).
The receptor mechanism for selecting between cations and anions is not well understood 
(eg. Galzi et al., 1992). However, the conductance of ions has been examined in nACh 
(Imoto et al., 1988; Villarroel et al., 1992; Herlitze et al., 1996) and glycine receptors 
(Bormann et a/., 1993) and the M2 region is implicated. A study by Tierney et a l., 
(1998) investigated the role of several polar residues in the M2 region (6', 10' and 13') 
of otißi GABAa receptors in anion conductance. Receptors that had the TIO'A 
mutation in both subunits responded to GABA but those that had either the T6'A or the 
T13'A mutation in both subunits produced receptors that do not respond to GABA, but 
were expressed in the plasma membrane at wild type levels. In T13'A mutated receptors 
high affinity muscimol binding was abolished. These results are consistent with the
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involvement of the threonine side chain of T6' and T13' in interactions with chloride ions 
that are critical for ion permeation.
1.3.4 Desensitisation
Receptors activate in response to agonist, in its continued presence receptors desensitise 
and deactivate. In whole-cell recordings agonist application results in a transient, rapid 
increase in current which reaches a maximum and then declines to a steady state level in 
the continued presence of agonist (Nicholls et a/., 1992). The reduction in maximal 
current reflects conversion of receptors to a high affinity desensitised state. Sensitivity 
to agonist returns seconds or minutes after the removal of agonist as receptors recover 
from desensitisation (Hille, 1992). It has long since been realised that the size of the 
peak current and the rate of onset of desensitisation are proportional to the agonist 
concentration. Experiments in cultured rat cortical neurons at the single channel level 
show that desensitisation decreases the single channel open probability (Frosch et a/., 
1992).
Desensitisation is an intrinsic property of most receptors, but its physiological 
importance and the underlying molecular mechanisms are not known (Nicholls et al., 
1992). It was originally postulated by Adams (1975), that “desensitisation results from 
the agonist molecule itself entering and blocking the open endplate channel”. More 
recent evidence from structural studies suggests that conformational changes in the 
receptor both in the extra-cellular binding region and in the membrane spanning regions 
may underlie the functional desensitised state(s) (Unwin, 1995). Structural changes in 
different functional states using Fourier transform infra-red (FTIR) difference 
spectroscopy found that channel inactivation that occurs during desensitisation may be 
predominantly due to a conformational change in the agonist binding pocket which could 
render the binding site incapable of initiating channel activation upon agonist binding 
(Baenziger and Chew, 1997).
In ligand-gated ion channels desensitisation provides a mechanism to shut down channels 
for long periods during excessive stimulation, presumably with agonist still bound 
(Huginar and Greengard, 1990; Hille, 1992; Jones and Westbrook, 1996). There is 
evidence that desensitisation may prolong rather than limit synaptic currents in GABAa 
receptors cultured hippocampal neurons (Westbrook and Jones, 1995).
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Desensitisation is dependent upon the subunit composition of receptors but differing 
subunit effects have been reported. Addition of the y2 subunit to a ß  subunits increases 
the rate of desensitisation in some studies (Dominguez-Perrot et a/., 1996; Tia et a/., 
1996) and reduces it in others (Verdoorn et al., 1990). Addition of the 72 subunit to 
human a jß i subunits expressed in S f)  cells slowed the rate of desensitisation (B. Cromer 
personal communication).
Intracellular phosphorylation may also play a role in the regulation of desensitisation and 
other cellular functions as all GABAa subunits contain consensus sequences for 
phosphorylation (For review see Stelzer, 1992).
Mutagenesis studies suggest that amino acid residues in the M2 region may be involved 
in the desensitisation process (Devilliers-Thiery et al., 1992; Im et a l., 1995a). 
Mutations at the leucine 9' position in the M2 region of nACh, 5-HT3 and GABAa 
receptors are shown to affect desensitisation and gating, as well as to increase the 
affinity for agonist (Revah et al., 1991; Yakel et a l., 1993; Labarca et a l., 1995; Tierney 
et a l., 1996). The L 9T  mutation in neuronal a-; ACh receptors also produces an 
additional conducting state at low concentrations of agonist. It is thought that a high 
affinity desensitised state has become permeable to ions, which would normally be 
prevented by a leucine from each subunit moving into the pore during desensitisation to 
occlude ion permeation (Revah et al., 1991).
In the following chapters the role of M2 in desensitisation and receptor function is 
investigated further.
• Chapter 3 investigates the role of L9’ in GAB A-activation and desensitisation.
• Chapter 4 identifies T12’ in the action of pentobarbital.
• Chapter 5 finds subunit differences in GABA-activation when T13’ is mutated.
• Chapter 6 examines the role of residues in the M l region in channel function.
Chapter Two
2. Methods
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2.1.1 Sf9-bacuIovirus expression system
The 6y9-baculovirus expression system was used to express human a iß i GABAa 
receptors, oti and ßi subunits used in this study will be referred to as a  and ß where 
possible. Previous functional studies indicate that this is a suitable system to use to 
investigate the structure and function of these receptors (Birnir et al., 1992, 1995, 
1997b; Tierney eta/., 1996, 1998).
The small size of S fi  cells, 10-15 pm in diameter makes them particularly suitable for 
whole-cell patch clamping because the solution around a cell can be changed rapidly. 
Fast solution exchange is required to measure decay rates of whole-cell currents under 
non-equilibrium conditions. Fast, simultaneous activation of receptors around the cell 
allows a more accurate estimate of the rate of desensitisation of receptors. The small 
size of the cells also reduces error associated with series resistance.
2.1.2 Receptor expression
Receptor expression refers to the protein produced by the cell. The level of a  subunit 
present in the plasma membrane was detected using an oti subunit specific monoclonal 
antibody (bd24) that binds in the extracellular domain. An antibody against the ß 
subunit was not available. It has been shown that a  and ß subunits must be expressed 
together in SJ9 cells in order to form receptors that bind muscimol (Tierney et al., 1996). 
Muscimol binding assays were therefore used to assess any changes in the level of a  and 
ß subunit assembly.
It should be noted that if receptors do not respond to GABA then both the presence of 
the a  subunit in the plasma membrane and muscimol binding must be detected to 
determine whether the subunits being expressed have assembled into pentamers.
Methods followed for expression of receptors using the baculovirus expression system 
are from King and Possee, 1992; O’Reilly et al., 1992 and Bishop, 1994 (in Gould, 
1994). The steps involved in the production of mutated receptors are summarised.
• Design of appropriate oligonucleotides to use as selection and mutagenic primers.
• Mutagenesis of either a  or ß subunit cDNA and restriction digestions to select for 
mutant plasmids.
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• Screening and identification of mutants by DNA sequencing.
• Mutation of plasmids in both subunits followed by DNA sequencing.
• Production of recombinant baculovirus by cotransfection and generation of PI virus.
• Detection of protein expression by Western blot.
• Propagation of virus to obtain high titre working stocks.
• Quantification of virus titre by plaque assay.
• DNA sequencing in from virus 
These steps are detailed in section 2.2.
The procedures used for flow cytometry experiments to detect the level of subunit 
expression are detailed in section 2.3.
The method used to measure high affinity muscimol binding is detailed in section 2.4.
The culture of SJ9 cells is detailed in section 2.6.
The equipment and solutions used for patch clamp experiments are described in section 
2.7.
Principle definitions and equations are given in sections 2.7.9 and statistical tests in 
section 2.7.10.
2.2 Molecular Biology
The composition of different solutions used are shown in section 2.5 for reference.
2.2.1 Site-directed mutagenesis
a  and ß human GABAa cDNA sequences in the dual promoter baculovirus transfer 
vector pAcUW31 (Clontech) were used. This plasmid is 11.3 kb in size. The oti protein 
was expressed under the P10 promoter and the ß under the polyhedrin promoter. 
Double stranded mutagenesis was used to introduce site-directed mutations to either a  
or ß human GABAa cDNA sequences (U.S.E. Mutagenesis Kit, Pharmacia Biotech). 
This unique-site elimination method was developed by Deng and Nickoloff (1992). It 
was used because it does not require the sub-cloning steps that are required with single 
stranded DNA methods. The methods used to produce 9 different mutated receptors are 
explained in this chapter.
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The remaining 5 receptor mutations were made by M.L. Tierney using single stranded 
DNA in M13 phage derivatives with the “Oligonucleotide directed in vitro mutagenesis 
system” from Amersham.
2.2.2 Oligonucleotide design and preparation
Oligonucleotides were designed according to criteria outlined in the U.S.E. Mutagenesis 
Kit and in Sambrook et al., (1989). Sequences were checked using the program 
"Amplify 1.2" (Macintosh) to search for additional non-specific binding sites on the 
plasmid. Oligonucleotide were synthesised at the Biomolecular Resource Facility, John 
Curtin School of Medical Research, Australian National University. Oligonucleotides 
were phosphorylated at the 5' end to ensure ligation with the 3' end of the newly 
synthesised DNA strand. They were obtained suspended in ammonium sulphate and 
subsequently freeze-dried under vacuum then resuspended in TE 1/10 buffer. 
Alternatively butanol precipitation was used. The DNA concentration was estimated 
from the UV light absorbence measured at 260 nm on a spectrophotometer (U-1100 
Hitachi, Ltd. Tokyo, Japan).
2.2.3 Mutagenesis reaction
Two oligonucleotides were used as primers in the mutagenesis reaction. A mutagenic 
primer was used to change one or two bases so that the amino acid coded for at a 
specific position was changed. A second primer was used as a selection primer in order 
to eliminate a unique non-essential Seal restriction enzyme site. It was changed to a 
Stul site. Oligonucleotide sequences are shown in Table 2.1.
The reaction mixture contained 0.025 pmoles plasmid DNA, 1.25 pmoles selection 
primer, 3 pmoles, target mutagenic primer, lOx One-Phor-All Buffer PLUS (Pharmacia) 
and d.H20. These were combined in a sterile centrifuge tube in total volume of 20 pi. 
The mixture was heated at 100 °C for 5 minutes to completely denature the DNA. It 
was then chilled quickly on ice for 5 minutes to favour annealing of single stranded DNA 
to the primers, rather than to the complementary DNA strand. This mixture was 
incubated at room temperature for 30 minutes. Nucleotide mix (7 pL) containing: 
dATP, dCTP, dGTP, dTTP, and ATP; and reaction mix (3 pL) containing: T4 DNA 
ligase, T4 DNA polymerase, and T4 gene 32 protein were added and the mixture was 
incubated at 37 °C for 60 minutes. The reaction was stopped by heat inactivating T4
Mutation Oligonucleotide sequence binding region
Seal —> Stul CTT GGTT GAGGCCT C ACC AGT C AC fwd (9596 bp)
Bgl2 —> Seal CCTC AT AGT ACT GT GATT GT AAAT fwd (3922 bp)
<x(L9T)ß GT CAT GGT G AAC AC AGTT GTT ACT CC rc M2 (3047 bp)
otß(L9'F) CGACGGT GTTT AC AAT GAC AACC fwd M2 (5135 bp)
oc(L9'Y)ß GT CAT GGT GT AC AC AGTT GTT ACT CC rc M2 (3047 bp)
aß(L9'Y) CGACGGT GT AT AC AAT GAC AACC fwd M2 (5135 bp)
a(Y231L)ß C ATT AT GC AT GGC AGG AGT GTTT G AAT AA 
CAAAGTAGCC
rc Ml (3139 bp)
ocß(Y226L) GC AAACCTT GAT GCCTTCT AC AC fwd M l (5037 bp)
Table 2.1 Oligonucleotides sequences used for site-directed mutagenesis
Oligonucleotide sequences used as primers to introduce mutations in either a  or ß human 
GABAa cDNA sequences in the dual promoter baculovirus transfer vector pAcUW31 
are shown. The amino acid changed and its position are indicated in brackets, after the 
subunit to which the oligonucleotide bound. The codon for the new amino acid or 
restriction enzyme site is underlined. The start of the primer binding region is indicated 
for cDNA specific forward (fwd) and reverse complementary (rc) primers. The subunit 
region mutated is indicated in brackets.
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DNA ligase at 75 °C for 20 minutes. It was then placed on ice for 5 minutes until the 
restriction enzyme digestion.
2.2.4 Primary restriction enzyme digestion
Plasmids in which the selection primer had bound during the annealing reaction would 
have a Stul site instead of a Seal site. Seal was used to linearise plasmids that did not 
contain the Stul -> Seal selection mutation. The restriction enzyme digest mixture 
contained: lOx one-phor-all buffer plus (Pharmacia), 10 units of Seal and d.H20 in a 
total volume of 35 pi. This was incubated at 37 °C for 2 hours in a dry heat block then 
either placed on ice, or heat inactivated and stored at -20 °C until the transformation 
procedure.
2.2.5 Transformation into MutS E. coli strain
Plasmid DNA was transformed into a repair-defective strain of E.coli (Mut S 
BMH71-18). The transformation procedure selected against plasmid DNA that had 
been cut by Seal because linear DNA is transformed 100 - 1000 times less efficiently 
than circular DNA. Thus, plasmid DNA that did not contain the selection mutation was 
selected against, increasing the ratio of mutant plasmids to wild type plasmids. This 
assumes that plasmids containing the selection mutation were also bound by the 
mutagenic primer. The probability of this occurring during the annealing reaction was 
increased by adding two-fold more mutagenic primer than selection primer.
1 ml of chilled (4° C) sterile filtered 0.1 M CaCl2, was added to an aliquot of frozen 
CaCl2 competent MutS cells after they had thawed on ice for 5 minutes. 200 pL of the 
diluted cells were added to 20 pL of the digested plasmid DNA from the mutagenesis 
reaction and placed on ice for 30 minutes. The cells were heat shocked for 45 seconds 
at 42 °C. The tube was cooled on ice for 2 - 5 minutes then filled with SOC medium 
and incubated at 37 °C for 45 minutes. Cells and plasmid DNA were transferred to a 
sterile conical culture bottle containing 3 ml of SOC supplemented with 20 mM glucose 
and 100 pg/ml ampicillin (sodium ampicillin, Fisons Pharmaceutical’s, Sydney, 
Australia), then incubated overnight in an air-shaker at 37 °C.
2.2.6 Isolation of plasmid DNA
Plasmid DNA was routinely isolated by mini-preparation using a Bresa-clean nucleic 
acid purification kit (Bresatec, Adelaide, SA). An E.coli culture was grown to the
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stationary phase in 2 - 5 ml liquid media (Luria Bertani media, SOC, or Terrific Broth), 
from 3 hours to overnight. 1 - 1.5 ml of liquid culture (depending upon the cell density) 
was transferred to a sterile centrifuge tube, centrifuged and the supernatant completely 
removed. The cell pellet was vortexed to resuspend the cells in 200 pL of cell 
resuspension solution. 200 pL of cell lysis solution was added and the contents mixed 
gently by inverting and rotating the tube. 200 pL of neutralisation solution was added
and the contents mixed in a similar manner. The tube was centrifuged at 14,000 rpm for 
5 - 1 0  minutes to pellet the white precipitate. The supernatant (500 pi) was removed 
and added to 500 pL sodium iodide solution and 5 pL binding resin, which was 
incubated at room temperature for 5 minutes in the dark. The resin and DNA were 
pelleted by a brief centrifugation and the supernatant was removed completely. The 
pellet was washed by soaking it in wash solution (Tris-EDTA buffer in 50% ethanol) for 
five minutes at room temperature followed by centrifugation. This was repeated 3 times. 
The pellet was then dried in a desiccator under vacuum for 15 - 20 minutes or in a 
vacuum centrifuge for 5 minutes. The binding resin plus DNA were resuspended in 
50 pL TE/10 or distilled water and incubated in a 45 - 55 °C water bath for 5 minutes, 
then centrifuged for 1 minute. The supernatant containing plasmid DNA was removed 
immediately and placed in a sterile centrifuge tube.
2.2.7 Secondary restriction enzyme digestion
Following DNA extraction, a second restriction digest was performed with Seal to 
further increase the proportion of mutant plasmids in the population. The digest mixture 
contained: 2 pi of purified plasmid DNA, lOx Boehringer buffer H, 10 units of Seal 
restriction enzyme and d.H20 in a total volume of 40 pi. This was incubated at 37 °C for 
2 hours. An additional 10 units of Seal was added and the incubation continued for 
another 2 hours. The digest mixture was placed on ice for five minutes or heat 
inactivated and stored at -20 °C until the transformation.
2.2.8 Transformation into E. coli strain XLl-blue
Plasmid DNA was transformed into XLl-blue to recover plasmid DNA from the pool of 
transformants using the same procedure as described for the transformation in MutS 
(section 2.2.5). Transformants were grown over night at 37 °C on agar plates 
containing: Luria Bertani (LB) media, 2 % agar (Bacto-Agar Difco Laboratories,
Detroit, Michigan, USA), 40 mM glucose, 15 pg/ml tetracycline and 200 pg/ml
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ampicillin. Eight colonies were streaked onto another agar plate and grown overnight as 
before. A small amount of each was used in a colony cracking gel to check that the 
correct sized plasmid was present before purification of the DNA (11.3 kb).
2.2.9 Colony cracking
A small amount of each colony was added to 40 pi colony cracking dye in a centrifuge 
tube. The cells were vortexed and incubated in a 75 °C water bath for 20 minutes. 
After one minute of centrifugation 15 pi of each sample was loaded on a 0.8%  
TAE/agarose gel. Colonies with the same sized plasmid as wild type were grown in 
liquid culture (Luria Bertani media, SOC or terrific broth, supplemented with 20 mM 
glucose and 100 pg/ml ampicillin) from 3 hours to overnight depending upon the amount 
of inoculum used.
2.2.10 Identification of mutant plasmids
Plasmid DNA was extracted as previously described using a Bresaclean DNA 
purification kit. Colonies were screened using restriction enzyme cuts. Stul was used 
to positively identify the plasmids that contained the selection mutation. Seal was used 
as a negative selector to identify plasmids that no longer contained a Seal site. Plasmids 
containing the selection mutation cut twice with Stul (4.1 kb and 7.2 kb fragments) and 
not at all with Seal. Those that the selection primer had not bound cut once with Stul 
and once with Seal. This screening procedure assumes that if the selection primer has 
bound then it is probable that the mutagenic primer has also bound.
Three of the plasmids that contained an additional Stul site were sequenced. Restriction 
enzyme digestion mixes contained: lOx buffer (recommended Boehringer buffer for
enzyme), 0.5 units of restriction enzyme, and water in a 15 pi volume. They were 
incubated at 37 °C for 90 - 120 minutes. SDS dye lysis buffer (5 pi) was added and 
samples run on a 1 % TAE/agarose gel (Type II: Medium EEO, Sigma). A 1 kb 
standard dye marker (Gibco) was used to determine fragment sizes.
2.2.11 DNA sequencing
The presence of each mutation was confirmed by DNA sequencing across the mutagenic 
primer binding region. Automated DNA sequencing was routinely carried out using an 
ctABI PRISM™ Dye Terminator Cycle Sequencing Ready Reaction Kit with 
AmpliTaq^DNA Polymerase, FS” (Perkin-Elmer). The labelling reaction included, 8 pi
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terminator ready reaction mix, 0.7 fig double stranded DNA template, 6 pmoles forward 
primer and d.H20 in a total volume of 20 pi. Sequences o f oligonucleotides used as 
primers in the sequencing reactions are shown in Table 2.2.
The reaction mixture was prepared for sequencing by overlaying with one drop of light 
mineral oil and amplification carried out on a DNA Thermal Cycler (Perkin Elmer/Cetus, 
Perkin Elmer Corporation, Norwalk, Connecticut, USA). Thermal cycling was carried 
out as follows: 96 °C for 30 seconds, 50 °C for 15 seconds, and 60 °C for 4 minutes. 
This was repeated for 25 cycles then held at 4 °C. The extension products were purified 
by ethanol precipitation which was sometimes preceded by spin column purification 
(QIAquick PCR Purification Kit, Qiagen Pty. Ltd., Victoria.). DNA was sequenced at 
the Biomolecular Resource Facility, Australian National University, Canberra. Colonies 
which contained the correct mutation were made into glycerol stocks and stored at 
-20 °C. Cells were grown on agar plates overnight then suspended in 33% glycerol and 
66% LB media in sterile centrifuge tubes and stored at -70 °C.
Mutations at the L9' position in M2 were also sequenced directly from working virus 
stocks (refer 2.2.22).
2.2.12 Methods used to obtain double mutants
Plasmids containing mutations in both a  and ß subunits (double mutations) were 
obtained by several different methods. Initially the procedures described for the single 
mutations were followed but the mutations were not incorporated. It is likely that the 
two oligonucleotides may have annealed to each other rather than to the denatured 
plasmid due to the high degree of sequence homology shared between the a  and ß 
sequences in the M2 region. Methods that did not require the addition of both 
mutagenic primers in the same reaction were used.
2.2.13 Method 1: mutagenesis using a plasmid mutated in the a subunit
A plasmid previously mutated in the a  subunit cDNA was used as a template in a 
subsequent mutagenesis reaction to mutate the homologous residue in the ß subunit. In 
the initial mutagenesis to obtain a single mutant a unique Seal site had been eliminated, 
therefore a different unique restriction enzyme site had to be removed. A Bgl2 site was 
mutated to a Seal site. The oligonucleotide sequence used is shown in Table 2.1. The 
procedure followed was the same as for the single subunit mutations. The greatest
Oligonucleotide sequence Primer Specificity Region
T AAGCC ACCTT AAGT AGGGAGTTT C a  fwd M l (3002 bp)
GTTATGACCACTCATTTCC a  fwd M2 (3195 bp)
GGAGCGT AT CC ACGACT ß fwd M2 (4975 bp)
Table 2.2 DNA sequencing primers for a  or ß GABAa cDNA
Oligonucleotides used as primers to initiate DNA sequencing reactions are shown. The 
start of the primer binding region is indicated for cDNA specific forward (fwd) primers 
in M l and M2 regions of each subunit. The ß cDNA specific forward primer was used 
to sequence oligonucleotide binding regions for mutations carried out in both M l and 
M2 transmembrane regions.
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distance between the binding sites for the mutagenic and selection oligonucleotides was 
10.1 kb. This large distance could reduce the probability that synthesis of a 
complementary strand would occur around the entire 11.3 kb plasmid. In order to 
prevent this from occurring an oligonucleotide was added to the mixture which reduced 
the greatest distance between oligonucleotide binding sites to 5.7 kb, but did not change 
any bases in a  or ß subunit coding regions.
2.2.14 Method 2: Restriction enzyme digestion, gel purification and ligation of
mutated fragmen ts
Plasmids mutated in either the a  subunit (a*ß) or the ß subunits (aß*) were cut with 
Bgl2 and Nhel restriction enzymes in buffer “M” (Boehringer). This produced a 9.9 kb 
fragment containing the a  subunit sequence and a 1.4 kb fragment containing most of 
the ß subunit sequence.
Fragments were gel purified then run on a 1% TAE/agarose gel. The gel was stained in 
ethidium bromide for five minutes then quickly photographed on a UV light box to 
locate the appropriate sized bands. A 9.9 kb fragment containing the a  subunit sequence 
was removed from plasmids mutated in the a  subunit (a*ß) and a 1.4 kb fragment wras 
removed from plasmids which contained the homologous mutation in the ßi subunit 
(aß*). DNA from the excised bands was purified using a Bresa-Clean gel purification 
kit. The gel was then rechecked under UV light to ensure that the correct sized bands 
had been removed. An approximate 1:5 ratio of plasmid-to-insert (9.9 kb : 1.4 kb) was 
used in the ligation reaction. These quantities were estimated visually from the 
brightness of the bands on the gel. Purified fragments were incubated in 5x ligation 
buffer at 13 °C overnight then transformed into XL 1-blue, grown on LB agar plates, and 
incubated overnight. Colonies were streaked out and a colony cracking procedure 
carried out on each to check that the fragments had ligated to form an 11.3 kb sized 
plasmid. Three to five colonies for each ligated plasmid were DNA purified and then 
sequenced to confirm that both subunits contained the correct mutation.
2.2.15 Method 3: Restriction enzyme digestion and ligation of mutant fragments 
The third method was a variation on the second. It was similar in that it involved a 
series of restriction enzyme cuts and a ligation, but differed in that it did not require gel 
purification of the DNA fragments. Bgl2 and Nhel enzymes were used to give a 9.9 kb
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fragment containing the a  subunit and a 1.4 kb fragment containing a portion of the ß 
subunit sequence which contained the mutated bases as before. However rather than gel 
purifying these fragments additional restriction enzymes digestions were carried out to 
cut the fragments containing the non-mutated cDNA into three pieces which would have 
a low probability of ligating together. a*ß was cut with Ncol and Pstl to cut the 
fragment containing the wild type ß subunit (1.4 kb) into three fragments (0.202, 0.424 
and 0.760 kb). The aß* plasmid was cut further with Stul to cut the wild type a  
subunit containing fragment (9.948 kb) into 3 pieces (0.216, 4.075 and 5.657 kb).
a*ß  and aß* digests were ligated together as described for method 2. When the ligated 
mixture was transformed, unligated digests were used as controls. Colony crackings 
were then performed on a selection of colonies from each transformed mix to screen for 
an 11.4 kb plasmid. If the number of ligated colonies showing the correct sized plasmid 
was greater than the total number of controls it would indicate that ligation of a*ß* 
together was favoured ahead of other arrangements. Three to five colonies were DNA 
purified and sequenced.
2.2.16 Production of recombinant baculovirus
Recombinant baculovirus was produced using “BacPAK6” baculovirus DNA (Clontech, 
Palo Alto, CA, USA). The viral DNA had already been linearised by restriction with 
Bsu36I in order to remove a fragment that includes part of an essential gene. The 
unrecombined large Bsu36I fragment of BacPAK6 is unable to produce viable viruses. 
The cotransfection procedure involves transfection of transfer plasmid DNA 
(pAcUW31) into Sf9 cells along with linear viral DNA. During homologous 
recombination of the plasmid and viral DNA a target gene is transferred from the 
transfer vector to the viral genome and is able to restore the integrity of an essential gene 
in the virus. This method results in a very high percentage of viral plaques containing 
recombinant viruses that have acquired the target gene.
4
A 35 mm tissue culture well was seeded with 150 x 10 Sf) cells growing at a density of
4
50 to 70 x 10 . Cells were incubated at 27 °C for 1 to 2 hours. The media was removed 
and 2 ml of serum-free Grace's Insect Media added (containing lactalbumin and 
yeastolate, but no foetal bovine serum), swirled gently, removed and 2 ml of serum-free 
media added. This was incubated at room temperature for 10 - 30 minutes. Mutated
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plasmid DNA was prepared by minipreparation purification with either a Bresaclean or a 
Jetstar DNA purification kit. DNA was diluted to 100 pg/ml in d.H20 and sterile filtered 
(Millipore 0.22 pm filter). 5 pi of plasmid DNA was then added to 5 pi BacPAK6 viral 
DNA (Bsu36I-digested, Clontech Laboratories Inc., USA) in a sterile polystyrene tube 
containing 40 pi d.H20. 50 pi of lipofectin (the transfection reagent) was added to the 
DNA mixture and incubated at room temperature for 15 minutes. The media was 
removed from the Sf) cell monolayer and 1.5 ml of serum free media added. 
Transfection reagent-DNA mix was added drop-wise to the plated cells, then incubated 
at 27 °C for 5 hours, or overnight. 1.5 ml of complete media was added then plates 
were sealed with parafilm and incubated at 25 ±2 °C for 72 hours. The media was 
removed and stored at 4 °C in sterile tubes. 1.5 ml of complete media was added and 
cells incubated a further 2 days before the medium was harvested. Plaque assays were 
then performed with the cotransfection supernatant to determine the virus titre.
2.2.17 Isolation and selection of recombinant baculovirus by plaque purification 
Individual plaques were isolated and used to produce PI virus stocks. Different 
concentrations of supernatant were used in the plaque assay to give very low numbers of 
virus particles so that only isolated cells would become infected. An agarose overlay 
was used to limit the spread of virus particles so that only adjacent cells would become 
infected. After several cycles of infection these formed a plaque that was isolated and 
used to propagate the virus.
Sf) cells were seeded at 1.5 x 10 cells/ml in 35 mm, 6 well plates containing 1 ml of 
supplemented Graces Insect Media. These were placed on a rocker for 60 minutes to 
allow the cells to adhere to the surface and form an even monolayer. The co-
-1 -2 -3
transfection supernatant was serially diluted to 10 , 10 , and 10 in serum free media. 
The media was removed from each well and 1 ml of each supernatant concentration 
added to separate wells in duplicate. Cells were placed on a rocker at room temperature 
for 90 minutes. The supernatant was removed and the cells overlaid with 3% sea plaque 
agarose in supplemented Grace’s media. Once this had solidified, each well was overlaid 
with 1 ml of supplemented media. The plate was sealed with parafilm and incubated at 
25 ± 2 °C for 5 days.
Plaques were chosen from wells which showed 10 well isolated plaques. It was usually 
necessary to stain the cell mono-layer in order to visualise the plaques. Cells were
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stained with 0.5% w/v neutral red, diluted 1/20 in phosphate buffered saline (PBS). 
Each well was overlaid with 1 ml of dye solution and incubated at 25 ± 2 °C for 1 hour. 
The liquid overlay was then removed and plates incubated overnight. Plaques appeared 
as clear patches in a background of red cells. Individual plaques were chosen from wells 
containing 10- 15  well isolated plaques. Sterile Pasteur pipettes were used to pick 
plugs of clear plaques which were expelled into individual sterile centrifuge tubes 
containing 1 ml of media.
2.2.18 Generation o f  PI virus stocks
An individual infectious virus plaque plug was used to inoculate a flask of cells to
6
generate a pure PI virus stock. Cells were seeded at 1.5 x 10 cells/ml in a 5 ml flask 
containing 2 ml of complete Grace’s Insect Media and placed on a rocker for 20 
minutes. The media was removed and the contents of a tube containing a plug from a 
plaque assay was added. This was placed on a rocker for 90 minutes then the media was 
replaced with 5 ml of fresh media. Flasks were incubated at 25 ± 2 °C for 6 days after 
which the supernatant (PI virus stock) was removed and stored in a centrifuge tube at
4 °C.
2.2.19 Detection o f protein expression using electrochemiluminescence
PI virus stocks were screened by Western blot analysis to check for GABAa receptor 
expression in infected cells. Immunoreactivity to the GABAa receptor was detected by 
electrochemiluminescence (ECL™ Western Blotting Detection Reagents, Amersham Life
Sciences, Buckinghamshire, England) using double anti-body labelling. 1 x 10 cells 
were plated on a 96 well plate and infected with 40 pi of PI virus supernatant for 90 
minutes on a rocker at room temperature. The supernatant was replaced with 200 pi of 
media and incubated at 25 ± 2 °C for 40 hours. Cells were resuspended in media and 
transferred to sterile 1.5 ml centrifuge tubes. Cells were pelleted by centrifugation, 
washed in PBS and resuspended in 50 pi of sample buffer. Cells were boiled for
5 minutes and pelleted. 20 pi of supernatant from each sample was loaded on a 10% or 
an 8 - 16% Tris-glycine gel (Novex, San Diego, CA, USA) and the protein separated by 
electrophoresis. The separated protein was transferred to a PVDF membrane filter 
(0.2 pm pore size, Novex San Diego, CA, USA) so that it could be exposed to an 
antibody against the GABAa receptor. The PVDF membrane was soaked briefly in
31
methanol, rinsed well in distilled water, and submerged in semi-dry buffer together with 
the gel. Six layers of filter paper were presoaked in semi-dry buffer and placed on the 
bottom electrode. The PVDF membrane was placed on top of this, followed by the gel 
and an additional six layers of presoaked filter paper. The gel transfer apparatus 
(Pharmacia, LKB, Novablot, Sweden) was set at 50 mA for one hour.
The PVDF membrane was rinsed in distilled water. Non-specific sites were blocked by 
immersing the membrane in blocking solution on a rocker for 10 minutes. The 
membrane was incubated in a primary monoclonal antibody (bd24) against the oti 
subunit of the GABAa receptor (diluted 1/1000 in blocking solution) on a rocker at 4 °C 
overnight. The membrane was rinsed 4 times in TBS, then washed for 5 minutes. This 
wash procedure was repeated 3 times. It was then incubated in secondary antibody, 
peroxidase conjugated rabbit anti-mouse immmunoglobulin (Dako A/S, Denmark) 
(diluted 1/200 in TBS) for one hour at room temperature on a rocker. The membrane 
was rinsed in TBS as before, then washed once for 15 minutes, twice for 5 minutes and 
then for one hour. The light produced by the chemiluminescence reaction from the 
oxidation of the secondary antibody label was detected by adding equal volumes of the 
two detection reagents to the surface of the membrane for one minute. The membrane 
was wrapped in plastic cling film and exposed to blue-light sensitive autoradiography 
film for 3, 10 or 30 seconds. The film was developed and bands identified that 
corresponded to the band for wild type. These PI viruses were used to generate high 
titre working stocks of virus.
2.2.20 Propagation of virus to obtain working stocks
A P2 viral stock was grown by inoculating a large volume of cells (50 - 100 ml) with PI 
virus. A P3 viral stock was propagated similarly from P2. Cells were grown from a
. 5 5
density of 1 . 5- 2  x 10 cells/ml up to 5 x 10 cells/ml in suspension culture, then 
infected at a multiplicity of infection (MOI) of approximately 0.1 - 0.2 pfu/cell by adding 
the required volume of virus stock. Virus titre was determined by plaque assay. Titres
7
of the PI virus stocks were approximately 3 - 4 x 10 pfii/ml. Titres of the P2 and P3
7 8
virus stocks ranged from 1 x 10 to 1 x 10 pfii/ml. Working stocks of virus (P2 and 
P3) were used for flow cytometry, confocal microscopy, muscimol binding and 
electrophysiological experiments.
32
2.2.21 Quantification of virus titre by plaque assay
The titre of P2 virus stocks were determined by plaque assay. The procedure followed 
was similar to that described for isolation of recombinant baculovirus by plaque
-5 -6
purification (cf. 2.2.17) except that PI virus stocks were serially diluted to, 10 , 10 ,
-7 -8
10 and 10 in media. Wells which contained between 5 and 30 plaques were used to 
estimate the number of pfu\ml for each PI virus. The number of plaques formed was 
averaged between duplicates.
2.2.22 DNA sequencing directly from baculovirus working stock
Mutations carried out at the L9' position in the M2 region were rechecked by 
sequencing directly from working virus stocks. A 300 base pair fragment flanking the 
mutated region in either the a  or ß subunit was amplified by polymerase chain reaction 
(PCR) using a Tbr^BeadM Hot Start Polymerase kit (Promega, Madison, WI, USA). The 
forward and reverse primers used are shown in Table 2.3. They were checked for 
specificity of binding using the Amplify 1.2 program (Macintosh).
Viral DNA was prepared by adding 20 pi of virus to 80 pi d.H20 and boiling the mixture 
for 10 minutes, then pelleting the denatured protein. The reaction was carried out at 
varying concentrations of MgCl2 in order to optimise the amount of free magnesium in 
the PCR reaction mix. The concentration of MgCl2in the Grace’s supplemented insect 
medium, in which the virus was suspended, was taken into consideration and the 
appropriate volume of diluted virus supernatant added. The amplification reaction 
consisted of: lOx reaction buffer, 0.2 mM each of; dATP, dGTP, dTTP, and dCTP, 
100 ng each of downstream and upstream primers (Table 2.3), 1.5 mM or 2.0 mM 
MgCl2 and template viral DNA in a 50 pi volume. One paraffin wax bead containing 
TaqDNA. Polymerase was added per reaction tube. The enzyme is retained in the bead 
until the wax melts at approximately 60 °C. This decreases the probability of non­
specific priming which can occur at low temperatures once all the PCR reaction 
components are mixed. The reaction mixture was overlaid with one drop of light 
mineral oil. The following thermal cycling profile was applied: denaturation at 96 °C 
for 5 minutes in the first cycle, and 1 minute in subsequent cycles, annealing at 55 °C for 
2 minutes, and extension at 72 °C for 1 minute. This was repeated for 40 cycles ending 
with a 10 minute extension on the last cycle then held at 4°C. The PCR products were 
run on a 1% TAE/agarose gel to check for the presence of the 300 base pair amplified
Oligonucleotide sequence Primer Specificity Region
GTT AT GACC ACTC ATTT CC a  5'(3195 bp)
TAGTGAAATAGTTTACTGTGG a  5'(2915 bp)
GGAGCGTATCCACGACT ß 5' (4975 bp)
TT AC AAAGGC AT ACT CC AGC AG ß 3 '(5254 bp)
Table 2.3 Oligonucleotides used in PCR reactions to amplify a or ß GABAa cDNA 
fragments
Oligonucleotides used as primers amplify 300 bp fragments of DNA are shown. The 
oligonucleotide binding site within the a  or ß cDNA sequence at the 3' or 5' end is 
indicated in brackets.
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fragment. Reactions for the same virus carried out at different MgCk concentrations 
that produced the correct sized PCR product were combined and purified using a 
QIAquick PCR purification kit (QIAquick PCR Purification Kit, Qiagen Pty. Ltd., 
Victoria.).
PCR products were sequenced across the mutated regions by automated DNA 
sequencing using an “ABI PRISM™ Big Dye™ Terminator Cycle Sequencing Ready 
Reaction Kit With AmpliTaq^DNA Polymerase, FS” (Perkin-Elmer). The labelling 
reaction included: terminator ready reaction mix (4 pi), PCR product DNA
(approximately 100 - 200 ng), forward primer (3 pmoles) and d.H20 in a final volume of 
20 pi. The primers used for the sequencing reactions are shown in Table 2.2. The cycle 
sequencing procedure followed is described in section 2.1.11.
2.3 Flow Cytometry Experiments
Procedures followed were similar to that described by Tierney et al., (1996). 1 x 106 
SJ9 cells were infected in duplicate with recombinant virus in 6 well plates (Linbro™, 
Flow Laboratories, Inc. McLean, Virginia, USA) at an MOI of 5 - 1 0  pfu/ml and 
incubated for at least 40 hours. Cells were transferred to bactotubes and centrifuged at 
3,000 rpm for 2 minutes then washed in PBS. In order to detect the level of a  subunit 
present in the plasma membrane, non-permeabilised cells were used. These were 
incubated in primary monoclonal antibody bd24 (1/50 dilution) for 15 to 30 minutes 
prior to fixing. Cells were washed twice in PBS, resuspended in 100 pi PBS and fixed in 
100 pi Zamboni's solution for 90 minutes, then washed as above.
In order to detect the total level of a  subunit present in the plasma membrane and in the 
cytoplasm, cells were permeabilised in PBS buffer containing 0.1% SDS plus 1% bovine 
serum albumin (Boehringer Mannheim, Germany) for 10 minutes. Permeabilised cells 
were incubated in primary monoclonal antibody and washed twice. All samples were 
then labelled with secondary antibody using a fluorescein isothiocyanate (FITC) 
conjugated sheep anti-mouse Ig antibody (Selinus) diluted 1/40 in PBS and incubated for 
1 5 - 3 0  minutes in the dark. The cells were washed twice then resuspended in PBS and 
analysed on a FACStar Plus flow cytometer (Becton Dickenson).
Results were analysed with the WinMDI 2.7 computer program (Scripts, CA) and run 
on an IBM-compatible computer. Data were displayed as plots of fluorescence intensity
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(x-axis) versus, relative cell number (y-axis). The level of background fluorescence was 
estimated from cells infected with the wild type parent baculovirus (AcNPV) and 
subtracted from all other values. These were then calculated as a percent of wild type 
fluorescence for either non-permeabilised or permeabilised cells.
2.4 Muscimol Binding Assay
The method used to measure high affinity muscimol binding determined radioactive 
[:,H]muscimol binding in permeabilised cells infected with recombinant baculovirus. 
Similar procedures have been used by Tierney et al., (1996) and Pregenzer et a/., 
(1993).
Sj9 cells were seeded at 1.4 x 107 cells/ml in 75 cm2 cell culture flasks (Corning®, 
Corning, NY, USA) from cells grown to a density of 2 x 106 cells/ml in spinner culture 
flasks. Cells were infected with 3 ml working stock virus (P2 or P3) at an MOl of 
approximately 5 - 1 5  pfii/ml and incubated at room temperature on a rocker for 
90 minutes. The virus was replaced with 10 ml media and incubated at 25 ± 1 °C for 
40 - 48 hours. Infected cells were resuspended and transferred to a centrifuge tube, then 
centrifuged at 1000 rpm for 10 minutes and resuspended in 4 ml of buffer containing: 
30 mM Tris-HCl pH 7.2. 2.5 mM CaCl2, 0.04% TritonX-100. Cells were incubated at 
room temperature for 20 minutes, pelleted by centrifugation and resuspended at a 
density of 1.7 x 106 cells/ml in bath solution containing: 180 mM NaCl, 1 mM CaCl2,
1 mM MgCl2, and lOmM MES adjusted to pH 6.2 with NaOH. Approximately 
6.8 x 105 cells (400 pi) were aliquoted into 1.5 ml centrifuge tubes then stored at 4 °C.
The concentrations of muscimol used consisted of 10% radioactively labelled (hot) 
[3H] muscimol (NEN™, Boston, MA, USA) and 90% cold muscimol (Sigma). The [~"H] 
muscimol and cold muscimol mixture was serially diluted to 5 times greater than the final 
concentration required and 100 pi of each concentration was added to 400 pi of cells 
and incubated at 4 °C for 30 minutes. The final concentrations of muscimol used were 
(nM): 0, 1,2, 4, 8, 16, 32, 64, 128, 256 and 512. Filters with a pore diameter of 5 pm 
(Millipore, Bedford, MA) were presoaked in cold muscimol for 10 - 2 0  minutes and 
placed on the filtration device. 200 pi of cells pre-incubated with muscimol were applied 
to the filters in duplicate. These were quickly washed with 2 ml of ice cold extracellular 
(bath) solution. Each filter was added to 5 ml of scintillation fluid (Emulsifier-Safe™,
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Packard Instrument Company, Groningen, The Netherlands) in a scintillation vial. The 
radioactivity in each sample was counted for 5 minutes on a Packard Scintillation 
Counter (Packard Tricarb 300, United Technologies Packard). Cells that had not been 
exposed to muscimol were used as background controls. The background radioactivity 
was averaged across 5 of samples of cells infected with recombinant baculovirus. Five 
standard total count samples were prepared containing a known amount of ['H] 
muscimol (10 fmoles) which was added to the cells in the scintillation vials (one vial per 
virus) following filtration. The values obtained at different muscimol concentrations 
were divided by the average of the total counts across five samples. Scintillation count 
values were multiplied by 10 to account for the 1/10 dilution of [3H] muscimol.
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2.5 Solutions
All solutions were diluted in water from a Milli-Q^ reagent water system (Milli-RO®4, 
Millipore Corporation, Bedford, Massachusetts, USA).
Buffers
Tris/EDTA Buffer (TE)
10 mM Tris 
1 mM EDTA 
pH 8
TE 0/101 
1 mM Tris 
0.1 mM EDTA 
pH 8
Ligation buffer
50 mM Tris-HCl (pH 7.5)
10 mM magnesium chloride 
100 pg/ml bovine serum albumin 
5 mM dithiothreitol 
1 mM spermidine 
1 mM ATP
Phosphate buffered saline (PBS)
137 mMNaCl
2.7 mM potassium chloride
8 mM di-sodium hydrogen orthophosphate
1.76 mM potassium di-hydrogen orthophosphate
pH 7.2
Zamboni's Solution (fixative)
2% formaldehyde 
15% picric acid 
0.1 M phosphate buffer 
pH 7.4
Solutions used for mini-preparation of DNA 
Cell resuspension solution 
50 mM Tris (pH 7.5)
10 mM EDTA
RNAse A 100 pg/ml (filter sterilised)
Cell lysis solution
0.2 M Sodium Hydroxide
1% SDS
Neutralisation solution
3 M potassium acetate 
11.5% glacial acetic acid 
pH 4.8
Solutions for DNA gels
TAE buffer 
40 mM Tris base 
1 mM EDTA 
0.1% glacial acetic acid 
pH 8
Colony Cracking Buffer 
9.7% glycerol 
4.6 mM EDTA 
50 mM sodium hydroxide 
0.5% SDS
0.25% bromocresol green
SDS lysis buffer 
5.8 mM sucrose 
0.5 mM EDTA 
0.01% SDS
0.2 % bromophenol blue 
Dissolved in TE/10 buffer
Solutions for protein gels
Tris buffered saline (TBS)
20 mM Tris 
150 mM NaCl
Tris-glvcine SDS running buffer 
25 mM Tris base 
192 mM glycine 
0.1 % SDS 
pH 8.3
Tris-glvcine SDS reducing sample buffer 
40 mM Tris-glycine (pH 6.8)
18% glycerol 
16% SDS
0.2 % bromophenol blue 
1 - 4% ß-mecaptoethanol
Semi-dry buffer 
48 mM Tris 
39 mM glycine 
20% methanol
Blocking solution
10% skim milk powder in TBS
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Media used to grow E. coli 
Luria Bertani media (LB)
1% tryptone
0.5 % yeast extract
86 mM sodium chloride
SOB medium 
2% tryptone 
0.5% yeast extract 
10.3 mM sodium chloride
6.7 mM potassium chloride
SOC medium 
2% tryptone 
0.5 % yeast
10 mM sodium chloride 
2.4 mM potassium chloride 
10 mM magnesium chloride 
10 mM magnesium sulphate
Terrific Broth
1.7 mM potassium dihydrogen orthophosphate 
7.2 mM di-potassium hydrogen orthophosphate 
1.2% tryptone
0.2 % yeast extract
Agar plates 
LB media
2% agar (Bacto-Agar Difco Laboratories, Detroit, Michigan, USA)
40 mM glucose 
15 pg/ml tetracycline 
200 fig/ml ampicillin.
Glvcerol/LB Solution (for long term storage of E.coli stocks containing transformed 
mutant plasmid)
33% glycerol
66% Luria Bertani media
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2.6 Cell Culture
2.6.1 Maintenance of Sf9 insect cells
SJ9 cells were stored in liquid nitrogen (-70°C) and thawed every 3 - 6  months. A vial 
of frozen cells was thawed rapidly by gentle agitation in a 37 °C water bath and 
transferred to a 25 cm2 cell culture flask (Corning®, Corning, NY, USA), containing 
5 ml of cold (4 °C) supplemented Grace’s Insect Media. Cells were incubated at 
25 ± 1 °C for 30 minutes to allow them to adhere to the surface of the flask. The media
was then replaced with 5 ml of warm (25 ± 1 °C) media. Once the cells had formed a 
confluent monolayer ( 5 - 1 0  days) they were passaged into larger flasks. After several 
passages the volume of near confluent cells growing in monolayer cultures was sufficient 
to transfer the cells to a 50 ml spinner flask (Bellco, Biotechnology USA). Cells were
6 5
routinely grown to a density of 2 - 3 x 10 cells/ml then diluted to 2 x 10 cells/ml. New 
spinners were seeded at a minimum of 5 x 10 cells/ml.
2.6.2 Cell culture media
Cells were grown in Grace’s insect medium supplemented with 10% foetal bovine serum 
(FBS), lactalbumin and yeastolate. Grace’s media was made up from powdered media 
(Sigma G-9771) in 5 litre batches using water from a Milli-Q® reagent water system 
(M illi-RO^, Millipore Corporation, Bedford, Massachusetts, USA). Sodium 
bicarbonate (0.3 5g/l, cell culture grade, Sigma) was added and the pH adjusted to 
6.15 - 6.18 with NaOH (10 M). Liquid media was sterile filtered through a 0.2 pm pore 
filter into sterile bottles and stored at 4 °C protected from the light.
Complete media was made up every 6 - 8  weeks by supplementing Grace’s Insect Media 
with heat treated 10% FBS (CSL Limited, Victoria, Australia), lx  lactalbumin 
hydrolysate and lx  yeastolate ultrafiltrate (Gibco BRL, Life Technologies Inc., Grand 
Island, NY, USA). The final pH was 6 .15-6 .25, and the osmolarity was 
310 - 330 mOsm.
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2.7 Electrophysiology Experiments
2.7.1 Expression o f a ß  GABAa receptors in Sf9 cells
Cells were infected during the mid-late linear phases of the growth curve at a density of 
l - 3 x l 0 6 cells/ml in 96 well plates (NUNC™ Brand Products, Nalge Nunc 
International, Denmark). Media (100 pi) was first added to each well followed by cells. 
Cells were left to adhere for 10-15 minutes. Media was removed and 30 - 50 pi virus 
(P3) added, at an MOI of 5 - 10 pfu/cell. Cells were infected for 90 minutes on a rocker 
then the virus was removed and replaced with 100 pi of complete media. Plates were 
incubated at 25 ± 1 °C for 33 - 45 hours prior to use in electrophysiology experiments.
2. 7.2 Patch clamp set-up
Patch-clamp experiments were carried out using an inverted microscope on an air 
suspension table to minimise vibrations that may disturb recordings. The table top was 
surrounded by a Faraday cage to shield the patch-clamp amplifier from electrical noise. 
There were mounting brackets for solution tubes. The pipette headstage and pipette 
holder were mounted on the microscope stage and pipette movement controlled with a 
3-way manipulator. Seven small drug perfusion tubes were mounted similarly and their 
movement controlled by a 3-way hydraulic micro-manipulator, positioned on the table 
top. An agar salt bridge (3 M potassium chloride) attached to a chloride-coated silver 
wire was used as a reference electrode in the perfusion bath. All components were 
grounded to a common earth.
2.7.3 Pipettes
Borosilicate glass capillaries (GC150F-15, Clark Electromedical Instruments, 
Pangbourne Reading, England) with an outer diameter of 1.5 mm and an inner diameter 
of 0.86 mm, containing an inner filament, were used to make patch electrodes. They 
were pulled in 5 stages on a horizontal micropipette puller (Flaming/Brown P-87, Sutter 
Instrument Co., Novato, California, USA). The tips were heat polished to smooth the 
edges of the pipette tip and to remove any dust that may have settled. Pipettes had 
resistance’s of 3 - 10 Mf2 when filled with pipette solution.
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2.7.4 Bath and pipette solutions
The bath solution contained: (mM): 180 NaCl (Analar), 1 CaCl2 (Analar), 1 MgCl2
(Analar) and 10 MES (Sigma), adjusted to pH 6.2 with NaOH (330 ± 5 mOsm/L). 
Pipettes were filled with a solution containing (mM): 178 NaCl, 1 CaCl2, 1 MgCl2, 5 
EGTA (Sigma) and 10 TES (Sigma) adjusted to pH 7.2 with NaOH (330 ± 5 mOsm/L).
4 mM ATP (adenosine 5’-triphosphate) was also added to 5 ml pipette solution prior to 
use.
2.7.5 Drug solutions
All drugs used for electrophysiology experiments were obtained from Sigma. GABA 
was diluted in bath solution and serially diluted from a 10 mM or 30 mM stock solution 
to obtain the required concentration range for use in dose-response experiments.
2.7.6 Whole-cell patch clamping
Infected cells were resuspended in media by gentle pipetting and transferred to a 
perfusion bath. They were left for 10-15 minutes to adhere to the base of the bath. 
Cells were perfused with extra-cellular (bath) solution at a rate of 10 - 14 ml/min. 
Experiments were carried out at room temperature (20 - 25 °C). A seal was formed 
between the patch electrode and the cell by gentle suction. A high voltage pulse was 
applied to disrupt the piece of membrane and form a whole-cell configuration. The cell 
was lifted off the glass plate, placed at the level of the drug application tubes, and bath 
flow begun. Cells were voltage clamped at -40 mV and series resistance compensation 
correction (80 - 100%) was used. It is important to reduce series resistance errors to 
improve the effective speed of the voltage clamp in order to be able to record fast 
current changes (Sakmann and Neher, 1995).
2.7. 7 Drug application protocol.
Drugs were applied directly to Sf) insect cells via microperfusion tubes using a fast flow 
perfusion system. In dose-response experiments a standard concentration of GABA was 
applied before and after all other concentrations used. Similarly, when other drugs were 
applied to a cell in combination with GABA, a control concentration of GABA was 
applied before and after. Results were only used from cells in which the peak current of 
the two standard GABA concentrations differed by less than 20%. Responses were 
calculated as a fraction of the averaged standard responses to GABA.
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2. 7.8 Data acquisition
Whole-cell currents were monitored with a current-to-voltage converter (Axopatch ID, 
Axon Instruments, Foster City, CA) and filtered at 1 kHz. An oscilloscope (digitising 
oscilloscope, Tektronix) connected to the amplifier was used to observe the signals. 
Data were digitised using an analog to digital converter (TL-1, DMA interface, Axon 
Instruments) at a sample rate of 2 kHz, using the 'Capture' data acquisition program (M. 
Smith, John Curtin School of Medical Research). Current responses were concurrently 
recorded using a VCR/PCM combination. A digital pulse code modulator (Sony) was 
used to convert the analogue signal to a pulse-code modulated signal which was 
recorded on videotape with a video cassette recorder (Akai). Data were analysed using 
the 'Channel 2' binary data analysis program (M. Smith, John Curtin School of Medical 
Research).
2.7.9 Equations and common definitions
Different equations were fitted to the data using SlideWrite™ software (version 4.0). 
Dose-response curves
Dose-response data were fitted with a Hill-type equation fitted using nonlinear least 
squares regression analysis.
I is the peak current produced following application of GABA, 7max is the value of the 
estimated maximal or “saturating” peak current response, [GABA] is the concentration 
of GABA and h is the Hill coefficient. EC50 is the GABA concentration that gave half- 
maximal current response.
Data from some dose-response experiments were best fitted by the sum of two Hill 
equations.
/  = /m„  • [GABAf/WECsc,)* + [GABA]4) (2 . 1)
/  = /m,x(i) • [GABA]‘(1)/(EC5o„)‘(1) + [GABA]‘(1)) + 
W )  • [GABA]‘(2)/(EC50(2 4(21 + [GABA]4'2')
(2.2)
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The current is assumed to come from two components so that I  = I  \ and I  2■ The 
symbols are defined above.
Ligand binding curves
Muscimol binding data were fitted by the Henri-Michaelis-Menton equation for a single 
class of binding site calculated by nonlinear least squares regression analysis.
Bound = Bmax . [muscimol]/ (Kd +[muscimol]) (2.3)
Bound is the amount of ['HJmuscimol bound (pmoles/106 cells), Bmax is the 
concentration that gives maximum ['Hjmuscimol binding (pmoles/106 cells), [muscimol] 
is the concentration of radioactive muscimol and Kd is the concentration that yields half 
maximal binding, the dissociation constant.
Current rise time
The time taken for the whole-cell current to increase from 10-90% of its maximal peak 
current upon application of GABA was calculated and is referred to as the rise time (Tr).
Current decay
The time taken for the peak current to decay by half is referred to as the 50% decay time 
(T5o). The time taken for the current to decay so that it was no longer detectable is 
referred to as the 100% decay time (Tioo). Current decay was also examined by 
measuring the plateau current amplitude after 1 second as a fraction of the peak current
( I  ls e c /Ip ) -
2.7.10 Statistical tests
Where applicable results are shown as the'mean ± 1 standard error of the mean (SEM). 
An F-test was used to determine whether the variances of two samples were equivalent. 
If there was no significant difference, the variances were pooled, otherwise they were 
assumed to be unequal. It was assumed that the underlying distributions were normal. 
A two tailed student /-test (p<0.05) was used to determine whether there was a 
significant difference between two means, /-tests were carried out on all data in which 
comparisons were made between two groups of data where n>3. Where a mean value is
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described as being x-fold greater than or less than another, the difference was 
statistically significant unless stated otherwise.
Chapter 3
3. Role of Leucine 9' in GABA-Activation and
Desensitisation
46
3.1 Introduction
A leucine residue at the 9' position (L9') in the middle of the M2 region is highly 
conserved across the nACh receptor family (Figure 1.3). It has been ascribed several 
different functional roles in channel gating and desensitisation. Unwin (1995) proposed 
that an L9' residue from each subunit faces into the pore at the level of the kink to form 
the gate of the channel. In homomeric a-j nACh neuronal receptors from chick brain, an 
additional conducting state was identified when L9' was mutated to threonine (L9T) 
(Revah et al., 1991; Devilliers-Thiery et al., 1992). The authors suggested that L9' is 
important for preventing ion permeation in a desensitised non-conducting state. Studies 
using the nACh receptor from muscle in which the L9' residue in the y subunit was 
changed to serine (L9'S) report changes in channel open time but no change in 
conductance (Filatov and White, 1995; Labarca et al., 1995). They suggest a role for 
L9' in setting the channel mean open time, rather than forming an actual gate structure.
The L 9T  and L9'S mutations markedly reduce the rate of desensitisation and lower the 
EC5o when present in either aiß2y2 GABAa (Chang et al., 1996) or nACh receptors 
(Revah et al., 1991; Devilliers-Thiery7 et a l., 1992; Filatov and White, 1995; Labarca et 
al., 1995). Interestingly, when leucine is changed to threonine in human otißi GABAa 
receptors a high resting conductance is produced in the absence of GABA which is 
reduced by penicillin, a GABAa channel blocker (Tierney et al., 1996). This is consistent 
with a role for L9' in preventing ion permeation in a closed or resting conformation.
In rat pi GABA receptors mutations L(317)9'A or T(314)6'A produce channels that 
open spontaneously in the absence of GABA and were inhibited by picrotoxin. When 
both these mutations were present, spontaneous channel openings occurred that were 
partially inhibited by low nanomolar concentrations of GABA and were reactivated at 
1 pM GABA (Pan et al., 1997). In human pi homomeric GABA receptors, replacing 
L(301)9' with small or polar residues increased the resting membrane conductance. The 
increased resting conductance was inhibited by picrotoxin and in some mutants it was 
also inhibited by GABA (Chang and Weiss, 1998).
Receptors carrying the L 9T  mutation in either the ßi subunit or in both a  and ßi 
subunits together did not respond to GABA, but those mutated in the otj subunit 
produced a current response that was slow to activate and desensitise (Tierney et al.,
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1996). The dose-response relationship for this mutant receptor was not significantly 
different from wild type receptors.
Given the apparent importance of L9' in receptor activation and desensitisation this 
chapter investigates the properties of this residue that are important in GABAa receptor 
function.
3.1.1 Mutational strategy
Mutations were carried out at the 9' position in human otißi GABAa receptors in order 
to determine which properties of this residue are important for preventing ion permeation 
in the absence of GABA. L9' was changed to either phenylalanine (L9T) or to tyrosine 
(L9'Y), which are larger in size than leucine (Table 3.1) and have an aromatic side chain. 
Phenylalanine has a benzyl group distal to the ß-carbon atom. Tyrosine has a phenolic 
group distal to the ß-carbon atom. Both are considered polar yet hydrophobic residues 
(Dougherty 1996). The hydroxyl group attached to the para-carbon of the benzene ring 
renders tyrosine capable of hydrogen bonding. The L9T and L9'Y mutations were more 
conservative in terms of maintaining residue size and hydrophobicity than the leucine-to- 
threonine mutation (L9T) (Tierney et a/., 1996).
It is difficult to define precisely, or to measure accurately, the hydrophobicity of an amino 
acid residue. The hydrophobicity of an amino acid is dependent upon the environment of 
the amino acid and is related to the free energy of transfer of the side chain from water to 
an apolar environment. A number of different hydrophobicity scales have been derived, 
using a variety of experimental and computational methods, which show much variation 
in rank order of hydrophobicity across amino acids (Eisenberg et al., 1982). Relative 
hydrophobicities of the different amino acids are shown in Table 3.1. The hydrophobicity 
of an amino acid is also dependent upon its accessible surface area. Taking surface area 
into account, residues are ranked in order of hydrophobicity as, T<L<F<Y (Creighton, 
1983). Because phenylalanine and tyrosine are similar in size and hydrophobicity, 
phenylalanine provides a suitable control to examine the effect of the hydroxyl group on 
the tyrosine residue on receptor function.
The mutations carried out in this study were designed to investigate whether the high 
resting conductance observed in L 9T  mutant a ß  GABAa receptors was due to the 
addition of an hydroxyl group. The hydroxyl group on the threonine residue could have
amino acid residue volume
(A 3)
relative hydrophobicity 
(kcal/mol)
threonine (T) 116.1 0.4
leucine (L) 166.7 1.8
phenylalanine (F) 189.9 2.5
tyrosine (Y) 193.6 2.3
Table 3.1 Properties of amino acid residues
Relative hydrophobicities of amino acid residues using the scale of Nozaki and Tanford 
(1971). Hydrophobicity values were obtained by measuring differences between the 
solubility of residues’ side chains in water and in ethanol, relative to glycine at 
0 kcal/mol. Values from Creighton, 1983.
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replaced the water molecules contributing to the hydration shell of a chloride ion and 
hence facilitate ion permeation whilst the receptor is in a closed or resting conformation. 
Receptors that have the L9'Y mutation would then be expected to show an increase in 
the resting membrane conductance, but those that have the L9T mutation should show 
no change. If the addition of an hydroxyl group is not sufficient to allow ion permeation 
in the absence of GABA then neither mutation should increase the resting membrane 
conductance.
In order to assess possible subunit-specific effects upon receptor function, SJ9 cells were 
infected with recombinant baculovirus containing a  and ß subunit cDNA that had been 
mutated in either the a  subunit or in the ß subunit or in both a  and ß subunits. 
Receptors mutated to tyrosine in the a  subunit were designated a(L9'Y)ß, those mutated 
in the ß subunit were designated otß(L9'Y) and those carrying the mutation in both 
subunits were designated a(L9'Y)ß(L9'Y). This format was also used for the leucine to 
phenylalanine mutations. Mutated receptors were assessed for any changes in their 
whole-cell current response to GABA, plasma membrane expression, muscimol binding 
and pharmacology.
3.2 Methods
Procedures used are detailed in Chapter 2.
3.3 Results
3.3.1 Resting membrane conductance is not increased
The resting membrane conductance was recorded in all cells expressing L9'F or L9'Y 
mutated GABAa receptors which responded to GABA. Data are summarised in 
Table 3.2. Resting membrane conductances in cells expressing a(L9T)ß, aß(L9T ), 
ot(L9'F)ß(L9'F), ot(L9'Y)ß, ocß(L9'Y) or ot(L9'Y)ß(L9'Y) receptors, were not 
significantly different from the conductance in wild type receptors. The lack of increase 
in the resting conductance in the L9'Y mutated receptors indicates that the hydroxyl 
group on the tyrosine is insufficient to increase the membrane conductance. This finding, 
together with the lack of effect of the L9T mutations on the resting membrane 
conductance, suggests that conservation of residue size at the 9' position is important to 
prevent ion permeation in the absence of GABA.
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3.3.2 L9 F  and L9 T  mutated receptors respond to GABA
Whole-cell currents produced in response to lOmM GABA in ot(L9'F)ß, otß(L9'F), 
a(L9'F)ß(L9'F), oc(L9'Y)ß, aß(L9'Y) and a(L9'Y)ß(L9'Y) receptors are shown in 
Figure 3.1 (L9T) and Figure 3.2 (L9'Y).
3.3.3 EC so is increased in ß  subunit mutated receptors
Receptors mutated at the 9' position in GABAa (Chang et a l., 1996) and nACh receptors 
(Revah et al., 1991; Filatov and White, 1995; Labarca et al., 1995; Zhang and Karlin, 
1998) often show a decrease in EC50. In order to determine whether there were any 
changes in EC50 for GABA, dose-response curves were constructed. Peak current 
amplitude is plotted against GABA concentration for L9T (Figure 3.3) and L9'Y 
mutated receptors (Figure 3.5). Curves normalised to the maximum current are also 
shown for L9'F (Figure 3.4) and L9'Y mutated receptors (Figure 3.6) to allow easier 
comparison between the curves. Data were fitted using equation 2.1. EC50 values and 
Hill coefficients are shown in Table 3.3. Values are shown as the mean ± 1SEM. 
Results in wild type receptors are shown for comparison (Birnir et al., 1995).
Wild type: The EC50 in wild type receptors is 11 ± 2 pM and the Hill coefficient is
1.3 ±0.03 (Birnir et al., 1995).
L 9 T  Mutated Receptors: The EC50 for a(L9'F)ß receptors was 57 ±  5 pM (n=17),
significantly greater than the EC50 for wild type receptors. The Hill coefficient was 
0.73 ± 0.04, significantly different from in wild type receptors. A Hill coefficient of less 
than one indicates negative cooperativity.
otß(L9'F) receptors had an even greater increase in EC50. Dose response data were 
recorded from 25 cells and were best described by equation 2.2. The EC50 for the higher 
affinity component of the dose-response curve was 11 ± 9 pM and the Hill coefficient 
was 1.1 ±0.7, values not significantly different from those in wild type receptors. The 
EC50 for the lower affinity component of the dose-response curve was 1131 ± 182 pM 
and the Hill coefficient was 1.3 ± 0.2. The presence of two separate components to the 
dose-response relationship may indicate the expression of two different receptor 
populations, one with a similar apparent affinity for GABA to wild type, and another that 
is increased by two orders of magnitude. The Hill values for each component were not 
significantly different from the Hill value in wild type receptors.
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Figure 3.3 GABA dose-response curves for L9'F mutated receptors
The peak current (I) is plotted against GABA concentration. The vertical bars show the 
mean ± 1SEM in 3 or more cells. Error bars are not visible if smaller than the symbol. 
The curves are a fit of equation 2.1 to the data. The EC5o for ot(L9'F)ß receptors (filled 
circles) was 57 ± 5 pM and the Hill coefficient was 0.73 ± 0.04 (n=17 cells). Data from 
cells expressing aß(L9'F) receptors (open circles) were best fitted using equation 2.2 
(n=25 cells). The EC50 values were 11 ± 9 pM and 1131 ± 182 pM for the higher and 
lower affinity components, respectively. The corresponding Hill coefficients were 
1.1 ±0 .7  and 1.3 ±0.2, respectively. The EC50 for ot(L9'F)ß(L9'F) receptors (open 
triangles) was 12 ± 4 pM and the Hill coefficient was 0.8 ± 0.2 (n=6 cells). The broken 
line represents the dose-response curve for wild type receptors (Birnir et al., 1995).
GABA (mM)
Figure 3.4 Normalised GABA dose-response curves for L9'F mutated receptors
The normalised peak current (/') of the whole-cell response to GABA is plotted against 
concentration. Currents elicited in each cell at different concentrations of GABA are 
shown relative to the current elicited by 10 mM GABA in L9T mutated receptors and to 
100 pM GABA in wild type receptors. The vertical bars show ± 1SEM in 3 or more 
cells. Error bars are not visible if smaller than the symbol. The curves for ot(L9T)ß 
receptors (filled circles) and a(L9T)ß(L9T) receptors (open triangles) are a fit of 
equation 2.1 to the data. Data from cells expressing otß(L9T) receptors (open circles) 
were best fitted using equation 2.2. The broken line represents the dose-response curve 
for wild type receptors (Birnir et a/., 1995).
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Figure 3.5 GABA dose-response curves for L9'Y mutated receptors
The peak current (I) is plotted against GABA concentration. The vertical bars show ± 
1SEM in 3 or more cells. Error bars are not visible if smaller than the symbol. The 
curves are a fit of equation 2.1 to the data. Cells expressing ot(L9'Y)ß receptors (filled 
circles) had an EC50 of 25 ± 2 pM and a Hill coefficient of 0.9 ± 0.1 (n=13 cells). Cells 
expressing aß(L9'Y) receptors (open circles) were best fitted using equation 2.2 (n=24 
cells). The EC50 values were 17 ± 26 pM and 2453 ± 1094 pM and the corresponding 
Hill coefficients were 1.2 ± 1.3 and 0.9 ±0.4, respectively. Currents produced at two 
concentrations are shown for cells expressing a(L9'Y)ß(L9'Y) receptors (open 
triangles). The broken line represents the dose-response curve for wild type receptors 
(Birnir et al., 1995).
10° 101 102 103 104 105 10
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Figure 3.6 Normalised dose-response curves for L9'Y mutated receptors
The normalised peak current (/') of the whole-cell response to GABA is plotted against 
concentration. Currents elicited in each cell at different concentrations of GABA are 
shown relative to the current elicited by 10 mM GABA in L9'Y mutated receptors and to 
100 pM GABA in a(L9'Y)ß and wild type receptors. The vertical bars show ± 1 SEM 
in 3 or more cells. Error bars are not visible if smaller than the symbol. The curve for 
a(L9'Y )ß receptors (filled circles) was fitted using equation 2.1. Data from cells 
expressing otß(L9'Y) receptors (open circles) were best fitted using equation 2.2. The 
broken line represents the dose-response curve for wild type receptors (Birnir et al., 
1995).
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The large variances in EC50 and Hill coefficients for the higher affinity component were 
probably because of the difficulty in accurately estimating the saturating concentration of 
GABA. Increasing the GABA concentration to the estimated saturating concentration 
for the higher affinity component, resulted in activation of the lower affinity component 
as well, preventing accurate estimation of the maximum current.
In order to determine whether the EC50 for GABA would be further increased when 
receptors were mutated in both subunits the dose-response relationship for 
a(L9'F)ß(L9'F) receptors was examined. The EC50 was 12 ± 4  pM (n=6), similar to 
wild type. The Hill coefficient was 0.8 ± 0.2 (n=6) which was not significantly different 
from that in wild type receptors.
L9Y Mutated Receptors'. The EC50 for a(L9'Y)ß receptors was 23 ± 4 pM (n=13), 
higher than for wild type receptors. The Hill coefficient was 0.96 ±0.12 (n=13).
As in the case of aß(L9'F) receptors, dose-response data for aß(L9'Y ) receptors were 
best fitted by the sum of two Hill equations (n=24). The EC50 for the higher affinity 
component of the dose-response curve was 17 ± 26 pM and the Hill coefficient was 
1.2 ± 1.3. The EC50 for the lower affinity component of the dose-response curve was 
2453 ± 1094 pM and the Hill coefficient was 0.9 ±0.4. When the concentration of 
GABA was increased to 50 mM the currents produced were 0.80 of the response to 
30 mM GABA (n=2). This reduction in current may be due to open channel block of 
receptors at this high GABA concentration.
In cells expressing oc(L9'Y)ß(L9'Y) receptors the peak current amplitude was about 5% 
of that in wild type receptors and the rate of desensitisation was increased (Figure 3.2 
and Table 3.2). These receptors were slow to recover from desensitisation (the order of 
minutes). This resulted in practical difficulties in constructing a dose-response curve. 
GABAa receptors are prone to “run down” of their whole-cell currents over successive 
applications of agonist. Slow recovery from desensitisation exacerbates this problem. 
“Rundown” is thought to be due to disruption of ATP-dependent phosphorylation 
processes involved in maintenance of GABAa receptor function (Gyenes et al., 1988). 
The presence of Mg2"-ATP in the pipette solution did not prevent this. Whole-cell 
current “run-down” caused particular difficulties in cells expressing oc(L9'Y)ß(L9'Y) 
receptors because they produced maximum currents of only 100 - 200 pA upon initial
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application of GABA. After several GABA applications it was difficult to distinguish 
differences between the small currents accurately, or to detect a current at all.
While dose-response curves cannot be constructed for ot(L9'Y)ß(L9'Y) receptors, it is 
still possible to investigate changes relative to wild type by determining the relative 
current amplitudes produced in response to GABA concentrations that produce maximal 
and half maximal currents in wild type receptors. These experiments were carried out at 
42 - 48 hours post-infection (hpi) in order to maximise the level of receptor expression. 
This had the disadvantage that at this late stage of infection the cells are particularly 
fragile. The current produced in response to 10 pM GABA as a ratio of the response to 
10 mM GABA in cells expressing oc(L9'Y)ß(L9'Y) receptors was 0.36 ± 0.01 (n=3). 
This is similar to the ratio of 0.31 ± 0.03 (n=6) for a(L9'Y)ß receptors at the same 
GABA concentrations. It is probable that the GABA dose-response relationship for 
ot(L9'Y)ß(L9'Y) receptors is similar to that for ot(L9'Y)ß receptors and therefore may be 
shifted to slightly higher concentrations than in wild type receptors.
In summary, the results obtained from the dose-response data for the L9T and L9'Y 
mutated receptors show that the EC5o is slightly increased in receptors mutated in the a  
subunit alone. Receptors mutated in the ß subunit alone had two components to their 
dose-response curves. Receptors with the L9T mutation in both subunits showed no 
change in EC50 compared to wild type receptors.
3.3.4 Maximal current is reduced
The maximum peak current recorded in each cell is dependent upon the level of receptor 
expression, which is dependent upon both the multiplicity of infection (MOI) and the 
time post-infection. In mutated receptors there may also be changes in the efficiency of 
receptor assembly and trafficking to the plasma membrane, which may affect the number 
of receptors present at the cell surface.
Peak current amplitudes of the whole-cell response to saturating concentrations of 
GABA in mutated and wild type receptors are summarised in Table 3.3. Saturating 
GABA concentrations for each receptor were determined from the dose-response curves. 
10 mM GABA was used in receptors mutated in the a  subunit alone or in both subunits 
and 30 mM was used in receptors mutated in the ß subunit alone.
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Wild type: The peak current produced in response to lOmM GABA in wild type
receptors was 3370 ± 612 pA (n=12).
L 9 T  Mutated Receptors: The peak current produced in response to 10 mM GABA in 
a(L 9T )ß  receptors was 765 ± 90 pA (n=15), about 23% of that in wild type receptors. 
The peak current produced in response to 30 mM GABA in aß(L 9T ) receptors was 
3958 ± 687 pA (n=6) which was not significantly different from that in wild type 
receptors. The peak current in response to 10 mM GABA in a(L9'F)ß(L9'F) receptors 
was 365 ± 68 pA (n=8), 11% of the maximum current in wild type receptors.
L9 T Mutated Receptors: The peak current produced in response to 10 mM GABA in 
ot(L9'Y)ß receptors was 672 ± 148 pA (n=T2), 20% of the maximum current in wild type 
receptors. The peak current in response to 30 mM GABA in otß(L9'Y) receptors was 
1428 ± 204 pA (n=5), about 42% of the value for wild type receptors.
In a(L9'Y)ß(L9'Y) receptors 10 mM GABA produced an unusual transient current 
(Figure 3.2C) that was 1 7 2± 26 p A (n=7) in amplitude. This 5% of the maximum 
current in wild type receptors. Experiments using this receptor were carried out at 42-48 
hpi to maximise the number of receptors present at the cell surface.
3.3.5 Desensitisation is increased in a  subunit mutated receptors
Normalised whole-cell currents are shown in Figure 3.7. Current activation and decay
times at saturating GABA concentrations are summarised in Table 3.2.
Wild type: The 50% decay time (T50) following application of lOmM GABA was
223 ± 43 ms (n=6) in wild type receptors. The current remaining one second following 
GABA application as a ratio of the peak current (IiSec/Ip) was 0.16 ± 0.03 (n=5).
L9 T  Mutated Receptors'. In ot(L9'F)ß receptors, the T50 following application of 10 mM 
GABA was 55 ± 5 ms (n=15), 25% of that in wild type receptors. The Iisec/Ip ratio was 
0.05 ± 0.01 (n=l 1), significantly less than in wild type receptors.
ln aß(L9'F) receptors, the T50 following application of 30 mM GABA was 290 ± 27 ms 
(n=6) and the Iisec/IP ratio was 0.24 ± 0.01 (n=4), not significantly different from in wild 
type receptors.
Figure 3.7 Normalised whole-cell currents for L9' mutated receptors
Whole-cell currents activated by saturating concentrations of GABA (10 mM or 30 mM) 
at -40 mV are shown for (A) L9T mutated receptors and (B) L9'Y mutated receptors. 
Currents were normalised to the amplitude in wild type receptors of 3.2 nA (bold line).
(A) ot(L9'F)ß(L9'F) receptors, 0.7 nA (thin line), oc(L9'F)ß receptors, 0.6 nA (thin 
broken line) and aß(L9T ) receptors, 2.8 nA (broken line in bold). (B) ot(L9'Y)ß(L9'Y) 
receptors, 0.2 nA (thin line), a(L9'Y)ß receptors, 0.5 nA (thin broken line) and 
otß(L9'Y) receptors, 0.8 nA (broken line in bold). Duration of currents for A and B is 800 ms.
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In a(L9T)ß(L9T) receptors, the T50 following application of lOmM GABA was 
27 ± 3 ms (n=8), about 12% of that in wild type receptors. The Iisec/Ip ratio was 
0.06 ± 0.02 (n=5), significantly less than in wild type receptors.
L 9rYMutated Receptors: In ot(L9'Y)ß receptors, the T50 was 78 ± 10 ms (n=T2), about 
35% of that in wild type receptors. The Iisec/IP ratio was 0.05 ± 0.01 (n=9), significantly 
less than in wild type receptors.
In aß(L9'Y) receptors the T50 following application of 30 mM GABA was 337 ± 29 ms 
(n=5), not significantly different from in wild type receptors. The Iisec/IP ratio was 
0.22 ± 0.03 (n=4), again not significantly different from in wild type receptors.
In a(L9'Y)ß(L9'Y) receptors, the T5o following application of 10 mM GABA was 12 ± 1 
ms (n=7), about 5% of that in wild type receptors. In the continued presence of 10 mM 
GABA, the current decayed to a negligible steady state current in 61 ± 9 ms (n=5).
Rise times: Rise times were increased in receptors mutated in the a  subunit, or in both 
subunits, but in receptors mutated in the ß subunit, rise times were not significantly 
different from wild type. The 10-90% rise time (Tr) in wild type receptors was 
16 ± 2 ms, n=6. In a(L9T)ß receptors the Tr was 7 ± 0.4 ms (n=15), significantly less 
than in wild type receptors. The Tr in aß(L 9T ) receptors was 12 ± 1 ms (n=6), not 
significantly different from in wild type receptors. In oc(L9'F)ß(L9'F) receptors the Tr 
was 9 + 1 ms (n=8), significantly less than in wild type receptors. The Tr for a(L9'Y)ß 
receptors was 10 ± 1 ms (n=12), significantly less than in wild type receptors. The Tr in 
aß(L9'Y ) receptors was 11 ± 1 ms (n=5), not significantly different from in wild type 
receptors. In a(L9'Y)ß(L9'Y) receptors the Tr was 9 ± 1 ms (n=7), significantly less 
than in wild type receptors.
In summary, receptors mutated in the a  subunit alone showed faster current rise times 
and desensitisation than in wild type receptors, but those mutated in the ß subunit alone 
did not. When mutations were in both a  and ß subunits, the rate of desensitisation was 
increased to a greater degree than when the a  subunit alone was mutated. An increase in 
the rate of desensitisation may prevent maximal activation of receptors, and therefore 
lead to underestimation of the maximum current.
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The reduction in the maximal current could be due to the mutations impairing the 
efficiency of receptor assembly and trafficking to the plasma membrane. These 
possibilities were therefore investigated.
3.3.6 a subunit plasma membrane expression
In order to determine whether the mutated receptors had been trafficked to the plasma 
membrane normally, experiments were carried out to detect the presence of the a  subunit 
in the plasma membrane. Flow cytometry experiments were carried out using an oti 
subunit specific antibody and a fluorescently labelled secondary antibody 
(cf. Methods 2.2.1). The level of a  subunit in the plasma membrane was determined in 
non-permeabilised cells. The total level of a  subunit expression was determined in 
permeabilised cells.
Plots of fluorescence levels in cells expressing L9'F mutated receptors are shown in 
Figure 3.8 and for L9'Y mutated receptors in Figure 3.9. Results are summarised in 
Table 3.4. Fluorescence was measured as a percent of the level for wild type in each 
experiment.
L9 T  M utated Receptors'. The level of a  subunit in the plasma membrane was 109 ± 9% 
(n=5) in a(L9'F)ß receptors and 84 ± 5% (n=5) in aß(L9'F) receptors, similar to wild 
type receptors. In a(L9T)ß(L9T) receptors the level of a  subunit in the plasma 
membrane was 51 ± 5% (n=10), approximately half that for wild type receptors.
The total level of a  subunit expression was 98 ± 6% (n=5) in aß(L 9T ) receptors and 
101 ± 15% (n=5) in aß(L9'F) receptors, similar to wild type receptors. In
a(L 9T )ß(L 9T ) receptors the total level of a  subunit expression was 75 ±6%  (n=10), 
less than for wild type receptors.
L9 Y M uta ted  Receptors: The level of a  subunit in the plasma membrane was 106 ± 17% 
(n=5) in a(L9'Y )ß receptors and 83 ± 8% (n=5) in aß(L9'Y) receptors, similar to wild 
type receptors. In a(L9'Y)ß(L9'Y) receptors the level of a  subunit in the plasma 
membrane was 60 ± 2% (n=5), less than in wild type receptors.
The total level of a  subunit expression was 110 ± 8% (n=5) in a(L9'Y)ß receptors and 
105 ± 12% (n=5) in otß(L9'Y) receptors, similar to wild type receptors. In
AB
relative fluorescence
Figure 3.8 Expression of the a  subunit for L9'F mutated receptors
Flow cytometric analysis of immunofluorescently labelled a  protein expression in Sfl 
cells infected with L9T recombinant baculovirus. Primary monoclonal antibody bd24 
was immunofluorescently labelled with a secondary FITC conjugated antibody at 42-48 
hours post-infection. The level of non-specific labelling was determined from the level of 
fluorescence in cells infected with the parent baculovirus AcNPV. Expression was 
calculated as a percent of the level for wild type. The levels of expression for non- 
permeabilised cells are shown in (A) and expression levels for permeabilised cells are 
shown in (B). The relative fluorescence levels are shown for cells infected with: AcNPV 
(black), wild type (dark blue), a(L9'F)ß (red), aß(L9'F) (light blue), and ot(L9'F)ß(L9'F) 
(green) recombinant baculovirus.
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a(L9'Y)ß(L9'Y) receptors, the total level of a  subunit expression was 82 ± 7% (n=5), 
slightly less than for wild type receptors.
In summary, reduced levels of a  subunit in the plasma membrane of cells expressing 
oc(L9'F)ß(L9'F) and oc(L9'Y)ß(L9'Y) receptors may account for only a small part of the 
reduction in whole-cell current.
3.3. 7 Muscimol binding
Although receptors were present in the plasma membrane, their ability to bind GABA 
may be impaired. In order to further assay assembly of a  and ß subunits, binding 
experiments were carried out using muscimol, a high affinity GABA agonist. 
Radioactive ["Hjmuscimol binding was determined in permeabilised cells infected with 
recombinant baculovirus (cf. Methods 2.3). The data were fitted using equation 2.3. 
Binding curves normalised to the Bmax are shown for L9'F (Figure 3.10) and L9'Y 
(Figure 3.11) mutated receptors. Kd and Bmax values are shown in Table 3.4
Wild type: The K<j was 38.9 ± 4.8 nM and the Bmax was 6.4 ± 0.9 pmoles per 106 cells 
(n=5) in wild type receptors.
L9TM utated Receptors: The Kd was 51.5 ± 8.4 nM and the Bmax was 7.0 ± 0.9 pmoles 
per 106 cells (n=3) in a(L9T)ß receptors. These values were not significantly different 
from those in wild type receptors. In aß(L9'F) receptors, the Kd was 85.0 ± 12.5 nM 
(n=4), significantly greater than in wild type receptors (2 tailed /-test, p<0.05). The Bmax 
was 6.4 ± 0.7 pmoles per 106 cells, which was not significantly different from in wild type 
receptors. In a(L9'F)ß(L9'F) receptors, the Kd was 54.5 ± 5.5 nM (n=4), not 
significantly different from in wild type receptors. The Bmax was 2.7 ± 0.3 pmoles per 106 
cells, significantly less than in wild type receptors.
L 9 Y  Mutated Receptors: In ot(L9'Y)ß receptors the Kd was 24.7 nM and the Bmax was 
3.6 pmoles per 106 cells (n=l). In otß(L9'Y) receptors the Kd was 47.6 nM and the Bmax 
was 4.7 pmoles per 106 cells (n=2). In oc(L9'Y)ß(L9'Y) receptors, the Kd was 
79.7 ± 12.6 nM (n=3), significantly greater than in wild type receptors (2 tailed /-test, 
p<0.05). The Bmax was 3.4 ± 0.4 pmoles per 106 cells, significantly less than in wild type 
receptors and similar to the Bmax in ot(L9'F)ß(L9'F) receptors.
------ ?
u  /  Il y  1
c
_ _ _i
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[3H] Muscimol (nM)
Figure 3.10 [3H]-MuscimoI binding to L9'F mutated receptors
Cells expressing GABAa receptors were assayed 42-48 hpi for the binding of [ H]- 
muscimol to cells pre-incubated in buffer containing 0.04% TritonX-100. Cells were 
incubated in a range of muscimol concentrations (1 - 512  nM) containing 10% [3H]- 
muscimol and 90% cold muscimol for 30 minutes at 4 °C. Data from each experiment 
were normalised to the Bmax value obtained by fitting equation 2.3 for a single class of 
binding site. Mutated receptors: (A) a(L9'F)ß, (B) aß(L9'F) and (C) a(L9T)ß(L9T) 
are indicated by filled circles. Wild type data are shown for comparison (open circles).
cc  0.4
CQ 0.2
[3H] Muscimol (nM)
Figure 3.11 [3H]-Muscimol binding to L9'Y mutated receptors
Cells expressing GABAa receptors were assayed 42-48 hpi for the binding of ["H]- 
muscimol to cells pre-incubated in buffer containing 0.04% TritonX-100. Cells were 
incubated in a range of muscimol concentrations (1 - 512 nM) containing 10% [3H]- 
muscimol and 90% cold muscimol for 30 minutes at 4 °C. Data from each experiment 
were normalised to the Bmax value obtained by fitting equation 2.3 for a single class of 
binding site. Mutated receptors: (A) a(L9'Y)ß, (B) ocß(L9'Y) and
(C) a(L9'Y)ß(L9'Y) are indicated by filled circles. Wild type data are shown for 
comparison (open circles).
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In summary, these results show differences in Kd and Bmax values that depend on the 
subunit(s) that were mutated and the residue that was substituted. aß(L9'F) receptors 
had an increased Kd, indicating a reduction in muscimol binding affinity. Reduced Bmax 
values for ot(L9'F)ß(L9T) and ot(L9'Y)ß(L9'Y) receptors indicate a reduction in the 
number of a  and ß subunits that are assembled. This is consistent with the reduced level 
of a  subunit in the plasma membrane for these receptors. These results indicate that 
receptors mutated in both subunits are assembled and present at the cell surface in 
significant numbers (about half that of wild type).
3.3.8 Pharmacology
When L9' was mutated to threonine in neuronal nACh receptors, the dose response 
relationship was shifted to lower concentrations and the pharmacology of the receptors 
was reversed; antagonists became agonists (Bertrand et al., 1992; Palma et a l., 1996). It 
is possible that the shifts in GABA dose-response relationship observed in L9T and L9'Y 
mutated receptors were also accompanied by changes in receptor pharmacology. The 
response of the mutated receptors to bicuculline (a competitive GABA antagonist) and 
pentobarbital (a positive allosteric modulator) were examined. The effect of 
pentobarbital is shown in Figure 3.12. Results are summarised in Table 3.5. Effects 
upon a (L 9 T ) (Tierney et al., 1996) and aß  wild type receptors (Birnir et al., 1995) are 
shown for comparison.
Receptors mutated in the ß subunit alone
Receptors mutated in the ß subunit alone were examined first because these mutants 
showed the greatest shift in EC5o for GABA.
Bicuculline: 100 pM bicuculline reduced the peak current produced in response to
100 |iM GABA to 0.16 ± 0.06 (n=3) in wild type receptors (Birnir et al., 1995).
In aß(L 9T ) receptors, 100 pM bicuculline reduced the peak current response to 10 mM 
GABA to 0.83 (n=2). 1 mM bicuculline reduced the peak current response to 10 mM 
GABA to 0.29 (n=l).
In aß(L9'Y ) receptors 100 pM bicuculline reduced the peak current to 0.22 of the 
response to 100 pM GABA (n=l).
A1 nA 
2 sec
c
1 sec
100 pA
1 sec
Figure 3.12 Modulation of GABA-activated current by pentobarbital
Current responses to 10 pM GABA (left trace) and 10 pM GABA in combination with 
100 pM pentobarbital (right trace) are shown. In (C) 1 mM GABA was used. Drugs 
were applied during the period indicated by the bar. Cells expressed: (A) aß  wild type, 
(B) a(L 9T )ß , (C) aß(L 9T ) and (D) a(L9'Y)ß(L9'Y) receptors.
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Pentobarbital: The effect of pentobarbital was assessed by changes in the mean current 
over the first second of the response to drug (Im) because pentobarbital can change the 
time course of the current generated by GABA (eg. Parker et al., 1986) 100 pM
pentobarbital potentiated the mean current induced by 10 pM GABA by a factor of 
2.25 ± 0.24 (n=5) in wild type receptors.
Concentrations of GABA that produced approximately half maximal current responses 
for each component of the dose response curve for aß(L 9T ) and aß(L9'Y ) receptors 
were used. In ocß(L9'F) receptors, 100 pM pentobarbital increased the mean current in 
response to 10 pM GABA by a factor of 4.40 ± 0.99 (n=4), significantly more than in 
wild type receptors. 100 pM pentobarbital increased the mean current in response to 
1 mM GABA by a factor of 1.8 (n=l).
In aß(L9'Y ) receptors, 100 pM pentobarbital increased the mean current in response to 
10 pM GABA by a factor 3.64 ±0.34 (n=3), significantly more than in wild type 
receptors (2 tailed t-test, p<0.05). 100 pM pentobarbital increased the mean current in 
response to 1 mM GABA by a factor of 1.2 ± 0.2 (n=3).
Receptors mutated in the a  subunit alone
Bicuculline: In a(L9'F)ß receptors 100 pM bicuculline completely inhibited the
response to 100 pM GABA (n=l). In a(L9'Y)ß receptors, 100 pM bicuculline reduced 
the response to 100 pM GABA to 0.05 ± 0.05 (n=3), not significantly different from in 
wild type receptors.
Pentobarbital: In a(L9'F)ß receptors, 100 pM pentobarbital reduced the mean current 
response to 10 pM GABA to 0.91 of (n=2). Similarly, in cells expressing a(L9'Y)ß 
receptors, 100 pM pentobarbital reduced the mean current response to 10 pM GABA to 
0.83 ± 0.04 (n=3) which was significantly different from the potentiating effect seen in 
wild type receptors. These results show that while the blocking action of bicuculline 
remained intact, potentiation by pentobarbital was abolished in the a  subunit mutated 
receptors.
Receptors mutated in a  and ß subunits
Pentobarbital: In a(L9'F)ß(L9'F) receptors, 100 pM pentobarbital reduced the mean 
current response to 10 pM GABA to 0.29 (n=l, measured for 100 ms). In
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ot(L9'Y)ß(L9'Y) receptors, 100 pM pentobarbital inhibited the mean current response to 
10 pM GABA to 0.33 (n=l, measured for 40 ms).
These results show that the potentiating effect of pentobarbital was maintained in 
receptors carrying either the L9'F or the L9'Y mutation in the ß subunit but not in the a  
subunit. When mutations are in both subunits, pentobarbital inhibited the response to 
GABA. It appears that pentobarbital has become a negative allosteric modulator but 
more observations are required to fully investigate this phenomenon.
Pentobarbital alone: Pentobarbital is also able to directly activate GABAa receptors. In 
wild type receptors, 1 mM pentobarbital produces a current that is 0.30 ± 0.14 (n=3) of 
the response to 10 pM GABA. (cf. Chapter 4.3.8). Pentobarbital may bind at a different 
site for its potentiating effect than it does to directly activate the receptor. It is possible 
that the potentiation by pentobarbital is altered in the double mutants but direct activation 
may still occur However no current was detected in response to 1 mM pentobarbital in 
either (L9T)ß(L9T) or ot(L9'Y)ß(L9'Y) receptors that responded to GABA (n=3).
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3.4 Discussion
3.4.1 Resting membrane conductance
The lack of any increase in resting membrane conductance in cells expressing L9'Y and 
L9T  receptors indicates that the presence of an hydroxyl group is insufficient to increase 
the resting membrane conductance. The increased resting conductance previously 
reported when threonine was substituted for leucine (L9T) can most likely be attributed 
to the reduced size of the threonine residue (Tierney et al., 1996). Both threonine and 
tyrosine contain an hydroxyl group capable of hydrogen bonding. This could 
theoretically replace a water molecule contributing to the hydration shell of a chloride ion 
and allow ion permeation in what is usually a closed conformation. The finding that 
neither L9'Y or L9T receptors increased the resting membrane conductance indicates 
that the size of the 9' residue is important to maintain a closed or resting conformation. 
These results do not determine whether a reduction in residue size alone would be 
sufficient to increase the resting membrane conductance. This could be determined by 
substitution of leucine with a range of smaller hydrophobic residues (eg. alanine, glycine 
or valine).
Effects of the L9' mutations upon the resting membrane conductance agree in many 
respects with results from a recent study by Chang and Weiss, (1998) in human pi 
GABAc receptors. When leucine was replaced with threonine pi(L9'T) the resting 
current was increased and when replaced by phenylalanine pi(L9T), it was not. 
However, when L9' was replaced by tyrosine pi(L9'Y) the resting conductance was 
again increased, but less than for pi(L9'T) mutated receptors.
The reason for the differences in resting conductance between a(L9'Y)ß(L9'Y) and 
Pi(L9'Y) receptors is not clear. There are functional and pharmacological differences 
between these receptor types, p subunits share only 30 - 38% sequence identity with 
GABAa subunits. GABAc receptors have a slightly larger pore size (5.6 Ä) than 
GABAa receptors (5.1 Ä) (Cherubini and Strata, 1997). This may be sufficient to 
explain why pi(L9'Y) receptors had an increased resting conductance and 
a(L9'Y)ß(L9'Y) receptors did not.
The location of the gate is still controversial. Unwin (1995) has suggested that L9’ is the 
gate. Other studies suggest that it is located at a more intracellular location in GABAa
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(Xu et a l 1995) and nACh receptors (Akabas et a/., 1994). A recent study by Wilson 
and Karlin (1998) in nACh receptors implicates residues at the intracellular end of M2 in 
the gating mechanism. Our results are consistent with L9' preventing ion permeation in 
the absence of GABA, but are not able to discriminate between L9' being the gate or 
occluding ion flow through the channel in an unbound receptor conformation.
3.4.2 ß  subunit specific increase in ECso
The shift in the GABA dose-response relationship to higher concentrations for L9T and 
L9'Y mutated receptors is a new finding that has not been reported before in L9' mutated 
ligand-gated receptors. The increase in EC50 was predominantly ß subunit specific. 
Mutation of the ß subunit produced a dose-response relationship which was best fitted by 
the sum of two Hill equations. One component had an E C 5 0  that was not significantly 
different from wild type. The other had an increase in E C 5 0  of two orders of magnitude. 
Mutation of the a  subunit alone increased the E C 5 0  2  to 5-fold. When the L9T mutation 
was in both subunits, the E C 5 0  was not significantly different from that in wild type 
receptors.
When leucine 9' was mutated to threonine in the ßi subunit of GABAa otißi receptors 
there were subunit specific effects on GABA-activation (Tierney et al., 1996). The 
response to GABA was completely abolished when the mutation was in the ß subunit or 
in both a  and ß subunits, but receptors were still able to bind muscimol. Due to the 
reduced size of the residue, the ß subunit may be unable to transmit conformational 
changes following GABA binding that are required for normal GABA-activation.
The increases in E C 5 0  observed in this study conflict with results reported for L9' 
mutations in other GABA receptors (Chang et al., 1996; Chang and Weiss, 1998). In rat 
a iß 2y2 GABAa receptors, the L9'S in mutation reduced the EC50 by about two orders of 
magnitude when the mutation was in either the a  or y subunit and reduced the EC50 by 
about three orders of magnitude when the mutation was in the ß subunit (Chang et al., 
1996). It is of note that the greatest shift in EC50 occurred when the mutation was in the 
ß subunit.
Reasons for differences in the direction of the shift in the dose-response relationship 
between the two receptors are not clear. Differences in the size and hydrophobicity of 
the residue substituted are unlikely to be responsible because the a(L 9’T)ß mutation in
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otißi GABAa receptors does not alter the EC50 (Tierney et al., 1996). Differences in the 
receptor isoforms present (eg. aß  or aßy) would produce receptors that differ in the 
number of mutated receptors in the complex. This would alter the interactions between 
residues at the 9' position and this may underlie the differences observed between studies.
The lack of change in EC50 when both subunits were mutated is comparable with findings 
in pi homomeric receptors. Mutation of L9' to phenylalanine, tyrosine, valine, or 
isoleucine had little effect upon the EC50 although, Hill coefficients were reduced from 
2.4 to approximately 1 (Chang and Weiss, 1998).
Similarly, mutation of L9' to either F, T or A in 5-HT3 receptors had little effect on the 
EC50 (Yakel et al., 1993). In contrast to the current findings, mutation of L9' in neuronal 
and muscle nACh receptors reduces EC50 values (Revah et al., 1991; Amin and Weiss, 
1993; Labarca et al., 1995).
3.4.3 Dual component GABA dose -response curves in ß  mutated receptors 
The cause of two components in the dose response curves is not obvious. Several 
interpretations are possible. It may reflect the presence of more than one population of ß 
subunit mutated receptors in this expression system. This may be due to effects on 
subunit assembly that alter receptor stoichiometry or subunit arrangement. It is also 
possible that there is only one population of receptors and that single channel properties 
have been altered in a concentration dependent manner. Several different explanations 
will be considered.
Receptor stoichiometry
The stoichiometry of aß  receptors is controversial but there is increasing evidence for a 
pentameric structure consisting of three a  subunits and two ß subunits (Im et al., 1995b; 
Chang et al., 1996). Many studies indicate that at least two a  subunits are present in 
GABAa receptors (Duggan et al., 1991; Pollard et al., 1993; Verdoorn, 1994; Im et al., 
1995b; Chang et al., 1996; Tretter et al., 1997; Jechlinger et al., 1998). The mutation in 
the ß subunit may have introduced a second receptor stoichiometry with a reduced 
apparent affinity for GABA. The increased EC50 for one component of the dose- 
response relationship may reflect the presence of more mutated ß subunits in the 
receptor. It cannot be ruled out that several additional receptor stoichiometries could 
form but this may add more components to the dose response curve than the two
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observed. A simpler explanation is that only the orientation of subunits relative to one 
another has changed giving two different receptor populations.
It cannot be ruled out that wild type receptors normally have variable stoichiometries and 
that the mutation has increased the affinity of one receptor population and not another. 
This is probably unlikely based on what is currently known about the stoichiometry of 
functional GABAa receptors.
Subunit arrangement
If specific interactions between a  and ß subunits are important for agonist binding and 
channel gating, then changing the subunit arrangement could affect the EC50. In a 
pentameric receptor containing three of one subunit isoform and two of another there are 
two possible subunit arrangements. The two identical subunits may be either adjacent to 
or separate from each other. The following discussion will assume a stoichiometry for 
ocißi wild type receptors of three a  subunits and tv/o ß subunits arranged a -ß -a -ß -a  
(Im et al., 1995b). ßi subunits would therefore be separated from each other 
(Figure 3.13 A).
ß  subunit mutated receptors: Substitution of L9' in the ß subunit by phenylalanine or 
tyrosine may have affected interactions between subunits due to the introduced aromatic 
residues. This may lead to formation of receptors with different properties, ß-ß dimers 
could be formed in preference to a-ß  dimers in the assembly of ß subunit mutated 
receptors. This could lead to the formation of receptors in which the ß subunits are 
adjacent to each other. Reduction in the amount of a-ß  dimers formed may mean that ß- 
ß dimers are more likely to interact with a  monomers to form receptors. The “new” 
receptors would contain only one interaction between a  and ß subunits that is in the 
same orientation as in wild type receptors. This would reduce the number of high affinity 
binding sites on the receptor from two to one. It may also affect formation of a low 
affinity GABA binding site or alter channel gating characteristics and therefore increase 
the EC50. The “new” receptors may greatly out number the “normal” receptors and 
therefore comprise a greater fraction of the whole-cell current than “normal” receptors.
a subunit mutated receptors: This explanation could be extended to receptors mutated 
in the a  subunit alone, a - a  dimers may prevail over a-ß  dimers but may be less affected 
than the ß-ß interaction. The presence of an a - a  dimer would have less effect upon 
subunit arrangement because receptors normally contain two adjacent a  subunits. This
A B
Figure 3.13 Subunit arrangements
The two possible subunit arrangements for a receptor stoichiometry of three a  subunits 
and two ß subunits are shown. In (A) the ß subunits are separated and in (B) they are 
adjacent.
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would result in no major change in EC50 as was observed in receptors mutated in the a  
subunit alone.
Receptors mutated in both subunits: Receptors mutated in both a  and ß subunits would 
presumably form both heteromeric and homomeric dimers. Interactions between 
subunits would be equally affected and it is unlikely that a specific combination would 
predominate during assembly. This would result in no major change in EC50, as observed 
in ot(L9T)ß(L9'F) receptors.
Single receptor population
Assuming a single receptor population in which the high affinity component is most 
affected by mutation of the ß subunit, and the low affinity component is most “normal”, 
single channel properties may be impaired at low GABA concentrations but close to 
“normal” at high GABA concentrations. Such effects may reduce the slope of the dose- 
response curve, but would be unlikely to separate it into two distinct components.
It seems most likely that the dual component dose-response curve arises from two 
different receptor populations. It cannot be ruled out that several additional receptor 
stoichiometries could have formed (with similar increases in EC50). The simplest and 
most likely explanation is that only the orientation of subunits relative to one another has 
changed, giving a new receptor with a different subunit arrangement.
3.4.4 Reduced maximum current and increased desensitisation in a  mutants 
Currents produced at saturating GABA concentrations were reduced in amplitude and 
the rate of desensitisation was increased in receptors mutated in either the a subunit or 
both subunits. In receptors mutated in both subunits, a subunit expression in the plasma 
membrane and Bmax values were also reduced. Reduced efficiency of receptor assembly 
may therefore contribute to the reduced currents in these receptors.
The degree of the increase in desensitisation was greater when both subunits were 
mutated than when only the a subunit was mutated. It remained unchanged in receptors 
mutated in only the ß subunit. It is possible that increased desensitisation, reduced peak 
currents and slight increases in EC50 values for a subunit mutated receptors may be due 
to effects upon receptor gating. The a subunit specific increase in desensitisation may 
suggest that the 9' residue interacts with other regions of the receptor that are important 
for gating yet are distinct from the interactions of the 9' residue in the ß subunit.
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The extremely fast rate of desensitisation in a(L9'Y)ß(L9'Y) receptors is unusual. An 
open conformation may have become unstable, altering channel gating and resulting in 
rapid decay of whole-cell currents. Another possibility is that a new open conformation 
can form that has an ion permeation pathway different from normal. It has been shown 
that when L9'(264) in the a i subunit of a iß iy2 receptors is mutated to cysteine (L9'C), it 
reacts with sulfhydryl reagents in both the presence and absence of GABA. This 
indicates that L9'C is exposed in the channel in both closed and open conformations (Xu 
and Akabas, 1996). The unusually fast rate of current decay in ot(L9'Y)ß(L9'Y) 
receptors may be due to the hydroxyl group on the tyrosine providing a different 
permeation pathway for ions than in wild type receptors.
In receptors carrying the L9'T mutation, only those mutated in the a  subunit responded 
to GABA, and these were slow to activate and slow to desensitise. They had a 10-90% 
rise time of 116 ± 15 ms, and took 1.1 ±0 .18  s to decay to 80% of the peak current 
(Tierney et al., 1996). Comparing this with the results from the current study, the rate of 
current activation and decay increases with increased size and hydrophobicity of the 
residue in the order, T<L<F=Y.
In receptors mutated in both subunits, the rate of desensitisation increased with increased 
size and hydrophobicity of the 9' residue. Phenylalanine and tyrosine are similar in size 
and hydrophobicity (Table 3.1). Therefore, it is possible that the enhanced 
desensitisation in L9'Y receptors compared to L9T may be due to the presence of the 
hydroxyl group on the tyrosine.
Similar trends have been described for pi GABAc, nACh, and 5-HT3 receptors, (Chang 
and Weiss, 1998; Revah et al., 1991; Yakel et al., 1993). pi receptors do not normally 
desensitise, but do when either L9T or L9'Y mutations are present (Chang and Weiss, 
1998). The rate of current decay increases in the order L<F<Y, similar to the order for 
the double mutants in the current study.
Increased desensitisation in L9’F and L9’Y mutated receptors, and reduced 
desensitisation in L9’T, are also reported in nACh and 5-HT3 receptors. The rate of 
desensitisation increased with increased size and hydrophobicity of the 9' residue, in the 
rank order S<T<V<L<F in neuronal 0 C7 nACh receptors (Revah et al., 1991). It is of 
note that a 90% reduction in peak current was reported in a?(L9'F) receptors, similar to 
our observation for a(L9'F)ß(L9'F) receptors. The desensitisation rate for 5-HT3
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receptors increased in the order, T<L<A<Y<F, for residues at the 9' position. (Yakel et 
al., 1993).
3.4.5 Changes in muscimol binding and receptor expression
The 2-fold increase in Kd in otß(L9'F) receptors indicates that the mutation had a small 
effect on the structure of a high affinity agonist binding site(s). There was no change in 
Bmax, suggesting that there was no reduction in the number of high affinity binding sites 
present. Interactions between subunits that are important in the formation of high affinity 
binding sites may have been altered so that the binding affinity of some sites was reduced.
Reduced Bmax values and reduced levels of a  subunit in the plasma membrane in 
a(L9'F)ß(L9'F) and a(L9'Y)ß(L9'Y) receptors indicates that receptor assembly may 
have been impaired. The K<j was increased by 2-fold in a(L9'Y)ß(L9'Y) receptors, 
indicating a reduction in binding affinity. The Kd was not changed in ot(L9'F)ß(L9'F) 
receptors. These results may indicate that a(L9'Y)ß(L9'Y) receptors had a more 
disruptive effect upon receptor assembly and muscimol binding than a(L9'F)ß(L9'F) 
receptors.
3.4.6 L9' interactions in receptor function
Effects of the L9'F and L9'Y mutations upon receptor assembly and channel function 
suggest that the 9' residue may be important in interactions between subunits. The 
mutations may have altered interactions between 9' residues that are important in GABA 
activation.
Leucine is hydrophobic and GABA binding may initiate allosteric changes in protein 
conformation that disrupt the relatively weak leucine-to-leucine interactions and enable 
the channel to form an open conformation (Unwin, 1995). While aromatic-aromatic 
interactions are typically weak hydrophobic interactions they are able to stabilise protein 
tertiary structure (Burley and Petsko, 1985). The conformational changes required to 
open the channel may be more difficult with phenylalanine or tyrosine residues at the 9' 
position in the ß subunit than with leucine in the same position.
Aromatic residues do not all interact in the same manner. The preferred interaction 
between phenylalanine residues is the “edge-to-face” perpendicular aromatic-aromatic 
interaction, in which the positively charged hydrogen atoms of one ring interact with the 
7t-electron cloud of a second aromatic ring, (as opposed to “face-to-face” stacking of
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benzene rings, which does not occur as frequently in protein structures). In the 
hydrophobic environment of a protein, electrostatic interactions are the dominant force in 
phenylalanine-phenylalanine interactions (Burley and Petsko, 1988; Singh and Thornton, 
1985; Hunter et a/., 1991). It has been shown the aromatic interactions of phenylalanine- 
phenylalanine and tyrosine- tyrosine can contribute equally to protein stability (Serrano et 
a/., 1991). Tyrosine residues are also capable of forming hydrogen bonds via their 
hydroxyl groups. The hydrogen bond includes an electrostatic dipole-dipole interaction 
and a charge transfer interaction, whereas the aromatic interactions are governed by 
weakly polar forces (Burley and Petsko, 1988). Differences in interactions between L9’F 
and L9’Y residues may underlie the functional differences observed between receptors. 
Modeling of these residues may show differences between leucine, phenylalanine and 
tyrosine in the interactions they could form.
A simple molecular model of the M2 region was generated using the Biosym/MSI 
programs to investigate possible interactions between residues at the 9' position. Models 
are shown in Figures 3.14 and 3.15. Five M2 regions from the a i subunit were modelled 
as a-helices and aligned length-wise such that an L9' residue from each subunit faced 
inward (Figure 3.14). When phenylalanine was substituted for L9' in this model, residues 
formed interactions via their benzene rings (Figure 3.15 A). In contrast, tyrosine residues 
interacted via their hydroxyl side chains (Figure 3.15 B). While this basic model does not 
consider possible structural constraints placed on the M2 region by other parts of the 
protein, it is consistent with what is known about interactions favoured by these residues. 
It indicates that differences between leucine-leucine, phenylalanine-phenylalanine and 
tyrosine-tyrosine residues could occur which may underlie the functional differences 
between mutated and wild type receptors.
3.4. 7 Pharmacology
Bicuculline: Higher concentrations of bicuculline were required to produce the same 
degree of inhibition at saturating GABA concentrations in oc(L9'F)ß receptors than in 
wild type receptors. This difference may reflect changes in low affinity binding site(s) for 
GABA and bicuculline. It is consistent with the reduction in high affinity muscimol 
binding in oc(L9'F)ß receptors.
Pentobarbital. Pentobarbital potentiated the response to GABA in receptors mutated in 
the ß subunit alone, but not in receptors mutated in the a  subunit alone. This is
Figure 3.14 Molecular model of the M2 region
A molecular model of the M2 region of the oti GABAa subunit was generated using the 
Biosym/MSI programs. Insight II was used for the modelling and Discover 95 for 
energy minimizations. The M2 regions are aligned so that L9’ residues face inward. L9’ 
residues are enlarged. The atoms are shown in the following colours: carbon (green), 
nitrogen (blue), hydrogen (white), and oxygen (red). A chloride ion is shown in yellow.
Figure 3.15 Molecular models of the M2 region with L9'F and L9'Y substitutions
A molecular model of the M2 region of the a, GABAa subunit was generated using the 
Biosym/MSI programs. Insight II was used for the modelling and Discover 95 for 
energy minimisations. The M2 regions are aligned so that 9' residues face inward and 
are enlarged. L9' residues replaced with phenylalanine residues (top) show “edge-to- 
face” interactions between the benzene rings. L9' residues replaced with tyrosine 
resides (lower) show interactions between their hydroxyl groups. The atoms are shown 
in the following colours: carbon (green), nitrogen (blue), hydrogen (white), and oxygen 
(red).
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consistent with the effect of pentobarbital in a(L 9T )ß  receptors in which potentiation by 
pentobarbital was also abolished (Tierney et al., 1996). The inhibitory effect of 
pentobarbital upon the response to GABA observed in receptors mutated in both 
subunits indicates that pentobarbital is still able to bind but that its effect upon gating has 
been modified. This suggests a role for L9’ in coupling pentobarbital binding to its 
potentiating effect.
3.5 Summary
This study demonstrates the importance of the L9' residue in the conformational changes 
that couple agonist binding to channel activation. Residues mutated at other positions in 
the M2 region in GABAa (Xißi receptors have shown no change in EC50 or in resting 
membrane conductance compared to wild type, V 5T  (Birnir et a l., 1997b), T6'A 
(B. Cromer, personal communication), TIO'A (Tierney et a l., 1998), T12'Q (cf. Chapter 
4), T13'A (cf. Chapter 5), supporting a unique role for L9' in the mechanisms involved in 
GABA activation.
The results suggest that interactions between M2 regions at the level of the 9' residue 
may be important for subunit-subunit contacts during subunit assembly and in receptor 
function They show that the size and hydrophobicity of L9' are important for 
maintaining a closed channel conformation in the absence of GABA.
The increase in EC50 suggests that the 9' residue in the ß subunit has a significant role in 
GABA activation. The findings in this study indicate that L9' may be important in the 
conformational changes which couple GABA binding to channel opening.
3.5.1 Future directions
Single channel analysis would be useful to determine whether the dual dose-response 
relationship for receptors mutated in the ß subunit alone is due to two separate 
populations of receptor that differ in their conductance or gating properties.
Effects of pentobarbital require further investigation. It is possible that the effects of 
other drugs that act on otißi GABAa receptors may also be altered in the a  subunit 
mutated receptors.
Fluorescence methods could be used to investigate relative movements between subunits 
immediately following agonist activation and during desensitisation.
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Chapter 4
4. Mutation of Threonine 12' to Glutamine in the 
Pi Subunit Abolishes Potentiation by 
Pentobarbital
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4.1 Introduction
Amino acid residues in the M2 region are highly conserved across the ACh receptor 
superfamily (Figure 1.3). Increasing evidence points to a role for residues in this region 
in desensitisation. When residues adjacent to leucine 9' were mutated in GABAa 
receptors desensitisation was altered (Im et al., 1995a; Birnir et al., 1997b; Tierney et 
al., 1998; B. Cromer, personal communication). Mutation of threonine 13' to alanine 
(T266A) in the a 6 subunit of HEK cells expressing ot6, ß2 and y2 subunits, increased the 
rate of desensitisation (Im et al., 1995a). Mutation of threonine 10' to alanine in 
both a i and ßi GABAa subunits increased the rate of desensitisation (B. Cromer, 
personal communication; Tierney et a/., 1998), while mutation of valine 5' to threonine 
reduced it (Birnir et al., 1997b). In neuronal nACh receptors, mutation of 6' threonine 
to glutamine (T244Q), and valine 13' to threonine (V251T), reduced the rate of 
desensitisation (Devilliers-Thiery et al., 1992). Mutation of other residues in this region 
(at 8' (L246T) and 10' (S248A) positions) did not alter desensitisation (Revah et al., 
1991). Taken together these results imply a role for M2 in receptor activation, 
desensitisation and pharmacology. It is not clear how the location of a particular residue 
and its chemical properties influence receptor function.
A threonine residue located approximately one helical turn above leucine 9', at the 12' 
position, is conserved across mammalian GABAa receptor subunits and among other 
subunits of the ACh receptor superfamily. In this study the 12' threonine residue was 
mutated to glutamine (T12'Q) which is similar in hydrophilicity to threonine. Threonine 
is 116.1 Ä'1 in volume compared to glutamine which is 143.9 Ä3. T l2 ' is at position 262 
in the a i subunit and position 267 in the ßi subunit of human otißi GABAa receptors 
(referred to as simply aß). In order to investigate possible subunit differences in 
receptor function the T l2 'Q  mutation was carried out in either the a  subunit (aT l2 'Q ß), 
the ß subunit (aßT l2 'Q ) or in both subunits a(T l2 'Q )ß(T l2 'Q ). The effects of these 
mutations upon the response to GABA and pharmacological properties of the receptor 
were examined.
4.2 Methods
Refer Chapter 2.
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4.3 Results
4.3.1 GABA-activated currents show increased desensitisation
Cells expressing oc(T12'Q)ß, aß(T12'Q) or ot(T12'Q)ß(T12'Q) receptors all produced 
whole cell currents in response to 10 mM GABA. Results are shown in Figure 4.1 and 
current characteristics are summarised in Table 4.1.
The 50% decay time (T50)was 92 ±16  ms (n=9) for a(T12'Q)ß receptors and 
124 ± 20 ms (n=l 1) for ocß(T12'Q) receptors, significantly different from the T5o in wild 
type receptors (223 ± 43 ms, n=6). In a(T12'Q)ß(T12'Q) receptors, the T50 was 
128 ± 32  ms (n=9), not significantly different from in wild type receptors. In the 
continued presence of 10 mM GABA, however, these receptors exhibited a negligible 
steady state current. This effect can be seen in Figure 4.1. In a(T12'Q)ß(T12'Q) 
receptors, no current was detected 0.9 ± 0.2 s (n=9) following application of GABA. 
Similarly, in otß(T12'Q) receptors no current was detected 1.4 ± 0.2 s following 
application of GABA. Increased, but incomplete, current decay was observed in 
a(T12'Q)ß receptors. The current remaining 1 second following GABA application, as 
a ratio of the peak current (lisec/IP), was reduced to 0.05 ± 0.01 (n=9), significantly less 
than in wild type receptors (0.16 ± 0.03, n=6).
The current rise times in cells expressing ot(T12'Q)ß, aß(T12'Q ) and
a(T12'Q)ß(T12'Q) receptors were, 6.1 ± 0.9 ms (n=9), 3.2 ± 0.3 ms (n=l 1), 4.2 ± 0.5 ms 
(n=9) respectively, upon rapid application of 10 mM GABA. These rise times are 
significantly faster than in wild type receptors (16 ± 2 ms, n=6). There was no reduction 
in peak current amplitude in any of the T12'Q mutated receptors.
4.3.2 GABA dose-response relationship
Receptors mutated in the M2 region that show changes in their rate of desensitisation 
often show changes in their dose-response relationship as well (Revah et al, 1991; 
Yakel et al, 1993; Filatov and White, 1995; Labarca et al., 1995; Chang et al., 1996).
In order to determine whether the altered desensitisation in T12'Q mutated receptors 
was accompanied by changes in EC50, dose-response curves were constructed 
(Figure 4.2). Data were fitted using equation 2.1. EC50 values and Hill coefficients are 
summarised in Table 4.2. Values are shown as the m ean±lSE M . Results were 
compared with those previously reported for wild type receptors (Birnir et al., 1995).
A B
2 sec 1 sec
c D
0.5 nA
1 sec
//
0.5 nA
1 sec
Figure 4.1 Whole-cell currents activated by 10 mM GABA
Whole-cell currents activated by a saturating concentration of GABA are shown. 10 mM 
GABA was applied during the period indicated by the bar to cells expressing: (A) wild 
type receptors, (B) a(T12'Q)ß(T12'Q) receptors, (C) ot(T12'Q)ß receptors or (D) 
aß(T12'Q) receptors. The current produced by wild type receptors (A) decayed to a 
plateau current in the continued presence of GABA. In (C) the current decay for 
a(T12'Q)ß receptors is shown at a higher resolution, revealing the presence of a small 
plateau current. In contrast, a(T12'Q)ß(T12'Q) and aß(T12'Q) receptors showed no 
detectable plateau.
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Figure 4.2 GABA dose-response curves and Scatchard plots
The peak amplitude of the whole-cell current activated by GABA are plotted against 
concentration. Dose-response curves and Scatchard plots of the same data are shown in: 
(A) and (B) for ot(T12'Q)ß receptors (n=10) (C) and (D) for aß(T12'Q) receptors, 
(n=17) and (E) and (F) for a(T12'Q)ß(T12'Q) receptors (n=21), respectively. Peak 
currents elicited in a cell by various concentrations of GABA were normalised to the 
current elicited in the same cell by 10 pM GABA in cells expressing ot(T12'Q)ß 
receptors and to 5 pM GABA in cells expressing aß(T12'Q) or a(T12'Q)ß(T12'Q) 
receptors. Symbols show the mean normalised current (/') and the vertical bars ± 1 SEM 
in 3 or more cells. Curves were fitted to the data in A, C and E using the Hill equation. 
The curve for wild type is also shown as a comparison. Scatchard plots are presented as 
line graphs. Figure and data are from Dr. B.Birnir.
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ln ot(T12'Q)ß receptors, the EC50 was 8 ± 1  and the Hill coefficient was 1.1 ±0.2 
(n=10) and in aß(T12'Q) receptors they were 15 ± 7 and 0.6 ± 0.2 (n=17), respectively. 
In ot(T12'Q)ß(T12'Q) receptors they were 6 ± 1  and 0.7 ±0.1 (n=21), respectively. 
EC50 values for the single mutants were not significantly different from wild type, but the 
EC50 was reduced to about half normal when receptors were mutated in both subunits. 
Hill coefficients of less than 1 for the ßi subunit mutated receptors indicates negative 
cooperativity. This is shown visually in Figure 4.2 by the reduced slope of the curves 
and greater sensitivity to low GABA concentrations. Reduced cooperativity is also 
demonstrated by the differing shapes of the corresponding Scatchard plots. The concave 
shape of the Scatchard plots for a(T12'Q)ß(T12'Q) and otß(T12'Q) receptors indicates 
either negative cooperativity or dissimilar binding sites. This differs from the convex 
shape of the Scatchard plot for ot(T12'Q)ß receptors, indicating positive cooperativity. 
These results show a 2-fold increase in the apparent affinity for GABA in the T12'Q 
double mutant and reduced cooperativity for receptors mutated in the ß subunit.
4.3.3 Muscimol binding is not affected
Some mutated receptors that show changes in their response to GABA and muscimol 
are thought to be due to effects upon agonist binding (Amin and Weiss, 1993). 
Muscimol binding assays were therefore used to detect possible changes in the high 
affinity ligand binding domains. Data were fitted using equation 2.3. Cells expressing 
ot(T12'Q)ß(T12'Q) receptors have a IQ of 23 nM (n=2) (Tierney, 1995), compared with 
a IQ of 29 ± 2 nM, n=8 in wild type receptors (Tierney et al., 1996). These results 
indicate that the T12'Q mutation probably did not alter the high affinity binding domains.
4.3.4 Pharmacology
The response of ot(T12'Q)ß(T12'Q) receptors to bicuculline, picrotoxin and penicillin 
was examined. Bicuculline competes with GABA in binding to the receptor. Picrotoxin 
has effects upon the channel which may be allosteric. Penicillin blocks the open channel. 
Due to their different properties, they provide useful tools to assess any effects the 
mutation may have had upon receptor function. Current traces showing inhibition of 
response to 100 pM GABA by the 3 different drugs are shown in Figure 4.3 and data 
are summarised in Table 4.3.
400 pA 300 pA
5 sec 3 sec
Figure 4.3 Effects of inhibitory drugs on a(T12'Q)ß(T12'Q) receptors
Currents elicited by 100 pM GABA alone (left trace) were compared with currents 
activated by GABA in the presence of different inhibitory drugs (right trace): (A)
100 pM bicuculline, (B) 100 pM picrotoxin, (C) lOmM penicillin and (D) 100 pM 
penicillin. Drugs were applied for the period indicated by the bar.
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Bicuculline: 100 pM bicuculline reduced the peak current produced in response to
100 pM GABA to 0.20 ± 0.05 (n=3), not significantly different from the inhibition 
produced in wild type receptors (0.16 ±0.06, n=3 (Birnir etal., 1995)).
Picrotoxin: 100 pM picrotoxin inhibited the peak current produced in response to
100 pM GABA to 0.57 ± 0.16, not significantly different from the inhibition produced in 
wild type receptors (0.46 ± 0.02, n=8 (Birnir et al., 1995)). The mean current measured 
for one second was reduced to 0.47 ±0.13 (n=5), which was significantly less than the 
inhibition produced in wild type receptors (0.12 ± 0.02, n=8 (Birnir et al., 1995)).
Penicillin: 10 mM penicillin reduced the peak current produced in response to 100 pM 
GABA to 0.03 ±0.02 (n=4). In wild type receptors lOmM penicillin completely 
inhibited the response to 100 pM GABA (n=3).
4.3.5 Penicillin produces a current upon removal
A “removal” ourrent was produced upon cessation of application of 100 pM GABA in 
combination with 10 mM penicillin in cells expressing oc(T12'Q)ß(T12'Q) receptors 
(Figure 4.3 C). This effect was more dramatic when 10 mM penicillin was applied with 
GABA than when 100 pM penicillin was used (Figure 4.3 D).
The removal effect of penicillin was also examined in wild type receptors to determine 
whether this phenomenon was due to the ot(T12'Q)ß(T12'Q) mutation or if it was an 
inherent property of aß  receptors. Results are summarised in Figure 4.4. In addition to 
completely inhibiting the response to 100 pM GABA in wild type receptors, 10 mM 
penicillin also produced a current upon removal (Figure 4.4 B). In three non-infected 
SJ9 cells 10 mM penicillin partially inhibited the background current but did not produce 
any increase in current upon removal of drug (Figure 4.4 A).
The effect of penicillin applied alone was then examined in wild type receptors to find 
out whether t-he presence of GABA was required for the removal-induced current. 
10 mM penicillin produced a removal-induced current (Figure 4.4 C) closely resembling 
that observed in the presence of 100 pM GABA (Figure 4.4 B). The peak amplitude of 
the removal current in this experiment was similar to that obtained with 100 pM GABA 
applied prior to penicillin. Thus the presence of GABA was not required for the 
penicillin-induced removal response, raising the possibility that GABAa receptors were 
not involved. In order to determine whether the penicillin removal current was caused
A B
200 pA
2 sec
c D
Figure 4.4 Effect of penicillin on wild type receptors
Whole-cell currents generated in response to (A) 100 pM GABA, (B) 100 pM GABA 
and 10 mM penicillin, (C) 10 mM penicillin and (D) 10 mM penicillin and 100 pM 
bicuculline. Drugs were applied for the time period indicated by the bar. Horizontal 
calibration bars show 2 sec for (A) and (B), and 4 sec for (C) and (D).
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by GABAa receptors, the effect of bicuculline upon this current was investigated. 
Application of 100 pM bicuculline in combination with 10 mM penicillin inhibited the 
current produced in response to removal of penicillin, indicating that GABAa receptors 
were responsible for this effect (Figure 4.4 D).
The amplitude of the peak current induced by removal of penicillin was time-dependent. 
The peak current amplitude increased with increasing duration of drug application. This 
effect is depicted graphically in Figure 4.5 for several cells expressing either 
ot(T12'Q)ß(T12'Q) or wild type receptors. Penicillin was applied to the same cell for 
increasing periods of time and the peak amplitude of the removal current measured. 
Despite some variation between cells, the general trend was that the peak current 
increased as the exposure time to 10 mM penicillin was increased.
4.3.6 Potentiation by pentobarbital is abolished
The potentiating effect of pentobarbital in ocißi well documented (Schofield et al., 1987; 
Blair et a l., 1988; Malherbe et al., 1990a; Moss et a l., 1991; Porter et al., 1992; Horne 
et al., 1993; Birnir et al., 1992, 1995). The effect of pentobarbital on GAB A-activated 
currents in T12'Q mutated receptors was examined. Current traces of modulation by 
pentobarbital are presented in Figure 4.6 and data are summarised in Table 4.4.
In ot(T12'Q)ß receptors, 100 pM pentobarbital potentiated the peak 10 pM GABA 
current by 2.08 ±0.22 (n=15), not significantly different from 2.13 ±0.18 (n=5) 
recorded for wild type receptors. The potentiating effect of pentobarbital in the 
presence of GABA was abolished in aß(T12'Q) receptors. The current produced in 
response to 100 pM pentobarbital in the presence of 10 pM GABA was 0.96 ±0.04 
(n=8) of the control. A similar lack of effect was found in ot(T12'Q)ß(T12'Q) receptors 
in which the response to GABA in the presence of pentobarbital was 0.89 ± 0.05 (n=5) 
of the control.
It has been reported previously that the potentiating effect of pentobarbital is most 
prominent at low GABA concentrations (Parker et al., 1986; Pritchett et al., 1988). In 
order to maximise current potentiation by pentobarbital the GABA concentration was 
reduced to 3 pM. No current potentiation was observed in either aß(T12'Q ) or 
a(T12'Q)ß(T12'Q) receptors (Table 4.4). The GABA concentration was also increased
ATime (sec)
Figure 4.5 Time dependence of penicillin-induced removal currents
The amplitude of currents produced upon removal of 10 mM penicillin are shown as a 
fraction of the maximum current recorded after different periods of exposure to penicillin 
in cells expressing, (A) wild type and (B) a(T12'Q)ß(T12'Q) receptors. Graphs show 
effects in individual cells (different symbols) after increasing periods of exposure to 
10 mM penicillin.
A0.1 nA
2 sec
B
2 sec
Figure 4.6 Modulation of GABA-activated current by pentobarbital
The current response to 3 pM GABA (left trace) and 3 pM GABA in combination with 
100 pM pentobarbital (right trace) are shown. Drugs were applied during the period 
indicated by the bar to cells expressing: (A) a ß  receptors, (B) a(T12'Q)ß(T12'Q)
receptors, (C) a(T12'Q)ß receptors and (D) aß(T12'Q) receptors.
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to 100 pM, but still no potentiating effect of pentobarbital was observed in cells 
expressing either a(T12'Q)ß(T12'Q) or aß(T12'Q) receptors (Table 4.4).
4.3.7  High pentobarbital concentrations show inhibition
Effects of higher concentrations of pentobarbital were also examined to test whether the 
dose-response relationship for pentobarbital modulation may have shifted to higher 
concentrations in the mutated receptors. In a(T12'Q)ß(T12'Q) receptors, 1 mM 
pentobarbital applied in combination with 10 pM GABA inhibited the GABA-activated 
peak current to 0.37 ± 0.06 (n=4) of control values. When application of GABA in 
combination with pentobarbital was removed from the cell, an increase in the whole cell 
current response was observed (Figure 4.7) similar to that observed on removal of 
penicillin. The removal current did not reach the same peak amplitude as the current 
produced by 100 pM GABA. A similar effect was observed in otß(T12'Q) receptors 
upon application and subsequent removal of 1 mM pentobarbital. In cells expressing 
either wild type or a(T12'Q)ß receptors, potentiation of the response to 10 pM GABA 
by pentobarbital was largely inhibited by 1 mM pentobarbital and a comparable removal 
current observed (Figure 4.7 A).
Inhibition of the potentiating effect of 1 mM pentobarbital in wild type and a(T12'Q)ß 
receptors may reflect a type of open channel block mechanism for pentobarbital at high 
concentrations. In receptors carrying the T12'Q mutation in the ß subunit, the response 
to GABA was partially inhibited by 1 mM pentobarbital. It appears that while the 
potentiating effect of pentobarbital was abolished when the T12'Q mutation was carried 
in the ß subunit, an inhibitory effect of pentobarbital at high concentrations remained 
intact.
The observation that pentobarbital can inhibit the GABA response at higher 
pentobarbital concentrations, and that this effect was greater in the ß subunit mutated 
receptors than in wild type, raises the possibility that the dose-response relationship for 
pentobarbital may have shifted to very low concentrations. Concentrations that normally 
potentiate may now inhibit. In order to test this possibility, low concentrations of 
pentobarbital were applied in combination with 3 pM GABA. Results are summarised in 
Table 4.5. 100 nM pentobarbital did not show any potentiation of the response to 3 pM 
GABA in a(T12'Q)ß(T12'Q) receptors, nor in otß(T12'Q) receptors. In addition,
A B
0.5 nA 0.25 nAl
2 sec 2 sec
Figure 4.7 Modulation of GABA-activated current by 1 mM pentobarbital
Current responses to 10 pM GABA (broken lines) and 10 pM GABA in combination 
with 1 mM pentobarbital (solid lines) are shown for cells expressing: (A) ot(T12'Q)ß or 
(B) a(T12'Q)ß(T12'Q) receptors. GABA was applied during the period indicated by 
the broken bar and GABA plus pentobarbital during the period indicated by the solid 
bar.
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lOnM pentobarbital did not potentiate the response to 3 pM GABA in 
a(T12'Q)ß(T12'Q) receptors (n=2).
4.3.8 Pentobarbital directly activates aß receptors
In addition to modulating the GABA current response, pentobarbital is also able to 
directly activate GABAa receptors (MacDonald and Olsen, 1994; Akaike et al., 1985; 
Peters et al., 1988; Robertson 1989; Yakushiji et al., 1989; Rho et al., 1996). Whole­
cell current traces in response to pentobarbital in mutated and wild type receptors are 
shown in Figure 4.8 and data are summarised in Table 4.6. No measurable current was 
detected in response to 100 pM pentobarbital in three cells expressing wild type 
receptors, yet robust currents were produced in response to 10 pM GABA. 1 mM 
pentobarbital, however, did elicit whole-cell currents that were 0.30 + 0.14 (n=3) of the 
peak current amplitude produced in response to 10 pM GABA. This GABA 
concentration is very close to the half-maximal GABA concentration for cells expressing 
wild type receptors (11 ± 2 , n=12). Therefore, the current produced in response to 
1 mM pentobarbital is approximately 15% of the predicted maximal GABA response.
In cells expressing a(T12'Q)ß(T12'Q) receptors, five out of seven cells produced 
currents in response to 100 pM pentobarbital. Peak current amplitudes ranged from 
40 pA to 170 pA. The current produced in response to 100 pM pentobarbital was 
0.10 ± 0.03 (n=4) of the peak current produced in response to 3 pM GABA which was 
810 ± 100 pA (n=4). This GABA concentration is less than the half maximal GABA 
concentration for this mutant (6 ± 1, n=21). This implies that the maximal current 
attainable in response to GABA would be at least twice that observed for 3 pM GABA. 
This means that the response to 100 pM pentobarbital is probably less than 5% of the 
expected maximal GABA response in these cells. Cells expressing ot(T12'Q)ß or 
aß(T12'Q ) receptors responded to direct activation by pentobarbital (1 mM) in a similar 
manner to wild type. These results show that while the potentiating effect of 
pentobarbital was abolished in ß mutated receptors, direct activation by pentobarbital 
was not impaired.
1 mM pentobarbital produced a removal current in wild type and mutated receptors. 
This was similar to the inhibitory effect 1 mM pentobarbital had on GAB A-activated 
currents in these receptors. This indicates that pentobarbital is able to activate the 
channel and yet inhibit current flow at the same concentration.
A B
C
2 sec
D
1 sec
Figure 4.8 Currents activated by pentobarbital
Currents generated by pentobarbital alone (left trace) and GABA (right trace) in the same 
cell are shown for: (A) aß  receptors, (B) a(T12'Q)ß(T12'Q) receptors, (C) a(T12'Q)ß 
receptors or (D) aß(T12'Q) receptors. In (A), (C) and (D) the response to 1 mM 
pentobarbital is compared with the response to 10 pM GABA; in (B) the response to 
100 pM pentobarbital is compared with the response to 3 pM GABA.
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4.4 Discussion
4.4.1 Subunit specificity
These results show that replacing a highly conserved threonine residue with glutamine at 
the 12' position in the M2 region of aß  GABAa receptors produces subunit specific 
changes in the functional properties of receptors. Receptors which had the T12'Q 
mutation in the ß subunit produced changes in function that were independent of 
whether the homologous residue in the a  subunit also contained the T12'Q mutation. 
The major subunit specific effect observed was abolition of potentiation by pentobarbital 
in receptors with the T12'Q mutation in the ß subunit. The reduction in apparent 
cooperativity, indicated by the concave shape of the Scatchard plots, and loss of the 
plateau current in desensitisation, were also ß subunit specific.
4.4.2 Effects on GABA activation and desensitisation
The change in shape of the Scatchard plots from convex to concave in 
a(T12'Q)ß(T12'Q) and aß(T12'Q) receptors, compared with a(T12'Q)ß receptors 
(Figure 4.2), indicates negative cooperativity. This may be due to a reduction in 
cooperativity of binding between different sites which normally exhibit positive 
cooperativity. It could also be due to reduced cooperativity between subunits that affect 
gating. The EC50 for a(T12'Q)ß(T12'Q) receptors was also decreased to 55% of the 
wild type E C 5 0 . This small change in the GABA dose-response relationship may reflect 
a slight change in receptor kinetics in which the ßi subunit has a greater influence upon 
the GABA-activated conformational changes than either the a  mutated subunit or wild 
type receptorsr This is compatible with a significant role for the ß subunit in transmitting 
conformational changes to other subunits following GABA binding.
The reduced rise and decay times in the T12'Q mutated receptors indicate a role for this 
residue in activation and desensitisation of receptors. The greater extent of 
desensitisation for the ß subunit mutated receptors suggests that this subunit has a 
greater influence upon the desensitisation process than the a  subunit.
It should be noted that the rate of desensitisation of whole-cell currents at saturating 
agonist concentrations is dependent on the rate of activation of receptors. Results from 
the desensitisation experiments described in section 4.3.1 were carried out under 
conditions in which the rate of solution exchange around the cell was about 1 ms. When
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the solution exchange around the cell was slowed, due to slower solution perfusion 
through the bath and hence a slower rate of drug application, rise times were at least 10 
times slower and small plateau currents were sometimes detected for the ß subunit 
mutated receptors. Even under these conditions the rate of current decay was still 
increased compared to wild type receptors.
The appearance of a plateau current upon slow application of agonist is probably due to 
asynchronous activation of the receptors over the cell surface, so that some receptors 
were opening or desensitised before others had bound agonist. The desensitisation 
observed under conditions of rapid application of high, saturating-agonist concentrations 
allows analysis of channel kinetics under non-equilibrium conditions. This enables a 
better macroscopic representation of channel kinetics because the rise of current mainly 
reflects the bound-open equilibrium and the decay presumably represents the equilibrium 
into desensitised states (Westbrook and Jones, 1995, 1996). Therefore, the results 
obtained under fast-flow perfusion conditions, where the plateau current was abolished, 
are a more accurate reflection of desensitisation of receptors than those obtained with 
slower drug application.
The increased desensitisation in ß subunit mutated receptors suggests that the various 
phases of desensitisation may be associated with subunit specific conformational changes 
or interactions. It is possible that T12'Q mutation in the ß subunit produced changes in 
the receptor structure that made the open conformation less probable. The results 
indicate that subunits contribute unequally to the conformational changes involved in 
desensitisation.
Mutations at other positions in the M2 region of otißi GABAa receptors (5', 6', 9', 10', 
and 13') also show changes in the rates of current decay (Birnir et al, 1997b; B. Cromer 
personal communication; Tierney et al., 1996, 1998; cf. chapter 5). Residues mutated in 
the M2 region of nACh (Revah et al., 1991; Devilliers-Thiery et al., 1992) and 5-HT3 
(Yakel et al., 1993) receptors also affect the rate of desensitisation. Desensitisation 
probably involves movement of the M2 region as a whole relative to other membrane- 
spanning regions.
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4.4.3 Pentobarbital modulation is specifically abolished
Complete abolition of the potentiating effect of pentobarbital in receptors carrying the 
T12'Q mutation in the ß subunit shows the importance of subunit specific roles in 
receptor function. At all GABA and pentobarbital concentrations examined the 
potentiating responses produced in ot(T12'Q)ß receptors closely resembled that of aß  
wild type receptors. Complete abolition of the potentiating effect of pentobarbital in 
receptors carrying the T12'Q mutation in the ß subunit, irrespective of whether the 
homologous residue in the a  subunit was mutated or not, shows ß subunit dominance in 
this effect. These results suggest a significant role for the ß subunit in the modulatory 
action of pentobarbital. They identify 12' threonine in the ß subunit as a discrete site in 
the molecular mechanisms that underlie the potentiating action of pentobarbital. This is 
a significant finding because the binding site(s) for pentobarbital and conformational 
changes involved in its modulatory action are unknown.
Using the results from these experiments it is not possible to determine whether 
pentobarbital binding has been affected or whether the allosteric conformational changes 
that link binding to the potentiating effect of pentobarbital have become uncoupled. It is 
possible that 12' threonine has altered the receptor structure so that pentobarbital cannot 
access its binding site. ßT12' could form part of a pentobarbital binding pocket. The 
asymmetric carbon structure of pentobarbital, means that it can exist in two enantiomeric 
forms; S(-) and R(+) (Franks and Lieb, 1994). The potentiating effect of pentobarbital 
shows some stereospecific requirements in spinal-neurons cultured from mice (Barker 
and Mathers, 1981; Huang and Barker, 1980).
Pentobarbital is lipid soluble and has a partition coefficient of 28.0; it therefore has a 
relatively high affinity for lipids and may rapidly enter into the membrane (Bowman and 
Rand, 1980; Nishi and Oyama, 1983). The stereospecificity of pentobarbital and its lipid 
solubility are compatible with there being a specific binding site for pentobarbital located 
in a hydrophobic region of the protein. According to accessibility studies, in cells 
expressing a iß 2Y2 GABAa receptors, when the threonine residue at the 12' position in 
the a i subunit is mutated to cysteine (T267C) it is not exposed in the channel lumen in 
either closed or open states (Xu and Akabas, 1996). It is therefore possible that 12' 
threonine forms part of a pentobarbital binding pocket on the hydrophobic face of the 
second membrane-spanning region. This hypothesis is consistent with other reports
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suggesting that hydrophobic interactions with lipid-facing residues in the second and 
third membrane-spanning regions may form binding pockets for anaesthetics (Forman et 
a l 1995; Beleih et al., 1997; Mihic et al., 1997; Krasowski et al., 1998).
4.4.4 Pentobarbital activation
Loss of potentiation by pentobarbital in ßi subunit mutated receptors, but retention of 
direct activation and the blocking effect at high concentrations suggests that 
pentobarbital may act upon the GABAa receptor via several distinct mechanisms. The 
small current produced in response to pentobarbital compared with GABA is consistent 
with results from other studies using otißi GABAa receptors, a iß i GABAa receptors, 
from bovine brain expressed in mouse fibroblasts, produced currents in response to 
300 pM pentobarbital that were similar in amplitude to that induced by 1 pM GABA in 
cells with a GABA EC50 of 5.6 ±0.2  pM (Horne et a/., 1993). In rat ocißi GABAa 
receptors expressed in Xenopus oocytes, 100 pM pentobarbital produced currents that 
were approximately 20% of the response to 500 pM GABA (Malherbe et al., 1990a). 
In human a iß i receptors expressed in Xenopus oocytes, the current produced in 
response to 50 pM pentobarbital was less than 30% of the current produced in response 
to 5 pM GABA (Sanna et al., 1995). In contrast, no current was detected in response 
to 50 pM pentobarbital in human otißi GABAa receptors expressed in HEK cells 
(Pritchett etal., 1988).
The ability of pentobarbital to directly activate receptors in which potentiation by 
pentobarbital has been abolished clearly indicates that these two actions occur by distinct 
mechanisms. This is consistent with the findings of Davies et al., (1997); coexpression 
of the 8  subunit, with a  and ß subunits, produced receptors that were no longer 
modulated by pentobarbital but were still capable of direct activation. (The same was 
true for propofol and pregnanolone in these receptors).
It is of note that the residue at the 12' location in the 8  subunit is also a threonine. This 
suggests that other receptor domains are probably also involved in the modulatory action 
of pentobarbital. Direct activation by pentobarbital does not occur in otiy and oci5 
heteromultimers, yet is still possible in ß2 or ß3 homomers (Cestari et al., 1996). This 
may suggest a requirement for the ß subunit in activation of the receptor by 
pentobarbital.
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4.4.5 Inhibition at high concentrations
The observed inhibitory effect of pentobarbital at high concentrations on the GABA- 
activated current is consistent with reports that raising the concentration to 1 mM or 
greater causes a reduction in the potentiating effect (Parker et a/., 1986; Yakushiji el al., 
1989; Malherbe et al., 1996; Rho et al., 1996; Cestari et a l., 1996). The “removal” 
current is similar to that observed in other studies (Akaike et al., 1985; Parker, et al., 
1986; Peters et al., 1988; Robertson et al., 1989; Cestari et al., 1996; Rho et al., 1996). 
The “removal” current produced with pentobarbital is similar to that produced by 
penicillin. Penicillin has been shown to block GABAa receptors via an open channel 
block mechanism (Twyman et al., 1992). Blocking of the “removal” current by 
bicuculline indicates that it was due to current flow through GABAa receptors.
Analysis of single channel events in cultured rat hippocampal neurons by Rho et al., 
(1996) showed that 1 mM pentobarbital reduces the mean open time and causes 
flickering of the unitary currents, reflecting fast channel block. They interpreted the 
“removal” current as the relief of channel block due to rapid dissociation of pentobarbital 
from a low affinity channel blocking site and a slow relaxation of the agonist effect.
This explanation may account for the effects of pentobarbital but cannot account for the 
penicillin-induced “removal current” when no agonist was present to first open channels. 
In the absence’ of an agonist, receptors have a low probability of opening. Spontaneous 
single channel openings have been observed for GABAa receptors in native neuronal 
receptors that are inhibited by bicuculline (B. Birnir, personal communication). 
Hippocampal neurons exhibit a “removal current” with lOmM penicillin (M. Lim, 
personal communication). It is possible that penicillin may block channels as they 
spontaneously open, and on removal of drug the channels are transiently open, thereby 
allowing current to pass. This idea is consistent with the observed increase in amplitude 
of the “removal current” with increased exposure time to 10 mM penicillin. It indicates 
that the number of channels blocked by penicillin increases with time.
The observation that bicuculline prevents the removal current produced by penicillin is 
unusual in that bicuculline is thought to inhibit GABA-activated currents by competing 
with GABA for a common binding region, yet produced an inhibitory effect in the 
absence of GABA. Presumably it prevented the penicillin-induced removal current by 
inhibiting the opening of spontaneously active GABAa receptors. This suggests that
81
bicuculline is acting as a negative allosteric modulator rather than simply as a 
competitive antagonist. This is consistent with a recent study in rat a iß 2Y2L GABAa 
receptors mutated in the ß2 subunit (Y157S) at a site implicated in GABA binding (Ueno 
et al., 1997). In these receptors bicuculline showed weak agonist activity (and 
potentiated the response to alphaxalone), consistent with allosteric inhibition of channel 
opening.
An inhibitory action of pentobarbital is not restricted to GABAa receptors. 
Pentobarbital has been found to depress the maximum amplitude and to accelerate the 
rate of voltage dependent inactivation of the calcium current in both snail neurons (Nishi 
and Oyama, 1983) and in frog sensory neurons (Maruyama et a l., 1988). Pentobarbital 
also inhibits sodium channels from rat brain and muscle (Rehberg et a l., 1995) and from 
the electroplax of electric eel (Wartenberg et al., 1994). The blocking effect of 
pentobarbital on both calcium and sodium channels occurred at a concentration range 
from approximately 100 pM to greater than 1 mM.
The lack of potentiation by 1 mM pentobarbital in a(T12'Q)ß and wild type receptors 
suggests an inhibitory effect of pentobarbital. The removal current seen at this 
concentration suggests relief of inhibition upon removal of 1 mM pentobarbital. The 
mechanisms underlying the inhibitory effects of pentobarbital are not clear but our 
results demonstrate that it is distinct from the positive modulatory action of 
pentobarbital since this effect remained intact in aß(T12'Q) and a(T12'Q)ß(T12'Q) 
receptors.
4.4.6 Pentobarbital binding sites
The results from this study cannot determine whether the T12'Q mutation in the ß 
subunit has directly affected pentobarbital binding or whether conformational changes 
that occur following binding have been altered. It is also possible that the mutation may 
prevent pentobarbital from reaching its binding site.
The effects of the T12'Q mutation in the ß subunit on receptor pharmacology are very 
specific. The ability of pentobarbital to directly activate ot(T12'Q)ß(T12'Q) receptors 
remained intact, as did the blocking action of pentobarbital at high concentrations. In 
addition, inhibition by bicuculline, picrotoxin and penicillin was retained, as was the 
degree of muscimol binding. There was also little change in the GABA EC50 value.
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Taken together these results indicate that the point mutations introduced had minimal 
effects on the overall structure of the receptor. T12' in the ß subunit could be located 
on the hydrophobic face of M2 and form part of a binding site for pentobarbital through 
which its potentiating action is mediated. Unidentified residues in M2 and in other 
membrane spanning regions of the ß subunit may also contribute to this hydrophobic 
binding pocket. Direct activation by pentobarbital could be mediated through another 
separate binding site at a different location, possibly on the ß subunit. The inhibitory 
effect of pentobarbital that occurs at high concentrations may be a separate more 
generalised effect that occurs at the level of the ion channel and is probably by an open 
channel block mechanism.
4.4.7  Role o f  M2 in anaesthetic action
Several studies have implicated residues in the M2 region in the action of anaesthetic and 
anticonvulsant drugs in GABAa (Wingrove et al., 1994; Mihic el al., 1997; Beleih et al., 
1997) and nACh receptors (Forman et al., 1995)
Wingrove et al., (1994) identified a role for the 15' residue in M2 of GABAa receptors 
in the action of the anti-convulsant loreclozole and the intravenous general anaesthetic 
etomidate. This residue is also implicated in both potentiation of the GABA response 
and direct activation by etomidate. In contrast, the modulatory and activating effects of 
etomidate were evident in receptors carrying the S15'N mutation in the ß 3 subunit 
(Beleih e ta l., 1997).
Mihic et al., (1997) identified residues at 12' and 15' positions in the M2 region of 
GABAa and glycine receptors in the actions of ethanol and two volatile anaesthetics; 
enflurane and isoflurane. They also identified a residue located toward the extracellular 
end of the M3 region which conferred sensitivity to these anaesthetics. Mutation of this 
residue (M286W) in the ß subunit of oi2 ßi receptors (but not the homologous residue in 
the a  subunit (A291W)) abolished potentiation by propofol (Mihic et al., 1997) but 
direct activation was not affected (Krasowski et al., 1998).
Involvement of residues in the M2 and M3 regions in the action of anaesthetics raises the 
possibility that a hydrophobic binding pocket for these drugs may exist between these
regions.
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Results from the current study and those of others are not able to determine whether 
residues implicated in the action of anaesthetic and anti-convulsant drugs actually form 
part of a binding site, or whether they are involved in gating, or allosteric conformational 
changes that occur following binding (Franks and Lieb, 1997). It is likely that more 
residues in other membrane spanning regions will continue to be implicated in the actions 
of different anaesthetic drugs. Direct evidence for the structure of these anaesthetic 
binding sites awaits higher-resolution structural information for the membrane spanning 
regions of these receptors. A fuller understanding of how anaesthetics bind to receptors 
and alter their channel function may lead to a dramatic improvement in the specificity of 
anaesthetic drug design and reduce the side effects associated with anaesthetic use.
4.4.8 Summary
These results clearly demonstrate subunit differences in modulation by pentobarbital and 
indicate a significant role for the ß subunit in the mechanisms that underlie its action. 
The experiments in this study cannot determine whether the loss of pentobarbital 
potentiation, reduced cooperativity, and the greater increase in desensitisation in ß 
mutated receptors are due to an effect upon a common mechanism. The increase in 
desensitisation occurred in all three T12'Q mutated receptors, but was most dramatic in 
ß mutated receptors. Both subunits are therefore involved in desensitisation, but do not 
contribute equally. Desensitisation is not unique to the T12' residue. Virtually all 
receptors mutated in the M2 region show changes in desensitisation, reflecting a role for 
M2 in conformational changes associated with desensitisation.
In comparison to the effect upon desensitisation, abolition of potentiation by 
pentobarbital showed ß subunit specificity. Changes in coupling between binding and 
gating may be expected to reduce or reverse the effect of pentobarbital, but the complete 
loss of function observed could be a direct effect upon the pentobarbital binding site. 
Direct activation and inhibition by pentobarbital but lack of a potentiating effect clearly 
indicates that these two actions of pentobarbital occur by distinct mechanisms.
The effects on cooperativity and desensitisation are consistent with a role for the ß 
subunit in transmitting conformational changes that occur following ligand binding to the 
membrane spanning regions.
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4.4.9 Future directions
It would be of interest to determine whether the action of any other anaesthetic agents 
are also affected by this mutation to allow further comparison with other studies.
Further mutations at this site may be useful to understand what types of interactions are 
involved in the modulatory effect of pentobarbital. This study showed that mutation of 
T12', to a larger residue of similar hydrophilicity in the ßi subunit, abolished 
pentobarbital modulation. If T12' does indeed comprise part of a binding pocket for 
pentobarbital, then increasing the hydrophobicity of the residue may increase the affinity 
for pentobarbital. A possible mutation for comparison with the effect of T12'Q on 
pentobarbital modulation is T12'V. This would increase the hydrophobicity of the 
residue with only a slight increase in size.
Chapter 5
5. Effects of Mutating 13' Threonine to Alanine
in the M2 Region
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5.1 Introduction
The M2 region of each subunit of the GABAa receptor is thought to contribute to an ion 
permeation pathway. Nine residues have been identified in the M2 region that are 
exposed in the channel, four of which are threonine residues, 6', 7', 10' and 13' (Xu and 
Akabas, 1993, 1996; Xu et al., 1995). They are potential candidates for providing 
solvation for permeating ions. Threonine (T) residues at 6', 10' and 13' positions were 
changed to alanine (A) in both subunits of ocißi GABAa receptors (Tierney et a l., 1998). 
Receptors responded to GABA when subunits were mutated at the 10' position, but not 
when mutated at either 6' or 13' positions. Receptors were, however, present in the 
plasma membrane at wild type levels. T6'A mutated receptors bound muscimol, T13'A 
did not. T13' is conserved among mammalian GABAa receptor subunits. Mutation of 
T13' to alanine (T268A) in the a 6 subunit of cells expressing rat a 6, ß2 and 72 GABAa 
subunits produced receptors that responded to GABA but the rate of desensitisation was 
increased 10-fold (1m et al., 1995a).
In order to examine whether the loss of response to GABA in oc(T13'A)ß(T13'A) 
receptors was subunit specific, mutations were carried out in either the a  subunit, 
a(T13'A)ß, or the ß subunit, aß(T13'A), of aß  GABAa receptors. 13' threonine is at 
position 263 in the a  subunit and at position 268 in the ß subunit. Replacement of 
threonine with alanine removed an hydroxyl group with little alteration in the size of the 
residue. Functional properties of mutant receptors were examined, including activation 
by GABA and other pharmacological agents, and compared with observations in wild 
type receptors. Muscimol binding and immunofluorescent labelling studies were also 
used to determine whether mutated receptors that did not respond to GABA were 
assembled and trafficked to the plasma membrane.
5.2 Methods
Refer Chapter 2.
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5.3 Results
5.3.1 GABA activation and desensitisation.
Cells expressing a(T13'A)ß receptors produced currents in response to 10 mM GABA 
whereas those expressing otß(T13'A) receptors did not. Responses to lOmM GABA 
are shown in Figure 5.1 and current characteristics are summarised in Table 5.1.
a(T13'A)ß receptors. The 50% decay time for cells expressing ot(T13'A)ß receptors 
was 3.5-times faster (62 ± 24 ms, n=14) than in wild type receptors (223 ± 43 ms, n=6). 
The 10-90% rise time was 10 ± 3 ms (n=14), not significantly different from in wild type 
receptors (16 ± 2 ms, n=6). The maximum peak current was 4.0 ± 0.7 nA (n=14), not 
significantly different from in wild type receptors (3.4 ±0 .6  nA, n=12).
5.3.2 The GABA dose response relationship is not altered
In order to determine whether increased desensitisation in a(T13 'A)ß receptors was also 
accompanied by changes in the apparent affinity for GABA, a dose-response curve was 
constructed. Data were fitted using a Hill-type equation (Equation 2.1). Dose response 
curves are shown in Figure 5.2 and EC50 and Hill coefficients in Table 5.1.
In ot(T13'A)ß receptors the EC50 was 9 ± 1  pM and Hill coefficient was 1.2 ± 0  1 
(n=16), not significantly different from values obtained in wild type receptors 
(11 ± 2 pM and 1.3 ± 0.1, respectively).
5.3.3 Receptor Pharmacology
The effects of drugs upon the response to GABA in ot(T13'A)ß receptors was examined. 
The inhibitory effects of bicuculline, picrotoxin and penicillin, and the potentiating effect 
of pentobarbital, upon the GABA response were examined. Results are shown in Figure
5.3 and are summarised in Table 5.2.
q(T13'A)ß receptors
Bicuculline: 100 pM bicuculline reduced the peak current produced in response to
100 pM GABA to 0.45 ±0.03 (n=5) which was significantly less than the inhibition 
produced in wild type receptors (0.16 ± 0.06, n=3 (Birnir et al., 1995)).
Picrotoxin: 100 pM picrotoxin inhibited the peak current produced in response to
100 pM GABA to 0.83 ± 0.09, which was significantly less than the inhibition produced
A B C
2nA
1 sec
D
1 sec
Figure 5.1 GABA-activated whole-cell currents
Whole-cell currents in response to 10 mM GABA in cells expressing: (A) ot(T13'A)ß 
receptors, (B) otß(T13'A) receptors, and (C) a(T13'A)ß(T13'A) receptors. (D) Whole­
cell current decay in response to 10 mM GABA in a cell expressing aß  wild type 
receptors (broken line) and in a cell expressing a(T13'A)ß receptors (solid line). 
Currents are normalised to the peak current amplitude in the cell expressing wild type 
receptors (3.2 nA). The duration of GABA application to wild type receptors (broken 
bar) and to a(T13'A)ß receptors (solid bar) are shown. The upper calibrations bars 
apply to A, B and C.
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Figure 5.2 GABA dose-response curve
Peak currents were normalised to the maximum current produced in response to GABA. 
Responses at different GABA concentrations were measured relative to the response to 
100 pM GABA in the same cell. Data were gathered from 16 cells. Solid circles show 
the mean normalised current (/') and the vertical bars ± 1SEM in 3 or more cells 
expressing ot(T13'A)ß receptors. The triangles represent individual cells. The solid 
curve is a fit of the equation 2.1 to the data. The broken line shows the dose-response 
curve for wild type receptors (Birnir et al., 1995).
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B
GABA+PenGABA
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Figure 5.3 Responses of a(T13'A)ß receptors to drugs
Whole-cell currents elicited in response to 100 pM GABA are shown (left trace) and in 
the presence of inhibitory drugs (right trace): (A) 100 pM bicuculline, (B) lOmM
penicillin and (C) 100 pM picrotoxin. (D) Current response to 10 pM GABA (left 
trace) and in the presence of 100 pM pentobarbital (right trace). Drugs were applied for 
the period indicated by the bar.
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in wild type receptors (0.46 ± 0.02, n=8 (Birnir et al., 1995)). The mean current 
measured for one second was reduced to 0.26 ± 0.04 (n=5) which was also significantly 
less than the inhibition produced in wild type receptors (0.12 ± 0.02, n=8 (Birnir et al., 
1995)).
Penicillin: 10 mM penicillin reduced the peak current produced in response to 100 pM 
GABA to 0.28 ± 0.04. The mean current measured for one second was reduced to 
0.08 ± 0.03, (n=4) of the control. In wild type receptorslO mM penicillin completely 
inhibited the response to 100 pM GABA (n=3). A “removal” current was observed 
upon cessation of penicillin application to a(T13'A)ß receptors.
Pentobarbital: Pentobarbital potentiated the peak current produced in response to
10 pM GABA by 1.64 ±0.24 (n=7), which was not significantly different from the 
potentiation produced in wild type receptors (2.13 ± 0.18, n=5). The mean current 
measured for one second was increased by a factor of 4.50 ±0.89 (n=7) which was 
significantly greater than in wild type receptors (2.25 ± 0.24, n=5).
qß(T13'A) receptors
No current was detected in response to 10 mM GABA in the presence or absence of 
100 pM pentobarbital (n=5) in cells expressing aß(T13'A) receptors. When lOmM 
penicillin was applied alone it partially inhibited the background current but no removal 
current was observed.
5.3.4 a subunit levels in the plasma membrane
It is possible that the lack of response to GABA in cells expressing aß(T13'A) receptors 
is due to the mutation impairing receptor assembly and trafficking to the plasma 
membrane. The level of the a  subunit present in the plasma membrane has been 
examined in non-permeabilised cells and total receptor expression examined in 
permeabilised cells (Tierney, 1995). Fluorescence is calculated as a percent of the level 
for wild type receptors in each experiment and results are shown in Table 5.3.
In ocß(T13'A) receptors the level of a  subunit in the plasma membrane was 125 ±11 % 
(n=3) and total expression is 97 ±9%  (n=3) (Tierney, 1995). In aß(T13'A) receptors 
the level of a  subunit in the plasma membrane was 41 ± 6% (n=4) and total expression is 
83 ±6%  (n=4) (Tierney, 1995). This indicates that the lack of response to GABA in
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aß(T13'A) receptors is partly due to reduced receptor levels at the cell surface. In 
a(T13'A)ß(T13'A) receptors the level of a  subunit in the plasma membrane was 
99 ± 5% (n=4) and total expression was 96 ± 3% (n=4).
The level of a  subunit in the plasma membrane for aß(T13'A) receptors is not 
significantly different from the level for the a  subunit expressed alone (54 ± 3%, n=4, 
Tierney et al., 1998). It is possible that the lack of response to GABA is because 
subunits do not form receptors that are able to bind agonist. Muscimol binding was 
therefore examined.
5.3.5 Muscimol binding
Kd and Bmax values estimated using equation 2.3 are shown in Table 5.3. It has been 
shown that the Kd for cells expressing oc(T13'A)ß receptors is 21 nM (n=2) and the B max 
is 4.6 pmoles per 106 cells (Tierney, 1995). This compares with a Kd of 29.0 ± 1.5 nM 
(n=8) and a B max value of 7.2 ± 0.7 pmoles per 106 cells reported for wild type receptors 
(Tierney et al., 1996). It has also been shown that cells expressing aß(T13'A) receptors 
are not able to bind muscimol (Tierney, 1995). This is similar to results for 
a(T13'A)ß(T13'A) receptors which do not bind muscimol either (Tierney et a l., 1998).
Reduced levels of a  subunit in the plasma membrane and lack of muscimol binding in 
cells expressing aß(T13'A) receptors indicates that a  and ß(T13'A) subunits are not 
forming heteromeric receptors that are able to bind agonist.
5.4 Discussion
5.4.1 ß  Subunit specific effects
These results show that replacing a threonine residue with alanine at the 13' position in 
the M2 region of a ß  GABAa receptors affects receptor function in a subunit specific 
manner. The lack of response to GABA and loss of muscimol binding were ß subunit 
specific. They are consistent with these two drugs sharing a common agonist binding 
site involving the ß subunit (Casalotti et al., 1986; Amin and Weiss, 1993). It is possible 
that the lack of response to GABA is due to effects at the level of the ion channel. 
Impaired ion permeation would be consistent with the T13'C residue in the a i subunit of 
a iß iy2 receptors being exposed in the channel (Xu and Akabas, 1993, 1996).
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Taken together, reduced a  subunit expression at the cell surface, lack of muscimol 
binding and lack of response to GABA are probably due to a  and ß(T13'A) subunits 
failing to assemble into functional receptors.
5.4.2 Desensitisation
The enhanced desensitisation observed when the oti subunit alone contained the T13'A 
mutation is consistent with results obtained when the homologous mutation was carried 
out in the ot6 subunit of rat oi6p2Y2 receptors (Im et a/., 1995a). The degree of increase 
in the rate of desensitisation differed between the two isoforms. Mutation of the a  
subunit of aß  receptors increased the rate of desensitisation 3-fold, whereas mutation of 
the a 6 subunit of a 6ß2Y2 receptors increased it 10-fold. The degree of the increase 
probably reflects the specific subunit combinations involved.
5.4.3 Changes in drug effects
Inhibition by bicuculline, picrotoxin and penicillin was reduced in a(T13'A)ß receptors. 
Pentobarbital slowed the rate of desensitisation, but did not affect the degree of 
potentiation of the peak current. It is unlikely that the binding of these drugs has been 
altered because they are thought to bind to different sites. There was no change in the 
apparent affinity for GABA, although desensitisation was increased. These results imply 
that the mutation has affected gating of the receptor.
5.4.4 Summary
The results in this chapter show that the T13' residue in the ß subunit is essential for 
receptor function. They are consistent with ßT13' being exposed in the channel (Xu and 
Akabas, 1993, 1996), but it remains to be determined whether it is directly involved in 
ion permeation, or plays a structural role in conformational changes associated with 
agonist activation, or interactions between subunits. The results support a role for M2 
in desensitisation and provide further evidence that the role of the ß subunit differs from 
that of the a  subunit.
5.4.5 Future directions
A ß subunit specific antibody would be useful for detecting any changes in the level of ß 
subunit present in the plasma membrane. Detection of the ß subunit in the plasma
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membrane, however, would not answer the question of whether a  and ß subunits are 
forming functional receptors on the cell surface.
A direct approach that could determine whether a  and ß subunits are forming 
heteromeric receptors would be to use fluorescence energy transfer to examine 
differences in fluorescence emitted between a  and ß subunits expressed alone, or 
together, and compare this with T13'A ß subunit mutated receptors.
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Chapter 6
6. Effects of Mutating Tyrosine to Leucine in the
Ml Region
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6.1 Introduction
While it is generally thought that the M2 region forms the pore of the channel, there is 
evidence that residues in the Ml region are also exposed in the channel. A fragment of 
the a  subunit containing the M l region (residues 208-243) was isolated from Torpedo 
nACh receptors, that was labelled by photoactivatable [3H] quinacrine azide (a channel 
blocker), indicating that it was exposed in the channel (DiPaola et a/., 1990). Residues 
in the Ml region of the a  subunit were mutated individually to cysteine and expressed 
with ß, y, and 5 subunits in Xenopus oocytes (Akabas and Karlin, 1995). The 
accessibility of each cysteine to covalent modification by charged sulfhydryl-specific 
reagents added extracellularly was examined. Residues exposed in the channel in the 
absence of ACh included, P211C, I215C, V216C, N217C, and I220C. Y213C was 
exposed in the presence and absence of ACh; V218C was exposed in the absence of 
ACh. The pattern of cysteine exposure suggested that the secondary structure in this 
part of M l is irregular.
It is possible that the polar residues in the M l region that are exposed in the pore may 
contribute to ion permeation because they would be able to provide solvation for 
permeating ions. A conserved proline residue in M l is also essential for ion channel 
function. Mutation of proline to leucine in both subunits of otißi GABAa receptors 
a(P233L)ß(Y228L) abolished the response to GABA, but receptors still bound 
muscimol (Tierney, 1995). Mutation of the homologous proline residue in the a  subunit 
in the nACh receptor to cysteine (P221C) expressed with ß, y, and 5 subunits also 
produced receptors that did not respond to agonist (Akabas and Karlin, 1995).
A tyrosine, located two residues above the conserved proline, was targeted for site- 
directed mutagenesis because it is conserved across mammalian GABAa receptor 
subunits (Figure 6.1). Tyrosine, a hydrophobic amino acid that has an hydroxyl group, 
was changed to leucine which is similar in size and hydrophobicity, but does not have an 
hydroxyl group (refer Table 3.1).
In this chapter the role of tyrosine at position 231 in the a  subunit and at position 226 in 
the ß subunit in human GABAa receptor function was investigated. Mutations were 
carried out in either the a  subunit, the ß subunit or in both subunits to investigate 
possible differences between subunits. Receptors that carried the tyrosine to leucine
Subunit
nACh a
nAChß
G A B A a P i
GABAa ai
Figure 6.1 Amino acid sequence of residues from the Ml region
Amino acid sequences are aligned for nACh a  subunit residues 209-225 and ß subunit 
residues 220-236, GABAa a  subunit residues 221-237 and GABAa ß subunit residues 
216-232 (12 residues from the proposed Ml region that are located more intracellularly 
are not shown). Residues conserved across mammalian GABAa receptors or also 
between nACh receptors are shaded. Mutated residues: Y231L in the a  subunit and 
Y226L in the ß subunit of GABAa receptors are in boxes. Residues mutated to cysteine 
in the nACh receptor that are exposed to sulfhydryl reagents in the presence or absence 
of ACh are shown for comparison and are underlined (Akabas and Karlin, 1995, Zhang 
and Karlin, 1997).
94
(Y—>L) mutation in the a  subunit were designated a(Y231L)ß, those mutated in the ß 
subunit were designated aß(Y226L) and those mutated in both subunits were designated 
a(Y23 lL)ß(Y226L). The effect of these mutations upon expression of receptors and 
the response to GABA were examined and results compared with previous observations 
in wild type GABAa receptors.
6.2 Methods
Refer to Chapter Two.
6.3 Results
6.3.1 GABA-activation and desensitisation.
Responses to 10 mM GABA in cells expressing a(Y231L)ß, aß(Y226L) or 
a(Y23 lL)ß(Y226L) receptors are shown in Figure 6.2. Current amplitudes and rise and 
decay times are summarised in Table 6.1. Differences in current decay between the 
receptors are shown in Figure 6.2 D.
Four out of thirteen cells expressing oc(Y231L)ß receptors responded to 10 mM GABA. 
The peak current amplitude was 72 ± 25 pA (n=4). This is much less than in wild type 
receptors (3370 ±612 pA, n=12). The 50% decay time was 290 ±121 ms (n=3) which 
was not significantly different from that in wild type receptors (223 ± 43 ms, n=6). The 
10-90% rise time was 12 ± 2 ms (n=3), not significantly different from that in wild type 
receptors (16 ± 4 ms, n=6).
In ocß(Y226L) receptors the peak current in response to lOmM GABA was 
2678 ± 676 pA (n=6), not significantly different from that in wild type receptors. The 
10-90% rise time was 8 ± 0.5 ms, significantly faster than in wild type receptors. The 
50% decay time was 84 ± 6 ms (n=6), faster than in wild type receptors.
No current was detected in response to lOmM GABA in 10 cells expressing 
a(Y23 lL)ß(Y226L) receptors.
6.3.2 Plasma membrane expression
It is possible that the lack of response to GABA in a(Y23 lL)ß(Y226L) receptors and 
the reduced amplitude of the GABA-induced current in ot(Y231L)ß receptors is due to 
effects of these mutations upon receptor assembly and trafficking to the plasma 
membrane. The level of expression of the a  subunit in the plasma membrane was
A B C
0.4 nA
1sec 2 sec
0.4 nA
2 sec
D
2 sec
Figure 6.2 GABA-activated whole-cell currents
The response to 10 mM GABA is shown for cells expressing: (A) a(Y23 lL)ß,
(B) aß(Y226L) and (C) a(Y231L)ß(Y226L) receptors. (D) Currents were scaled to the 
peak amplitude produced in wild type (3.2 nA, broken line) to allow comparison of 
current decay in cells expressing ot(Y231L)ß (thin line) and aß(Y226L) (bold line) 
receptors. The duration of GABA application to wild type receptors is indicated by the 
upper bar, and to a(Y231L)ß and aß(Y226L) receptors by the lower bars, respectively.
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therefore examined in non-permeabilised cells. Total receptor expression was 
determined in permeabilised cells. Fluorescence was calculated as a percent of the level 
for wild type receptors. Data are summarised in Table 6.1 and Figure 6.3.
In a(Y231L)ß receptors, the level of a  subunit in the plasma membrane was 47 ± 3 % 
(n=5) and total expression was 90 ± 8 % (n=5). This indicates that the reduction in 
current in response to GABA may be partly due to reduced receptor levels at the cell 
surface. In aß(Y226L) receptors, the level of a  subunit in the plasma membrane was 
72 ± 1 7 %  (n=5) and total expression was 102 ± 1 5 %  (n=5). In cells expressing 
ot(Y231L)ß(Y226L) receptors, the level of the a  subunit in the plasma membrane was 
reduced to 16 ± 2 % (n=5). When these cells were permeabilised, the total level of a  
subunit expression was 90 ± 6 % (n=5). This indicates that the lack of response to 
GABA in a(Y23 lL)ß(Y226L) receptors is largely due to reduced receptor levels at the 
cell surface.
These results show that the a  subunit is expressed within the cell but is not trafficked to 
the cell surface normally. The degree of reduction in the a  subunit present at the cell 
surface for a(Y231L)ß and otß(Y226L) receptors totals 81% which is similar to the 
reduction for a(Y23 lL)ß(Y226L) receptors (84%).
The a(Y231L)ß mutation may also have affected GABA binding, channel gating or ion 
permeation. The small magnitude of the current response to GABA and lack of 
response in some cells made dose-response experiments difficult. The current response 
to 30 mM GABA was not greater than the response to 10 mM GABA in 2 cells. It is 
possible that drugs which potentiate the response to GABA may be able to increase the 
small currents observed. The effect of pentobarbital was therefore examined.
6.3.3 Pentobarbital
Results obtained using pentobarbital are shown in Figure 6.4 and summarised in 
Table 6.2. In ot(Y231L)ß receptors, 100 pM pentobarbital potentiated the peak current 
response to 10 mM GABA by a factor of 8.0 ±2.5 (n=4). In wild type receptors 
100 pM pentobarbital potentiated the peak current in response to 10 pM GABA by 
2.13 ±0.18 (n=5). Cells expressing ot(Y231L)ß receptors that did not produce a 
detectable current in response to 10 mM GABA produced currents of 157 ±41 pA 
(n=3) when 100 pM pentobarbital was also present.
A~r ' ................10»
relative fluoresence
Figure 6.3 a  subunit expression of Ml region mutated receptors
Flow cytometric analysis of immunofluorescently labelled oti protein expressed in Sf) 
cells infected with L9’Y recombinant baculovirus mutated in both a, and ß, subunits. 
Primary monoclonal antibody bd24 was immunofluorescently labelled with a secondary 
FITC conjugated antibody at 42-48 hours post-infection. The level of non-specific 
labelling was determined from the level of fluorescence in cells infected with the parent 
baculovirus AcNPV. Expression was calculated as a percent of the level for wild type. 
The levels of expression for non-permeabilised cells are shown in (A) and expression 
levels for permeabilised cells are shown in (B). The relative fluorescence levels for one 
experiment are shown for cells infected with: AcNPV (black), wild type aß (dark blue), 
a(Y231L)ß (red), aß(Y226L) (light blue), and a(Y231L)ß(Y226L) (green) 
recombinant baculovirus.
A100 pA
2 sec
B
400 pA
2 sec
Figure 6.4 Effect of pentobarbital on ot(Y231L)ß receptors
Whole-cell currents elicited in response to GABA are shown (left trace) and in the 
presence of 100 pM pentobarbital (right): (A) Potentiation of the response to 10 pM 
GABA in cells expressing wild type receptors, (B) Potentiation of the response to 
10 mM GABA in cells expressing a(Y231L)ß receptors. Drugs were applied for the 
period indicated by the bar.
GABA +GABAa Receptor 1 1 mM Pb / I gAB A
100 pM PB
a ß  (WT) 2.13 ±0.18 (n=5) 0.30 ± 0.14 (n=3)
a(Y23 lL)ß(Y226L) 8.0 ±2.5 (n=4) 0 (n=4)
Table 6,2 Modulation and direct activation by pentobarbital
The potentiating effect of 100 pM pentobarbital (PB) is given as a fraction of the 
peak current amplitude (Ip) in response to GABA. The control GABA 
concentrations used were 10 pM GABA in wild type receptors and 10 mM in 
a(Y23 lL)ß(Y226L) receptors. Data show the mean ± 1 SEM. The number of cells 
used for each experiment is indicated in brackets.
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1 mM pentobarbital is able to directly activate wild type receptors and produced a 
current that was 0.30 ± 0.14 (n=3) of the response to 10 pM GABA. If pentobarbital 
and GABA activate the receptor by different mechanisms it is possible that direct 
activation by pentobarbital may be unaffected by the a(Y231L)ß mutation. No current 
was detected in response to 1 mM pentobarbital in 4 cells that did respond to 10 mM 
GABA and we're potentiated by 100 pM pentobarbital.
It would be useful to examine whether ot(Y231L)ß(Y226L) receptors can respond to 
GABA in combination with pentobarbital to determine whether receptors are able to be 
activated. Muscimol binding experiments would also be useful to determine whether 
heteromeric receptors are able to form. These experiments were not carried out due to 
time constraints.
6.4 Discussion
6.4.1 a subunit expression in the plasma membrane
The reductions in the level of a  subunit in the plasma membrane for receptors with the 
Y—>L mutation indicates that trafficking of receptors to the plasma membrane was 
severely impaired. This is probably because they could not assemble normally. The 
greater reduction in the level of a  subunit in the plasma membrane in ot(Y231L)ß 
receptors, compared to aß(Y226L) receptors, suggests that residues at this position in 
the a  subunit have a greater influence upon receptor assembly than those in the ß 
subunit. The level of a  subunit in the plasma membrane was reduced by the greatest 
degree when the Y—»L mutation was in both subunits. These results suggest that 
aY231 and ßY226 are involved in interactions between subunits during receptor 
assembly.
6.4.2 Effects upon the response to GABA
These results show that replacing a tyrosine residue with leucine at position 231 in the a  
subunit and the homologous residue in the ß subunit at position 226 in the M l region of 
human aß  GABAa receptors affects the response to GABA in a subunit specific manner. 
Reduced receptor levels at the cell surface can partly account for the greatly reduced 
GABA current in a(Y231L)ß receptors and the lack of response to GABA in 
a(Y231L)ß(Y226L) receptors.
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In receptors mutated in only the a  subunit, current amplitudes were greatly reduced but 
rise and decay times were unaffected. In contrast, receptors mutated in only the ß 
subunit had normal current amplitudes but rise and decay times were increased. 
Increased desensitisation in aß(Y226L) receptors suggests a role for M l in 
desensitisation. The ability of GABA to activate oc(Y231L)ß receptors was clearly 
impaired because very high concentrations of GABA were required to produce any 
current response. The decrease in a  subunit in the plasma membrane for a(Y231L)ß 
receptors, by about half compared to wild type, is unlikely to fully account for the much 
greater reduction in current amplitude. The level of a  subunit in the plasma membrane 
was greatly reduced in a(Y231L)ß(Y226L) receptors but was still present suggesting 
that some pentameric receptors may have formed. The lack of response to GABA was 
mostly due to impaired assembly and trafficking of receptors to the plasma membrane.
6.4.3 Pentobarbital effects
The potentiating effects of pentobarbital upon channel gating appear unaffected in 
a(Y231L)ß receptors despite impaired GABA-activation. In a(Y231L)ß receptors the 
small current response to 10 mM GABA was potentiated 8-fold by pentobarbital but in 
wild type receptors the response to 10 gM GABA was only potentiated 2-fold 
(refer 4.3.6). Potentiation by pentobarbital normally shifts the GABA dose-response 
relationship to lower concentrations without affecting the maximum current (Akaike et 
a/., 1985; Rho et a l., 1996). In a(Y231L)ß receptors, the amplitude of the current 
potentiated by pentobarbital was much greater than the maximum current produced by 
high concentrations of GABA. Some cells did not respond to GABA alone but did 
respond to GABA in combination with pentobarbital. These findings suggest that 
pentobarbital potentiation and GABA activation occur by distinct mechanisms. 
Alternatively the mutations may have introduced differing conformational changes that 
affect a common gating mechanism.
6.4.4 Summary
The findings in this chapter indicate that Y231 and Y226 residues are involved in 
interactions between subunits that are important for normal receptor assembly.
The increased rate of current decay in otß(Y226L) receptors indicates that 
desensitisation involves residues in the M l region in addition to those identified in the
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M2 region. The region of M l where ßY226 is located could interact with residues in 
M2 in desensitisation. This finding adds to increasing evidence that many regions of the 
receptor are involved in desensitisation.
The results indicate a role for Y231 in GABA-activation, but are not able to determine 
at what level of receptor function it is involved. It is possible that Y231 is exposed in 
the channel and that replacement of tyrosine with a nonpolar residue has severely 
impaired ion permeation. This seems unlikely due to the large increase in current 
produced by pentobarbital. The mutation could have altered the structure of the GABA 
binding site so the energy required to form an open conformation is greatly increased 
and high agonist concentrations are required to activate the channel.
The finding in nACh receptors that residues in the upper third of the M l region are 
exposed to chemical reagents raises the possibility that residues in this region may not be 
located in a membrane-spanning domain at all but could exist extracellularly (Akabas and 
Karlin, 1995). This would place aY231 in closer proximity to residues (Y157 and 
Y205) that have been implicated in GABA binding in the ß2 subunit (Amin and Weiss, 
1993). Residues mutated in the M2-M3 extracellular loop region have been suggested 
to be important in the allosteric transduction mechanism that couples agonist binding to 
channel activation in the nACh receptor (Campos-Caros et a l., 1996) and in the glycine 
receptor (Lynch el al., 1997). It is possible that Y231 is involved in interactions that 
couple agonist binding to channel activation. Y231 could interact with residues in the 
M2-M3 loop to transmit conformational changes between the a  subunit and the ß 
subunit following GABA binding. If the hydroxyl group of Y231 is important for such a 
function then the Y231L mutation would severely reduce the efficiency of this process. 
This could explain why GABA-activated currents were only produced at very high 
GABA concentrations.
Similar effects upon GABAa receptor activation have been found when residues located 
two positions above-and-below Y231 were mutated. Mutation of the conserved proline 
in M l to leucine ot(P233L)ß dramatically reduced the current amplitude in response to 
GABA (B. Birnir, personal communication). This effect was also observed when the 
glutamine two residues above Y231 was mutated to leucine ot(Q229L)ß (B. Cromer, 
personal communication). The aP233 and aY231 residues may have similar roles to 
aY231 in channel function. All three may be aligned on the same face of M l and could
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contribute to ion permeation or interact with residues in other regions or subunits. If 
residues P233, Y231 and Q229 do lie on the same face of M l this would be consistent 
with a ß-sheet conformation for this region of the a  subunit.
6.4.5 Future directions
In order to determine whether the aY231 is involved in ion permeation or gating, the 
effect of the a(Y23 lL)ß mutation upon single channel properties should be investigated.
Chapter 7
7. Summary and Conclusions
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The main findings from each chapter will be summarised in relation to common themes. 
Subunit specificity
The use of site-directed mutagenesis to study the structure and function of human otißi 
GABAa receptors has clearly shown that subunits do not contribute equally to receptor 
assembly, muscimol binding, desensitisation or response to GABA and pentobarbital.
Receptor assembly
The findings in this study suggest that residues in M l and M2 provide points of contact 
between subunits that are essential for normal receptor assembly. The Y—»L mutations in 
M l showed a  subunit specificity whereas T13'A mutations showed ß subunit specificity. 
The observed subunit specificity indicates that a  and ß subunits do not contribute equally 
to receptor assembly. This is probably due to differences between subunits in the specific 
residues that are involved in subunit-subunit interactions.
Desensitisation
Effects upon desensitisation varied depending upon the position of the residue and the 
substitution made. L9' mutations showed a  subunit specificity in desensitisation; the rate 
of desensitisation increased with increased size and hydrophobicity of the residue side 
chain. The Y-»L mutations in Ml and T12'Q mutations in M2 showed the greatest 
increase in desensitisation when the ß subunit was mutated. Desensitisation was also 
increased in T13'A receptors mutated in the a  subunit. Conformational changes that 
occur during desensitisation clearly involve residues in M l and M2 regions. Residues in 
both a  and ß subunits contribute to this process but their relative contributions differ 
depending upon the location of the residue and properties of the side chain present.
GABA-activation
Residues mutated in M2 showed ß subunit specificity in their response to GABA 
compared to the residue mutated in M l which showed a  subunit specificity. In L9' 
mutated receptors the apparent affinity for GABA was decreased when the mutation was 
only in the ß subunit. In T12'Q mutated receptors, cooperativity was reduced when the 
mutation was in the ß subunit. The response to GABA was abolished when the T13'A 
mutation was in the ß subunit. These findings demonstrate the importance of the ß 
subunit in transmitting conformational changes involved in GABA-activation.
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The role of the ß subunit in receptor activation may be analogous to that of the a  subunit 
in nACh receptors which undergoes conformational changes that transmit movements 
initiated upon agonist binding down to residues in the membrane spanning regions.
Pentobarbital potentiation
The findings in this study show that T12' in the ß subunit is critical for potentiation by 
pentobarbital. This is the first time that a discrete site has been implicated in the action of 
pentobarbital. Loss of pentobarbital potentiation in L9' a  subunit mutated receptors, 
inhibition of the GABA response when both subunits were mutated and potentiation in 
L9' ß subunit mutated receptors are probably due to effects upon the allosteric 
mechanism of pentobarbital potentiation. L9' is probably involved in the conformational 
changes that couple pentobarbital binding to its effects upon gating.
The small currents produced in response to GABA in a(Y231L)ß receptors and the large 
potentiation produced by pentobarbital indicate that this region of M 1 is important in 
conformational changes involved in GABA activation but not pentobarbital potentiation. 
This finding indicates a role for Ml in GABA activation and further supports separate 
mechanisms of action for GABA and pentobarbital.
Future directions
These mutagenesis studies have provided new information about the functional 
contribution of different residues and subunits to GABAa receptor function. A more 
detailed understanding of GABAA-receptor structure awaits higher resolution images of 
the membrane-spanning regions for ligand-gated ion channels. Fluorescence methods 
could be useful techniques to use in future studies, as they may provide information on 
the relative movement between subunits during conformational changes.
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